



# ESCM

European Congress of C

## Preliminary

### Vienna, Austria

11-15 April 2025



<http://www.escmid.org/congress-e>

# ESCMID Global

Clinical Microbiology & Infectious Diseases

## Programme



[events/escmid-global](https://www.escmid.org/events/escmid-global)

# ESCMID Global 2025 - Programme

Friday, 11 April 2025

SP1

08:30 – 10:30

Hall 0

CLN

Special Session

Antimicrobial Stewardship in Different Scenarios

- Chairs
- Murat Akova (Ankara, Türkiye)
- Andre Fuchs (Augsburg, Germany)
- Maddalena Giannella (Bologna, Italy)
- Angela Huttner (Geneva, Switzerland)
- Benedikt Huttner (Geneva, Switzerland)
- Jose Ramon Pano-Pardo (Zaragoza, Spain)
- Galadriel Pellejero-Sagastizábal (Zaragoza, Spain)
- Holger Rohde (Hamburg, Germany)
- Oana Sandulescu (Bucharest, Romania)
- Jeroen Schouten (Nijmegen, Netherlands)
- Valentijn Schweitzer (Utrecht, Netherlands)
- Thomas Tängdén (Uppsala, Sweden)
- Suzanne Van Asten (Nijmegen, Netherlands)
- Dafna Yahav (Ramat-Gan, Israel)

Co-organised with: ESCMID Education Subcommittee

EW001

08:30 – 10:30

Hall 2

CLN IPC

Educational Session

Surgical site infections: principles and practice in the era of multidrug resistance

- Chairs
- Gabriel Birgand (Nantes, France)
- Efthymia Giannitsioti (Athens, Greece)

- W0001
- 08:30
- Evolving antimicrobial resistance: do we need a change in surgical antimicrobial prophylaxis?  
Camilla Rodrigues (Mumbai, India)
- W0002
- 08:50
- Role of decolonisation and bowel decontamination in regions of overwhelming multidrug resistance  
Prasannakumar Palanikumar (Vellore, India)
- W0003
- 09:10
- Screening for MDR GNR colonisation: is there evidence for prophylaxis  
Elisabeth Presterl (Vienna, Austria)
- W0004
- 09:30
- Perioperative prophylaxis in special populations in the era of MDR  
Divyashree Shanthamurthy (Mumbai, India)

EW002

08:30 – 10:30

Hall 3

ANT

Educational Session

Demystifying pharmacokinetics and population pharmacokinetics: a toolkit for non-experts

- Chairs
- Shampa Das (Liverpool, United Kingdom)
- João Paulo Telles (Sao Paulo, Brazil)

- W0005
- 08:30
- Pharmacokinetics 101: navigating the basics for optimal dosing  
Linda Aulin (Leiden, Netherlands)
- W0006
- 08:50
- The ABCs of population pharmacokinetic models  
Erwin Dreesen (Leuven, Belgium)
- W0007
- 09:10
- Looking into the crystal ball: exploring the fabulous world of PK-PD simulations  
Vincent Aranzana-Climent (Poitiers, France)
- W0008
- 09:30
- Decoding population pharmacokinetic papers: interpreting, comparing and discussing results  
Iris K. Minichmayr (Vienna, Austria)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

EW003

08:30 – 10:30

Hall 5

DX

Educational Session

## Challenges in identification and relevance of slow-growing pathogens

*Chairs* *Kerrie Davies (Leeds, United Kingdom)*  
*Yann Dumont (Nancy, France)*

- W0009**     **08:30**     **Sampling and culturing anaerobes***Hugo Cruz (Porto, Portugal)*
- W0010**     **08:50**     **I have an anaerobe: what is it and does it matter?***Kathleen Boiten (Groningen, Netherlands)*
- W0011**     **09:10**     **Actinomyces in clinical samples: when is it worth the trouble?***Eija Inkeri Könönen (Turku, Finland)*
- W0012**     **09:30**     **Nocardiosis: when to test and how to manage results?***David Lebeaux (Paris, France)*

Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI), ESCMID Study Group for Clostridioides difficile (ESGCD)

---

**EW004**     **08:30 – 10:30**     **Hall 6**

**CLN** **DX** **IPC**

Educational Session

## A hard nut to crack in HIV

*Chairs* *Yoav Keynan (Winnipeg, Canada)*  
*Justyna Kowalska (Warsaw, Poland)*

- W0013**     **08:30**     **Viral reservoir: what a physician should know***Ivailo Alexiev (Sofia, Bulgaria)*
- W0014**     **08:50**     **Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians***Jose Arribas (Madrid, Spain)*
- W0015**     **09:10**     **Chronic vascular and pulmonary disease and HIV: what can we do about it?***Susanne Dam Poulsen (Copenhagen, Denmark)*
- W0016**     **09:30**     **Opportunistic infections: most common and most deadly***Milena Stevanovikj (Sopje, North Macedonia, Republic of)*

Co-organised with: Euroguidelines in Central and Eastern Europe Network Group

---

**EW005**     **08:30 – 10:30**     **Hall 8**

**DX**

Educational Session

## Diagnostic parasitology in the XXIst century: is microscopy "+" still useful?

*Chairs* *Miriam José Álvarez-Martínez (Barcelona, Spain)*  
*Caroline Rönnberg (Stockholm, Sweden)*

- W0017**     **08:30**     **Artificial Intelligence for the diagnosis of parasitic infections***Bobbi Pritt (Rochester, United States)*
- W0018**     **08:50**     **Histopathology of parasitic infections***Richard Bradbury (Townsville, Australia)*
- W0019**     **09:10**     **Molecular diagnosis vs. microscopy in the diagnosis of parasitic infections***Sitara Sr Ajjampur (Vellore, India)*
- W0020**     **09:30**     **Paleoparasitology: what diagnostic tools?***Ayman El-Badry (Cairo, Egypt)*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

---

**EW006**     **08:30 – 10:30**     **Hall 9**

**PRO** **PHEI**

Educational Session

## Vaccine hesitancy: from issues to solutions through developing communication skills

*Chairs* *Monia Chemais (Soignies, Belgium)*  
*Petar Velikov (Sofia, Bulgaria)*

- W0021**     **08:30**     **Vaccine hesitancy and its consequences***Noni Macdonald (Halifax, Canada)*
- W0022**     **08:50**     **Why are patients and parents hesitant about vaccination?***Eve Dube (Quebec City, Canada)*
- W0023**     **09:10**     **Using social media to deal with vaccine hesitancy***Muge Cevik (St Andrews, United Kingdom)*

## ESCMID Global 2025 - Programme

W0024	09:30	Strengthening vaccine confidence in patients and parents <i>Tba</i>
-------	-------	---

**Co-organised with: ESCMID Vaccine Study Group (EVASG)**

**SP2** **11:00 – 12:00** **Hall O**

Special Session

PRO

## Principles of systematic reviews (with and without meta-analysis)

## *Chairs*

Chiara Iaria (Palermo, Italy)  
Miranda Langendam (Amsterdam, Netherlands)  
Blin Nagavci (Gjakove, Kosovo)  
Mical Paul (Haifa, Israel)  
Luigia Scudeller (Pavia, Italy)

**Co-organised with: ESCMID Education Subcommittee**

<b>ME007</b>	<b>11:00 - 12:00</b>	<b>Hall 2</b>
--------------	----------------------	---------------

**11:00 - 12:00**

## Meet-the-Expert

AMR

DX

## How to interpret resistance patterns from antibiograms

M0025 11:00 *Tommaso Giani (Florence, Italy)*

**M0026**      **11:12**      *Diaz Lorena (Santiago, Chile)*

ME008 11:00 – 12:00 Hall 3

**11:00 - 12:00**

## Meet-the-Expert

CLN

## Children are not just small adults: interactive paediatric cases

**M0027**     **11:00**     *Julie Toubiana (Paris, France)*

**M0028**    **11:12**    *Sanjay Patel (Winchester, United Kingdom)*

ME009 11:00 – 12:00 Hall 5

**11:00 - 12:00**

## Meet-the-Expert

IPC

## How to practise WHO Guidelines for the prevention of bloodstream infections and other intravascular catheter infections

**M0029**    **11:00**    *Kushlani Jayatilleke (Battaramulla, Sri Lanka)*

**M0030**    **11:12**    *Walter Zingg (Zurich, Switzerland)*

ME010 11:00 – 12:00 Hall 6

**11:00 – 12:00**

## Meet-the-Expert

PHEI

## Can we stop vertical transmission of syphilis, HIV and hepatitis? Regional experience

<b>M0031</b>	<b>11:00</b>	<i>Ecaterina Noroc (Chisinau, Moldova, Republic of)</i>
--------------	--------------	---

**M0032**    **11:12**    *Fakhriddin Nizamov (Almaty, Kazakhstan)*

**Co-organised with: Euroguidelines in Central and Eastern Europe Network Group, United Nations International Children's Emergency Fund (UNICEF)**

ME011 11:00 – 12:00 Hall 8

**11:00 – 12:00**

## Meet-the-Expert

CLN

## Biofilm-related nontuberculous mycobacterial infections: ongoing nightmare

<b>M0033</b>	<b>11:00</b>	<i>Jaime Esteban (Madrid, Spain)</i>
--------------	--------------	--------------------------------------

**M0034**    **11:12**    *Philippe Morand (Paris, France)*

Co-organised with: ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Mycobacterial Infections (ESGMYC)

ME012 11:00 – 12:00 Hall 9  
Meet-the-Expert

PHEI

How to understand infectious disease risks in changing climates

M0035 11:00 Kimberly Fornace (Singapore, Singapore)  
M0036 11:12 Rachel Lowe (Barcelona, Spain)

SP3 13:30 – 14:30 Hall 0  
Special Session

IPC

Top five mistakes in Infection prevention and control

Chairs Maeve Doyle (Waterford, Ireland)  
Barbara Juliane Holzkecht (Copenhagen, Denmark)  
David Ong (Zoetermeer, Netherlands)  
Arjana Tambic Andrasevic (Zagreb, Croatia)

Co-organised with: ESCMID Education Subcommittee

ME013 13:30 – 14:30 Hall 2  
Meet-the-Expert

CLN TRN

Orthopaedic implant infections: new approaches for improved outcomes

M0037 13:30 Marjan Wouthuyzen-Bakker (Groningen, Netherlands)  
M0038 13:42 Trisha Peel (Melbourne, Australia)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

ME014 13:30 – 14:30 Hall 3  
Meet-the-Expert

CLN

Timing of antimicrobials in sepsis and septic shock - the sooner the better?

M0039 13:30 Laura Evans (Seattle, United States)  
M0040 13:42 Evangelos Giamarellos-Bourboulis (Athens, Greece)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

ME015 13:30 – 14:30 Hall 5  
Meet-the-Expert

CLN

PrEP in Europe: Current gaps and solutions

M0041 13:30 Teymur Noori (Stockholm, Sweden)  
M0042 13:42 Milosz Parczewski (Szczecin, Poland)

Co-organised with: European AIDS Clinical Society (EACS)

ME016 13:30 – 14:30 Hall 6  
Meet-the-Expert

CLN

Short regimens for treating drug-susceptible and drug-resistant tuberculosis: Insights from guidelines





**Co-organised with: ESCMID Guidelines Subcommittee**

**14:45 – 15:45**

CLN

## Multidisciplinary management of bone and joint infections: is there a recipe for success?

**M0056**     **14:57**     *Tiziana Ascione (Naples, Italy)*

**Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)**

**14:45 - 15:45**

PHEI

## How to manage and prevent travellers' diarrhoea

**M0058**     **14:57**     *David Tribble (Bethesda, United States)*

**14:45 - 15:45**

CLN DX IPC

## How to diagnose and treat infectious complications in critically ill patients receiving ECMO support

**M0060 14:57** *Giacomo Grasselli (Besana In Brianza, Italy)*

**Co-organised with: European Extracorporeal Life Support Organization (EuroELSO)**

**16:15 – 18:15**

CLN

### Multidisciplinary approach to early sepsis management

Markus Bald (Lüdenscheid, Germany)  
Aleksandra Davidovic (Luedenscheid, Germany)  
Charalambos Dokos (Lüdenscheid, Germany)

**Co-organised with: ESCMID Education Subcommittee**

**16:15 – 18:15**

AMR DX

## AMR surveillance: current challenges and new perspectives

*Chair* *Tomislav Mestrovic (Varazdin, Croatia)*

W0061	16:15	<b>The essentials of GRAM project: data sources, methodology and challenges in estimating AMR burden</b> <i>Authia Gray (Washington, United States)</i>
-------	-------	--

W0062	16:35	<b>Networks for surveillance of AMR in animal pathogens</b> <i>Lucie Collineau (Lyon, France)</i>
-------	-------	--

W0063	16:55	<p><b>Transition to genomic-based methodology for surveillance and outbreak detection to effectively combat AMR</b>  <i>Camilla Wiuff Coia (Copenhagen, Denmark)</i></p>
-------	-------	--

W0064	17:15	Implementing and running hospital-wide genomic surveillance of pathogens <i>Alexander Mellmann</i>
-------	-------	--



# ESCMID Global 2025 - Programme

(Münster, Germany)

Co-organised with: ESCMID Education Subcommittee, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Veterinary Microbiology (ESGVM)

**EW026** **16:15 – 18:15** **Hall 3**  
Educational Session

AMR

**New insights into antifungal agents and resistance**

*Chairs* *Anuradha Chowdhary (New Delhi, India)*  
*Jon Salmanton-Garcia (Cologne, Germany)*

**W0065** **16:15** **Emerging resistance in *Candida tropicalis*** *Sharon Chen (Sydney, Australia)*

**W0066** **16:35** **Mechanisms of resistance in *Candida glabrata*** *David Perlin (Nutley, United States)*

**W0067** **16:55** **Surveillance of resistance in *Aspergillus* species** *Maiken Cavling Arendrup (Copenhagen, Denmark)*

**W0068** **17:15** **Environmental surveillance for antifungal resistance** *Eveline Snelders (Wageningen, Netherlands)*

**EW027** **16:15 – 18:15** **Hall 5**  
Educational Session

ANT CLN TRN

**Going Viral! Phage Therapy Clinical rounds**

*Chairs* *Gregory German (Maple, Canada)*  
*Ameneh Khatami (Sydney, Australia)*

**W0069** **16:15** **Clinical cases and lessons from the STAMP protocol** *Holly Sinclair (Nsw, Australia)*

**W0070** **16:35** **Difficult cases treated with phages** *Ghady Haidar (Pittsburgh, United States)*

**W0071** **16:55** **Challenging osteoarticular cases treated with phages** *Tristan Ferry (Lyon, France)*

**W0072** **17:15** **Treating urinary tract infections with phages: dream or reality?** *Saima Aslam (San Diego, United States)*

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

**EW028** **16:15 – 18:15** **Hall 6**  
Educational Session

CLN VAX

**Addressing infection challenges in immunocompromised patients: a case-based exploration**

*Chairs* *Maddalena Giannella (Bologna, Italy)*  
*Asma Nasim (Karachi, Pakistan)*

**W0073** **16:15** **Challenges in managing gastrointestinal infections in patients with primary immunodeficiency** *Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)*

**W0074** **16:35** **Respiratory infections in patients receiving CAR-T cells or bispecific monoclonal antibodies** *Gemma Reynolds (Heidelberg, Australia)*

**W0075** **16:55** **Mycobacterial infections in patients with HIV infection** *Graeme Ayton Meintjes (Observatory, South Africa)*

**W0076** **17:15** **Breakthrough fungal infections in haematopoietic cancer and in stem cell transplantation** *Dimitrios P. Kontoyiannis (Houston, Tx, United States)*

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (IICHS)

**EW029** **16:15 – 18:15** **Hall 8**  
Educational Session

TRN

**Impact of diabetes on infectious diseases: what should we know?**

<i>Chairs</i>		<i>Mark G. J. De Boer (Leiden, Netherlands)</i> <i>Suzanne Van Asten (Nijmegen, Netherlands)</i>
W0077	16:15	<b>The impact of diabetes and host-pathogen interaction and gut microbiome</b> <i>Reinout Van Crevel (Nijmegen, Netherlands)</i>
W0078	16:35	<b>Diabetes and invasive fungal infections</b> <i>Jochem Buil (Nijmegen, Netherlands)</i>
W0079	16:55	<b>Viral infections and diabetes: is there a connection?</b> <i>Malin Flodström-Tullberg (Stockholm, Sweden)</i>
W0080	17:15	<b>Pathogenesis of diabetic wound infection</b> <i>Tba</i>

EW030	16:15 – 18:15	Hall 9
Educational Session		

DX

IPC

Primer on infection prevention and control: the crucial support by clinical microbiology

<i>Chairs</i>		<i>Nico Tom Mutters (Bonn, Germany)</i> <i>Margreet C. Vos (Rotterdam, Netherlands)</i>
---------------	--	--

W0081	16:15	<b>Microbial fundamentals: building blocks of infection prevention and control</b> <i>Laurence Armand-Lefevre (Paris, France)</i>
W0082	16:35	<b>Optimising environmental sampling in infection control: rational use of the microbiology laboratory</b> <i>John E. Coia (Esbjerg, Denmark)</i>
W0083	16:55	<b>The crucial role of molecular typing in infection control</b> <i>Stefanie Kampmeier (Würzburg, Germany)</i>
W0084	17:15	<b>How can we link diagnostic and antibiotic stewardship?</b> <i>Constantinos Tsioutis (Nicosia, Cyprus)</i>

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

Saturday, 12 April 2025

SY036	08:30 – 10:30	Hall 15
2-hour Symposium		

ANT

The quality of antibiotics used in the communities of LMICs

<i>Chairs</i>		<i>Thi Thuy Nga Do (Ha Noi, Vietnam)</i> <i>Christina Obiero (Kilifi, Kenya)</i>
---------------	--	---

S0105	08:30	<b>The quality of antibiotics and their potential impact on patient outcome and AMR</b> <i>Paul Newton (Oxford, United Kingdom)</i>
S0106	09:00	<b>Community antibiotic access and use in Sub-Sahara Africa</b> <i>Samuel Afari-Asiedu (Kintampo, Ghana)</i>
S0107	09:30	<b>Encountered challenges and reflections on conducting multi-country medicine quality studies</b> <i>Noudy Sengxeu (Vientiane Capital, Lao People's democratic republic)</i>
S0108	10:00	<b>Confusion in appearance of common used antibiotics in LMICs</b> <i>Heiman Wertheim (Nijmegen, Netherlands)</i>

SY031	08:30 – 10:30	Hall 6
2-hour Symposium		

CLN

VAX

To screen or not to screen prior to transplant?

<i>Chairs</i>		<i>Laura Alicia Barcan (Buenos Aires, Argentina)</i> <i>Oscar Len (Barcelona, Spain)</i>
---------------	--	---

S0085	08:30	<b>HHV-8 Screening</b> <i>Alessandra Mularoni (Palermo, Italy)</i>
S0086	09:00	<b>TB screening and prevention in endemic regions</b> <i>Rubina Naqvi (Karachi, Pakistan)</i>

# ESCMID Global 2025 - Programme

S0087	09:30	<b>Screening for and prevention of chagas in immunocompromised hosts</b> <i>Marcelo Victor Radisic (Buenos Aires, Argentina)</i>
S0088	10:00	<b>Screening of lung donors for Mollicutes</b> <i>Michael G Ison (Derwood (MD), United States)</i>

EF003	08:30 – 09:30	Arena 1
	ePoster Flash Session	

CLN VAX

## On the frontiers of vaccine driven prevention

Chair *Maria Ganczak (Zielona Gora, Poland)*

E0021	<b>Changes in dose interval can impact T cell responses but not antibody levels in individuals receiving the modified vaccinia Ankara Mpox vaccine</b> <i>J. Parsons* (Liverpool, United Kingdom), K. Subramaniam, L. Turtle, S. Dobson, L. Goodwin, C. Jones, T. Jones, P. Shellman, A. Uriel, S. Jones, A. Otter, S. Laidlaw, M. Carroll</i>
E0022	<b>A phase 1 study with an innovative approach for an HIV-1 prophylactic vaccine</b> <i>P. Garbes* (Newark, United States), C. Chang, H. Wraight, R. Norton, S. Ouyang, S. Shen, H. Gao, D. Montefiori, J. Heptinstall, S. Sawant, G. Tomaras, J. Zhu, K. Braz Gomes, M. Giffear, K. Damjanoska, J. Li</i>
E0023	<b>A Pragmatic Randomized Trial to Evaluate Bivalent RSV Prefusion F Protein–based Vaccine Effectiveness for Preventing RSV Hospitalizations in Older Adults (DAN-RSV): Rationale &amp; Trial Design</b> <i>M. Lassen* (Copenhagen, Denmark), S. Christensen, N. Johansen, K. Skaarup, D. Modin, B. Claggett, C. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, M. Lindholm, L. Køber, S. Solomon, J. Jensen, C. Martel, C. Schwarz, E. Gonzalez, M. Skovdal, P. Zhang, B. Gessner, N. Aliabadi, E. Begier, T. Biering-Sørensen</i>
E0024	<b>Six-month Immunogenicity of mRNA-1345 RSV Vaccine in Adults Aged ≥60 Years</b> <i>M. Desai* (Cambridge, United States), E. Comstock, L. Lan, A. Kapoor, F. She, C. Reuter, J. Goswami, F. Priddy, R. Das</i>
E0025	<b>Comparative Immune Responses to Homologous and Heterologous SARS-CoV-2 Vaccination Using DNA and Protein Platforms</b> <i>S. Prieto Martín Gil* (Madrid, Spain), S. Prieto Martín Gil, M. López Siles, J.A. Infantes Lorenzo, E. Lorente, D. Fousteris, B. Cano Castaño, A. Tajuelo, D. López, V. Mas Lloret, E. Gato, A. Pérez, M.J. Mcconnell</i>
E0026	<b>Quantitative correlates of protection against SARS-CoV-2 variants using individual-level reconstructed antibody kinetics</b> <i>T. Russell* (London, United Kingdom), E.C. Wall, A.J. Kucharski, J. Hellewell, O. Hague, H. Townsley, J. Gahir, M. Shawe-Taylor, D. Greenwood, R. Harvey, M.Y. Wu, D.L. Bauer, E.J. Carr</i>
E0027	<b>Effectiveness of the 2023-24 seasonal influenza vaccine in UK healthcare workers: results from the SIREN prospective cohort study</b> <i>L. Mcgeoch* (London, United Kingdom), S. Foulkes, H. Whitaker, K. Munro, J. Khawam, D. Sparkes, A. Charlett, C. Brown, A. Atti, J. Islam, S. Hopkins, N. Andrews, V. Hall</i>
E0028	<b>Immunogenicity and safety of second COVID-19 booster and Influenza vaccination coadministration.</b> <i>Wagenhäuser* (Würzburg, Germany), J. Reusch, J. Mees, A. Gabel, N. Petri, M. Krone</i>
E0029	<b>The degree of immunization against the Measles virus of the infant population in Sibiu county, Romania</b> <i>S. Cristea* (Sibiu, Romania), C. Grigore</i>

EF004	08:30 – 09:30	Arena 3
	ePoster Flash Session	

ANT

## Pharmacology from bench to the bedside

Chair *Alina Karoline Nussbaumer-Pröll (Wien, Österreich, Austria)*

E0030	<i>Enterococcus faecalis</i> impairs <i>Escherichia coli</i>
-------	--

		response to antibiotics in a dual-species intracellular infection model <i>F. Van Bambeke* (Brussels, Belgium), G. Wang</i>
E0031		In vitro investigations of ceftazidime-avibactam and fosfomycin against carbapenemase-producing <i>Enterobacterales</i> clinical isolates <i>M. Martens* (Hamburg, Germany), F.M. Docobo-Perez, C. Sauco Carballo, J. Rodriguez-Baño, S. Marchand, L. Keomany, I. Portillo-Calderon, M. Gianella, S. Ambretti, B. Secci, S.G. Wicha</i>
E0032		<i>In vivo</i> activity and PK of the novel siderophore-cephalosporin AR-2126 in a lethal lung infection model in mice infected with a carbapenem-resistant <i>Pseudomonas aeruginosa</i> following subcutaneous administration <i>W. Wicha* (Bruck An Der Leitha, Austria), S. Paukner</i>
E0033		Synergistic Potency Unveiled: $\beta$ -Lactam and $\beta$ -Lactamase Inhibitor Combination against <i>Mycobacterium abscessus</i> with Dual Action of $\beta$ -Lactamase Inhibition and Multi-Target Receptor Inactivation <i>E. Shin* (Cleveland, United States), K.M. Dousa, C.R. Bethel, M. Nantongo, S.M. Holland, E.J. Rubin, J.B. Bulitta, K. Barry, R.A. Bonomo</i>
E0034		Pharmacokinetic/pharmacodynamic evaluation of benzoxaborole MRX-5 in mouse pneumonia model with <i>Mycobacterium abscessus</i> infection <i>W. Wang* (Foster City, United States), S. Liu, B. Rimal, Y. Xu, Q. Dai, G. Lamichhane</i>
E0035		Pharmacokinetic/pharmacodynamic modelling of immune response and meropenem activity in immunocompetent and neutropenic mouse lung infection models <i>R. Saporta* (Uppsala, Sweden), N. Tassi, O. Ticha, V. Biordi, A. Ginosyan, I. Loryan, E.I. Nielsen, I. Bekeredjian-Ding, B. Kerscher, L.E. Friberg</i>
E0036		Implementation of a model-based nomogram for amoxicillin precision dosing in patients suspected of infective endocarditis: preliminary results of the NOMOBA-AMX multicentre study <i>P. Le Turnier* (Cayenne, French Guiana), S. Jamard, A. Lorleac'h, C. Deschanvres, F. Andry, A. Coste, P. Danneels, T. Guimard, P. Gicquel, H. Harrabi, N. Issa, J.B. Lainé, R. Lamberet, A. Le Bot, M. Maillet, P. Petitgas, V. Rabier, S. Sunder, J.M. Turmel, D. Boutoille, C. Delaunay, M. Grégoire, A.G. Leroy, M. Wargny, R. Bellouard</i>
E0037		No time to waste: hospital-wide assessment of IV-vial and line residuals and impact on target attainment. <i>D. Vanneste* (Leuven, Belgium), M. Gijssen, W. Zhang, O. Elkayal, V. Caubergs, J. Wauters, S. Desmet, E. Dreesen, I. Spriet</i>
E0038		Population pharmacokinetic modelling of colistin in critically-ill patients on sustained low-efficiency dialysis: implications for dose selection <i>D. Fuhs* (Parkville, Australia), A. Boonyasiri, T. Naorungroj, L. Wang, J. Wang, R. Ratanarat, J. Li, R. Nation, T. Visanu, C. Landersdorfer</i>

SY034	08:30 – 10:30	Hall 10
	2-hour Symposium	
	IPC	
Endoscopy: infection risks and mitigation		
Chairs <i>Elisabeth Presterl (Vienna, Austria)</i> <i>Gordon Ramage (Glasgow, United Kingdom)</i>		
S0097	08:30	Should we be concerned about infection from contaminated endoscopes? <i>Claire Aumeran (Clermont-Ferrand, France)</i>
S0098	09:00	Prevention of multidrug-resistant infections from contaminated duodenoscopes <i>Margreet C. Vos (Rotterdam, Netherlands)</i>
S0099	09:30	Understanding the causes of medical device contamination: it is all biofilm! <i>Roberto Rusconi (Milan, Italy)</i>
S0100	10:00	Does the European medical Device Regulation bring us safer duodenoscopes? <i>Markus Hell (Salzburg, Austria)</i>

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Nosocomial Infections (ESGNI)

# ESCMID Global 2025 - Programme

OS002	08:30 – 10:30	Hall 11
	2-hour Oral Session	
	<div>DX</div>	
Translating metagenomics into clinical practice		
Chairs	Benjamin Peter Howden (Parkville (Victoria), Australia) Paula Mölling (Örebro, Sweden)	
00011	<b>Nanopore metagenomic sequencing for rapid bloodstream infection diagnostics evaluated in a prospective observational study</b> <i>H.L. Nielsen* (Aalborg, Denmark), C. Thygesen, K.K. Søgaard, A.B. Sørensen, S.M. Karst, A.L. Krarup, M. Albertsen</i>	
00012	<b>Interpretative Criteria for Adjudicating Clinical Significance to Next-Generation Sequencing Results from Bronchial-alveolar Lavage and Bronchial Wash.</b> <i>J. Alexander* (Orlando, United States), A. Charles</i>	
00013	<b>Implementing same-day respiratory metagenomic diagnostics in paediatric intensive care</b> <i>R. Hammond* (London, United Kingdom), A. Kopec, J. Brown, J. Hatcher, A. Alcolea-Medina, R. Batra, D. Ward, L.B. Snell, J. Breuer</i>	
00014	<b>Detection of pathogenic microorganisms using metagenomic next-generation sequencing in ICU patients with ongoing antibiotic therapy</b> <i>T. Schroeder* (Nuertingen, Germany), M. Eliwi Alsaffan, A. Dervishi, P. Kawaletz, H. Stäudle</i>	
00015	<b>Analysis of metagenomic pathogen detection compared to conventional diagnostics: clinical usage and relevance for patient outcomes</b> <i>E. Siegel* (Mainz, Germany), V. Bianco-Wilhelmi, S. Koch, C. Seckert, C. Hamm, D. Teschner, O. Kriege, D. Grimm, I. Sagoschen, D. Schreiner, M. Bodenstein, G. Cakas, S. Hagge, S. Vieira-Silva, T. Sparwasser</i>	
00016	<b>Same-day pan-microbial metagenomics for personalized therapy and pathogen surveillance on the intensive care unit: a single-centre prospective study</b> <i>L.B. Snell* (London, United Kingdom), A. Alcolea-Medina, G. Humayun, N. Al-Yaakoubi, D. Ward, C. Alder, V. Patel, F. Vivian, C. Meadows, W. Duncan, R. Paul, N. Barrett, R. Batra, J. Edgeworth, J. Whitehorn, G. Nebbia</i>	
00017	<b>Evaluation of the diagnostic efficacy of targeted next-generation sequencing in the detection of pathogens in bronchoalveolar lavage fluid from patients with lower respiratory tract infections in ICU</b> <i>B. Ran* (Taiyuan, China), Y. Liu, X. Wu, X. Lin, X. Li, Q. Zhan, C. Wang, L. Huang, T. Zhai, Y. Cai, Y. Song, Q. Zhang, C. Zhang, J. Hao, L. Jin, Z. Huang</i>	
00018	<b>Prognostic and diagnostic value of Next-generation sequencing in female reproductive tract infection and HPV persistence</b> <i>C. Peng* (Shiyan, China), S. Qi, C. Jiachang, P. Chunyan, W. Taiquan, X. Xianru, Y. Jianying, Y. Qirong, Z. Pengyuan, L. Jun</i>	
00019	<b>A promising approach to rapid, non-culture diagnosis of invasive fungal infections (IFIs) by targeted next-generation sequencing (tNGS)</b> <i>M.H. Nguyen* (Pittsburgh, United States), H. Badrane, B.A. Stevens, S. Cheng, G. Guigon, E. Santiago, M. Rambaud, B. Hao, E. Driscoll, W. Maynard, C. Clancy</i>	
00020	<b>Implementation of Clinical Metagenomics in France: Insights from a Five-Years Study</b> <i>M. Dutkiewicz* (Paris, France), T. Ghelfenstein-Ferreira, L. Feghoul, S. Mercier-Delarue, A. Senhaji, A.L. Munier, F. Caméléna, J. Le Goff, M. Salmona</i>	

SY035	08:30 – 10:30	Hall 12
	2-hour Symposium	
	<div>PHEI</div>	

Barriers to TB/HIV elimination in low- and high-incidence settings		
Chair	Daria Podlekareva (Copenhagen, Denmark)	
S0101	08:30	<b>HIV and TB epidemic: the storm hasn't subsided yet</b> <i>Tetiana Koval (Poltava, Ukraine)</i>
S0102	09:00	<b>Approaches for latent and active TB screening in</b>

		<b>people living with HIV</b> <i>Raimonda Matulionyte (Vilnius, Lithuania)</i>
S0103	09:30	<b>Integration of HIV and TB care to improve patient outcome in resource-limited settings</b> <i>Akaki Abutidze (Tbilisi, Georgia)</i>
S0104	10:00	<b>How researchers can influence policy and practice in HIV/TB care</b> <i>Jens D. Lundgren (Copenhagen, Denmark)</i>

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), Euroguidelines in Central and Eastern Europe Network Group

EW041	08:30 – 10:30	Hall 13
	Educational Session	

CLN DX VAX

**RSV infections: diagnosis, surveillance and treatment in the advent of vaccines**

*Chair* *Monika Redlberger-Fritz (Vienna, Austria)*

W0126	08:30	<b>Costs of RSV infection, compared to other respiratory viruses</b> <i>Barbara Rath (Besançon, France)</i>
W0127	08:50	<b>Virology and host interactions of RSV</b>
W0128	09:10	<b>RSV surveillance in the EU/EEA in the vaccine era</b> <i>Eeva Broberg (Solna, Sweden)</i>
W0129	09:30	<b>RSV fusion inhibitors and monoclonals: current status and future developments</b> <i>Peter Openshaw (London, United Kingdom)</i>

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Society for Influenza and other Respiratory Viruses (ISIRV)

EW042	08:30 – 10:30	Hall 14
	Educational Session	

CLN

**Traumatic wound infections: diagnosis and treatment options**

*Chairs* *Amparo Fernández-Rodríguez (Madrid, Spain)*  
*Veroniek Saegeman (Sint-Niklaas, Belgium)*

W0130	08:30	<b>Multidrug-resistant infections after trauma in warzone</b> <i>Shehan Hettiaratchy (Hampton, United Kingdom)</i>
W0131	08:50	<b>Fungal infections during natural disasters</b> <i>Anuradha Chowdhary (New Delhi, India)</i>
W0132	09:10	<b>Bacteriophage therapy for multidrug-resistant wound infections in trauma</b> <i>Tristan Ferry (Lyon, France)</i>
W0133	09:30	<b>Infection of burn wounds</b> <i>Nur Benzonana (Istanbul, Türkiye)</i>

Co-organised with: ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA), SEIMC (Sociedad Española Enfermedades Infecciosas Microbiología Clínica), International Society of Antimicrobial Chemotherapy (ISAC)

SY037	08:30 – 10:30	Hall 16
	2-hour Symposium	

CLN DX

**Unveiling the challenges: nosocomial infections in ECMO-supported patients**

*Chairs* *Antonios Katsounas (Bochum, Germany)*  
*Jordi Riera (Barcelona, Spain)*

S0109	08:30	<b>Source of infection and pathogens</b> <i>Christian Eckmann (Hannover, Germany)</i>
S0110	09:00	<b>Prophylaxis and empiric treatment</b> <i>Giacomo Grasselli (Besana In Brianza, Italy)</i>
S0111	09:30	<b>Diagnostic criteria and definitions</b> <i>Graeme Maclaren (Singapore, Singapore)</i>
S0112	10:00	<b>Microbial films</b> <i>Marta Hernández-Meneses (Barcelona, Spain)</i>

Co-organised with: European Extracorporeal Life Support Organization (EuroELSO)

# ESCMID Global 2025 - Programme

EW039		08:30 – 10:30		Hall 2
		Educational Session		
		CLN DX		
Are urinary tract infections still the same?				
Chairs		Suzanne Geerlings (Amsterdam, Netherlands) Agnes Maria Sonnevend (Pécs, Hungary)		
W0118	08:30	Update on paediatric UTI	Michael Buettcher (Luzern, Switzerland)	
W0119	08:50	Diagnosis and treatment of UTI in the era of antimicrobial resistance	Jennifer Kranz (Aachen, Germany)	
W0120	09:10	Can UTI be prevented?	Chris Harding (Newcastle Upon Tyne, United Kingdom)	
W0121	09:30	Fungal and parasitic infections of the urinary tract	Gladys Mbwanji (Mwanza, Tanzania, United republic of)	
EW040		08:30 – 10:30		Hall 3
		Educational Session		
		ANT CLN		
OPAT: from aged wine to new vintage				
Chairs		Birgit Koch (Rotterdam, Netherlands) Sonia Luque (Barcelona, Spain)		
W0122	08:30	OPAT: principles, practice and checklists	Charlotte Quintens (Leuven, Belgium)	
W0123	08:50	COPAT: complex outpatient parenteral antimicrobial therapy	Ronald Andrew Seaton (Glasgow, United Kingdom)	
W0124	09:10	Antimicrobial stability and other challenges for OPAT practice?	Mark Gilchrist (London, United Kingdom)	
W0125	09:30	New OPAT safety and efficacy data to guide practice	Matthew Rawlins (Murdoch, Australia)	
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), Society of Infectious Diseases Pharmacists (SIDP)				
EW038		08:30 – 11:30		Hall 4
		Educational Session		
		AMR DX		
EUCAST Educational Workshop				
Chairs		Marlene Amara (Le Chesnay Cedex, France) Alasdair P. Macgowan (Bristol, United Kingdom)		
W0113	08:30	EUCAST update	Sören G. Gatermann (Bochum, Germany)	
W0114	08:50	Setting clinical breakpoints, assessing evidence	Anouk Edwina Muller (The Hague, Netherlands)	
W0115	09:10	Benzylpenicillin susceptibility testing of <i>S. pneumoniae</i> by disk diffusion	Gunnar Kahlmeter (Tävelsås, Sweden)	
W0116	09:30	What to do when there are no breakpoints	Barbara Juliane Holzknecht (Copenhagen, Denmark)	
W0117	09:50	Detection of resistance mechanisms	Christian Giske (Stockholm, Sweden)	
Co-organised with: EUCAST Steering Committee				
OS001		08:30 – 10:30		Hall 5
		2-hour Oral Session		
		AMR PHEI TRN		
One Health means resistance everywhere				
Chairs		Alessandra Carattoli (Rome, Italy) Prasannakumar Palanikumar (Vellore, India)		



O0001	<b>Decoding the role of <i>bla</i><sub>CPE</sub>-carrying plasmids on wings: A holistic view using the One Health approach</b> <i>S.A. Martínez-Álvarez* (Logrono, Spain), P. Châtre, T. Cardona-Cabrera, P. François, U. Höfle, M. Zarazaga, J.Y. Madec, M. Haenni, C. Torres</i>
O0002	<b>A novel isolation room model leveraging culture-independent Hi-C metagenomics for tracking antimicrobial resistance transmission between patients and hospital environmental reservoirs</b> <i>V. Koh* (Singapore, Singapore), R. Cabrera, J. Chua, J.S. Lee, N.S.B. Haidi Fitri, Z.X. Tan, X. Huan, N.M. Thevasagayam, T.K.B. Lee, K. Marimuthu, O.T. Ng</i>
O0003	<b>Deciphering the pathogenic potentials and epidemiological identities of <i>Staphylococcus pseudintermedius</i> colonizing companion dogs in Sao Paulo</b> <i>I.B. Moses* (Sao Paulo, Brazil), L. Sartori, D.A. Henriques, M.M. Marini, F.M. Lima, R.X. Espinosa, I. Orlandino Da Silva, F.F. Santos, L. Gonzaga, A.T. Ribeiro De Vasconcelos, A.C. Gales</i>
O0004	<b>Recent progress towards integrated surveillance of antimicrobial resistance in France</b> <i>L. Collineau* (Lyon, France), S. Bareille, G. Birgand, L. Lacmago, B. Lange, O. Lemenand, C. Chauvin</i>
O0005	<b>Exploring the plasmidome of 3rd generation cephalosporin-resistant Enterobacterales in wild birds: Insights into horizontal gene transfer and AMR dissemination</b> <i>B. Timmer* (Debrecen, Hungary), L. Miló, B. Koleszár, C. Freytag, Á. Lovas-Kiss, L. Laczkó, G. Kardos</i>
O0006	<b>Emergence of mobile colistin resistance in <i>Klebsiella</i> at human-animal-environment interface in Bangladesh</b> <i>S. Rahman* (Oxford, United Kingdom), A. Pondit, J. Parkhill, S. Saha, S.M.R. Islam, P.I. Disha, S.A. Nasreen, M.A.K. Azad, T. Walsh, R. Farzana</i>
O0007	<b>Unveiling the invisible: antimicrobial resistance genes and pathogenic microbial diversity in sewage of North India's largest industrial hub, A metagenomic perspective</b> <i>I. Singh* (Chandigarh, India), R. Sharma, A. Arora, B. Mohan, N. Taneja</i>
O0008	<b>Culturomics as a tool for ONE HEALTH approach: Unveiling the role of unknown microorganisms as antibiotic resistance carriers in wastewater samples</b> <i>E. Ouranou* (Heraklion, Greece), A. Psaroulaki, D. Chochlakis, M. Malliarou, K. Tryfinopoulou, A. Ntoula, E. Intze, I. Lagouvardos</i>
O0009	<b>One Health intervention impacts on antibiotic resistance in Denmark, England and Senegal: A mathematical model comparison</b> <i>G. Knight* (London, United Kingdom), R. Booton, J.V. Robotham, K. Aluzaite, D. Belay, J. Guitian, M. Dione, E. Emes</i>
O0010	<b>Clinically important sequence types and resistance genes in <i>Enterobacteriaceae</i> from coastal environments and gulls</b> <i>V. Silva* (Lisbon, Portugal), M. Quintelas, M. Caniça, R. Rivière, P. Poeta, G. Igrejas</i>

SY032	08:30 – 10:30	Hall 7
	2-hour Symposium	
	TRN	
New insights into <i>Candida</i> pathogenesis		
<i>Chairs</i> <i>Aleksandra Barac (Belgrade, Serbia)</i> <i>Joshua Nosanchuk (Bronx, United States)</i>		
S0089	08:30	<b>Insights into the evolution of <i>Candida</i> under antifungal pressure</b> <i>Attila Gacser (Szeged, Hungary)</i>
S0090	09:00	<b>How do <i>Candida</i> extracellular vesicles modify virulence during disease?</b> <i>Leonardo Nimrichter (Rio De Janeiro, Brazil)</i>
S0091	09:30	<b>The commensal to pathogen transition: kind to killer</b> <i>Ilse D. Jacobsen (Jena, Germany)</i>
S0092	10:00	<b>Fungal-bacterial interactions: who wins?</b> <i>Rebecca Hall (Canterbury, United Kingdom)</i>

# ESCMID Global 2025 - Programme

SY033

08:30 – 10:30

Hall 8

2-hour Symposium

TRN

## Single-cell approaches to dissect cellular phenotypic heterogeneity of bacterial pathogen populations.

Chairs

Christian Stephan Lentz (Tromsø, Norway)  
Annelies Zinkernagel (Zurich, Switzerland)

- S0093

08:30

Adaptive evolution and phenotypic heterogeneity of bacterial pathogens during infections  
*Christoph Ernst (Cologne, Germany)*
- S0094

09:00

Single-cell imaging and heterogeneity in antimicrobial resistance  
*Stefano Pagliara (Exeter, United Kingdom)*
- S0095

09:30

Single-cell RNAseq and heterogeneity in bacterial transcription  
*Anna Kuchina (Seattle, United States)*
- S0096

10:00

Dissecting the function of individual bacteria in their spatial context  
*Knut Drescher (Basel, Switzerland)*

SY043

09:30 – 10:30

Hall 1

1-hour Symposium

IPC

## Year in infection control

Chairs

Nico Tom Mutters (Bonn, Germany)  
Ermira Tartari (Msida, Malta)

- S0134

09:30

Andrew James Stewardson (Melbourne, Victoria, Australia)
- S0135

10:00

Kalisvar Marimuthu (Singapore, Singapore)

EF005

09:30 – 10:30

Arena 2

ePoster Flash Session

CLN DX

## It's all in the blood

Chair

Colin R. Mackenzie (Neuss, Germany)

- E0039

Limited delayed incubation of blood culture bottles has limited effect on yield and time-to-positivity  
*L. Hardy\* (Antwerp, Belgium), A.S. Heroes, E. Genbrugge, B. Gleeson, C. Ferreyra, T. Vermoesen, E. Corsmit, B. De Smet*
- E0040

Unnecessary clinical interventions due to blood culture contamination in a large Canadian hospital network  
*C. Hall\* (Hamilton, Canada), C. Fuller, S. Ramondino, C. Main*
- E0041

Utility of sigmoidal growth curve when no organisms are seen on Gram stain in positive blood cultures  
*D. Crilly\* (London, United Kingdom), A. Bapat, J. Youngs, G. Maloney, E. Drakes*
- E0042

Clinical microbiology laboratory consultancy to optimize blood culture workflow: Analysis of results  
*C. Magri\* (Rome, Italy), C. Magri, G. Menchinelli, D. Squitieri, B. Fiori, M. Cacaci, B. Posteraro, G. De Angelis, M. Sanguinetti*
- E0043

Comparison of Syndromic Sepsis Panel and Standard Blood Culture Results: Contribution to Patient Management  
*S. Buyukberber\* (Ankara, Türkiye), S. Aydogan, B. Dinc, N. Coplu, S. Turan, S.S. Yakin, H. Dal, T. Kayan*
- E0044

Predicting blood culture positivity using machine learning with complete blood and differential counts in a tertiary care hospital of Türkiye  
*Ö. Türkmen Recen\* (Izmir, Türkiye), M. Kiplapınar, H. Özdemir, S. Kurutepe, H. Gazi*
- E0045

Performance of direct pathogen and  $\beta$ -lactamase detection workflow using MALDI-TOF MS from positive blood culture specimens  
*K. Kosai\* (Nagasaki, Japan), Y. Kawamoto, K. Yanagihara*
- E0046

Waiting for follow-up blood cultures is not always necessary for diagnosis of central line-associated bloodstream infections  
*L. Van Balen\* (Maastricht, Netherlands), R. Koeck*

**E0047** Economic and health gains associated with the adoption of the 2-hour phenotypic antimicrobial susceptibility testing in patients with bloodstream infection in Europe *C. Pina-Vaz\* (Oporto, Portugal), F. Aragão, C. Palos, C. Mimoso, I. Neves, M.J. Janeiro, J.A. Paiva*

**EF006** 09:30 – 10:30 **Arena 4**

AMR ANT CLN ePoster Flash Session

**Emerging developments in antifungal pharmacology**

*Chair Roger Brüggemann (Nijmegen, Netherlands)*

**E0048** **NATURE-US: the natural history of antifungal failure in invasive candidiasis** *L. Ostrosky-Zeichner\* (Houston, United States), P.G. Pappas, M.H. Miceli, A. Spec, C.Z. Grimes, F. Lewis, M. Mammadova, E. McKie, M. Middle, M. Kordalewska, D.S. Perlin, D.P. Kontoyiannis, O.A. Cornely, J. Vazquez, D. Angulo*

**E0049** **The antidepressant vortioxetine enhances resistance toward multiple azoles** *S. Rizzo\* (Rome, Italy), M. Cacaci, V. Di Pilato, S. Di Bella, U. Albert, B. Posteraro, M. Sanguinetti, F. Bugli, R. Torelli*

**E0050** **Enhancing Isavuconazole Pharmacokinetics: A Comprehensive Population (PPK) Model from Three Phase 3 Trials and Covariate Exploration** *A. Desai\* (Northbrook, United States), L. Kovanda*

**E0051** **Identification of efflux inhibitors for *Candida albicans* through a drug repurposing strategy** *D. Marques\* (Lisbon, Portugal), S. Santos Costa, L. Rodrigues*

**E0052** **Clinical outcomes of micafungin 100 mg vs. 150 mg daily for the treatment of *Candida auris* fungemia** *J. Hou\* (Chicago, IL, United States), Y. Wang, R. Burgos, L. Danziger, E. Drwiega*

**E0053** **Resolution of clinical signs in adults with invasive candidiasis and/or candidaemia treated with rezafungin or caspofungin: ReSTORE and STRIVE trial pooled analysis** *G.R. Thompson\* (Davis, California, United States), A. Soriano, M. Bassetti, P.M. Honore, J. Vazquez, S. Dickerson, O.A. Cornely*

**E0054** **Ibrexafungerp is effective in treatment of patients with candidiasis, including candidaemia, caused by *Candida auris*: a multicentre, open-label study (CARES)** *M.H. Miceli\* (Ann Arbor, United States), T.F. Patterson, D. Juneja, G.R. Thompson III, P. Vergidis, A. Spec, T.J. Walsh, D. Angulo, J. Breed, N. Yaddanapudi, R.S. Siebert, E. McKie, F. Lewis, M. Middle, M. Hoenigl*

**E0055** **High-dose isavuconazole therapy is well-tolerated and significantly improves survival in a fruit fly model of invasive mucormycosis** *S. Wurster\* (Houston, United States), N.D. Albert, N.P. Wiederhold, R.E. Lewis, D.P. Kontoyiannis*

**E0056** **Pharmacokinetics, pharmacodynamics, safety, and efficacy of innovative dosing schedules of liposomal amphotericin B for treatment of experimental invasive pulmonary aspergillosis in persistently neutropenic rabbits** *R. Petraitiene\* (New York, United States), E. Naing, A. Garcia, V. Zigmantaite, R. Grigaleviciute, A. Pockevicius, M. Zimmerman, A.H. Groll, T.J. Walsh, V. Petraitis*

**FO050** 11:00 – 12:00 **Arena 1**

PHEI Open Forum

**HIV: a global ethical Conundrum**

*Chair Seif Al-Abri (Muscat, Oman)*

**F0147** 11:00 **HIV, from key population to general population: a Pandora's Box** *Syed Faisal Mahmood (Karachi, Pakistan)*

**F0148** 11:10 **Ethical considerations in preventing mother-to-child HIV transmission** *Glory Alexander (Bangalore, India)*

**F0149** 11:20 **HIV drug trials in Africa: ethical concerns** *Shah Reena*

# ESCMID Global 2025 - Programme

(Nairobi, Kenya)

**F0150      11:30      HIV-related stigma and discrimination in the healthcare setting** *Teymur Noori (Stockholm, Sweden)*

Co-organised with: ESCMID Ethics Advisory Committee (EEAC)

**EF014      11:00 – 12:00      Arena 2**  
ePoster Flash Session

IPC   PHEI

## Infection control and prevention around the World

*Chair      Divyashree Shanthamurthy (Mumbai, India)*

**E0092      WHO Global Survey on Infection Prevention and Control Minimum Requirements: Laying the Foundation for 2030 Global Targets** *P. Bischoff\* (Geneva, Switzerland), S. Tomczyk, G. Satta, E. Tartari, A. Meinen, P. Rogers, L. Cihambanya, C.R. Ana Paula, I. Hewedy, Z. Li, P. Ramon-Pardo, A. Singh, B. Allegranzi*

**E0093      Healthcare-associated infections in african intensive care units: A multicentre prospective cohort study** *B. Gaye\* (Dakar, Senegal), N. Madani, J. Ben Khliil, A. Ben Souissi, B. Seydina Alouine, G.F. Otiobanda, R.M. Hamidi, M.S. Chaibou, P.A. Leye, L. Oualili, T. Dendane, K. Abidi, M. Bouaziz, R. Ammar, M. Elombila, W. Najja, M. Kahloul, R. Herch, R. Tourni, E. Ennouri, M. Boussarsar, N. Ben Mrad, A. Soumare, T.M. Diop, N. Brahmi, A. Ben Jazia, H. Ben Ghezala, A.A. Messadi, H. Fredj, A. Mokline, S. Abdellatif, T. Badis, L. Messaoud, A. Bouzid, S. Feki, H. Cheikhrouhou, A. Hachimi, B. Khemlich, F.Y. Bah, A.B. Faye, L. Ouanes Besbes, Z. Hammouda, M.S. Mebazaa, S. Elatrous, S. Ayed, W. Sellami, A. Ben Amri, M. Ferjani, O. Bouhamed, N. Hajjem, H. Daddy, M. Gagara Mayaou, B. Marou Soumana, B. Diallo, B. Gafsi, F. Ben Salem, E. Milli, B. Idali, T. Merhabene, N. Ben Slimane, F. Kaaniche Medhioub, R. Allala, C. Kaddour, N. Baffoun, R. Hammami, H. Allouche, H. Ghadhoun, S. Soui, H. Hmouda, R. Ben Dabebiss, A. Sidibe, N. Diani, N. Benmouhoub, M.S. Ado Zakari, O. Mamane Nassirou, O. Bachar Loukoumi, A. Ben Fraj, H. Jaoua, K. Ben Fadhl, T. Abdoulaye, T. Bagouma, H. Arfaoui, O. Kaabachi, O. Nasri, C. Ben Massoud, M. Niandou, M. Nanzir Sanoussi, H. Bassama, A. Jebri, H. Ben Fradj, A. Hafyene, N. Soraa, O. Kechini, A. Felhi, R. Abouqal, Y. Coulibaly*

**E0094      Epidemiology of community-acquired versus hospital-acquired sepsis in acute hospitals in Ireland - 2016-2022.** *E. Liddy\* (Dublin, Ireland), A. Vellinga, D. Amin*

**E0095      Epidemiology of Central Line-Associated Bloodstream Infections (CLABSIs) in a Network of Ten Hospitals across Greece: A 30-Month Surveillance Study – GRIPP-SNF Network** *I. Kopsidas\* (Neo Psychiko, Greece), E. Kourkouni, G.C. Tsopela, D. Kousi, A. Moutou, P. Varda, P. Pantelidou, A. Karaiiskou, D. Kaitelidou, T. Zaoutis, A. Koutsoukou*

**E0096      Characterisation of plasmids disseminating antibiotic resistance in *Klebsiella pneumoniae* isolates from Pretoria, South Africa** *T. Govender\* (Pretoria, South Africa), A. Moultrie, M. Moodley, J. Featherston, M. Mohlamonyane, J. Pitout, T. Hamiwe, T. Lentswe, S. Liknaitzky, K. Salvador-Oke, A. Smith, I. Arshad, M. Said, M. Ehlers, M. Kock*

**E0097      Transmission dynamics of carbapenemase-producing bacteria between hospital and household settings in Benin** *K. Sintondji\* (Abomey-Calavi, Benin), V. Dognon, B. Legba, B.G. Hougbenou, K. Fabiyi, H. Koudokpon, A. Dalsgaard, Y.M.G. Hounmanou*

**E0098      Evaluating the impact of a rapid screening test for carbapenem-resistant organisms in Brazilian intensive care units.** *M. Salomão\* (Sao Paulo Sp, Brazil), B. De Almeida Lessa Castro, C. Loredana P. A. M. Bezerra, E. Lino Dos Santos Junior, C. Lee Luna Fernandes, A. Pereira Funari, S. Bollinger, F. C. Lessa, G. Mahon, M. Westercamp, M. Chiarastelli Salomao*

**E0099      Genomic Insights into the Rapid Rise of *Pseudomonas aeruginosa* ST463: A High-Risk Clone's Adaptive Strategy in China** *X. Dong\**

(Hangzhou, China)

EF0100

**Nanopore long-read only genome assembly for public health surveillance of Enterobacterales bloodstream infections and plasmid epidemiology in England: A pilot study***D. Nagy\** (Oxford, United Kingdom), N. Stoesser, S. Lipworth, V. Pennetta, G. Rodger, K. Hopkins, C. Jones, T. Nexus Study Group, S. Hopkins, D. Crook, A.S. Walker, J. Robotham, K.L. Hopkins, A. Ledda, D. Williams, R. Hope, C.S. Brown

EF015

11:00 – 12:00

Arena 3

ePoster Flash Session

ANT

CLN

DX

**Advances in the diagnosis and treatment of skin, bone, and joint infections**

Chair

Norma Jung (Köln, Germany)

EF0101

**Potential benefits of PET-CT in the management of bone and joint infections in infective endocarditis: a retrospective analysis from the Mayo Clinic***F. Petri\** (Milan, Italy), F. Borronovo, O.K. Mahmoud, R. Igwilo-Alaneme, T. Matsuo, S. El Zein, D. De Simone, A. Gori, E. Berbari

EF0102

**Synovial fluid microRNA biomarkers enable accurate diagnosis of periprosthetic joint infection***B.J.H. Frank\** (Vienna, Austria), T. Krammer, J. Pfeiffer-Vogel, T. Nguyen, A. Diendorfer, M. Hackl, J. Hofstaetter

EF0103

**Diagnostic accuracy of 16S rDNA PCR, multiplex PCR and metagenomic Next-Generation Sequencing in periprosthetic joint infections: a systematic review and meta-analysis***F. Olearo\** (Hamburg, Germany), S. El Zein, E. Portillo M, A. Zapf, H. Rohde, E.F. Berbari, M. Wouthuyzen-Bakker

EF0104

**Comparison of microbiology, management and outcome between patients with native and with post-surgical vertebral osteomyelitis: a 7-year retrospective study***G. Franceschi\** (Modena, Italy), M. Pellegrino, M. Del Monte, A. Bedini, L. Benassi, A. Soffritti, A. Tili, E. Dema, M. Palmisani, A. Veroni, G. Pavesi, M. Cristina

EF0105

**Cefiderocol real-life use in bone and joint infection: a retrospective French multicenter study***A. Diarra\** (Tourcoing, France), V. Delastours, A. Bleibtreu, H. Wille, N. Sayre, N. Rouzic, K. Jaffal, I. Strachinaru, B. Valentin, M. Bermejo, P. Gazeau, A. Baldolli, B. Lefevre, A. Asquier, J. Courjon, R. Larcher, L. Escaut, L. Deconinck, N. Taar, V. Dacquet, T. Ferry, I. Eberl, M. Degrendel, P. Patoz, P.Y. Tortai, O. Robineau, E. Senneville

EF0106

**Real-Life Experience with Dalbavancin as Suppressive Antibiotic Treatment in orthopaedic implant-related infections.***R. Escudero-Sánchez\** (Madrid, Spain), S. De La Villa Martínez, A. Rico Nieto, M. Sanchez-Somolinos, M. Tacias Pitarch, M. Salaver Lletí, M. Correa Ballester, R. Blanez Hernández, E. Calabuig Muñoz, M. Montero Alonso, L. Guío Carrion, J. Gomez Junyent, M.L. Sorli, F. Braojos Sanchez, A. Muñoz Gomez, M.J. Nuñez Oranto, E. Baos Muñoz, R. Manzano Lorenzo, J. Perez-Somarribas Moreno, J.M. Barbero Allende, M.J. Garcia Pais, F.J. Martínez Marco, A. Galeote Rivas, B. De La Torre Escuredo, J. Cobo

EF0107

**Short or Long Antibiotic Regimes in Orthopaedics: the SOLARIO multicentre randomised controlled trial***M. Dudareva\** (Oxford, United Kingdom), M. Scarborough, M. McNally, M. Kumin, C. Scarborough, W. Vach, J. Ferguson

EF0108

**Clinical and Antibacterial Diversity of *Staphylococcal* Phenotypes in Skin and Soft Tissue Infections: A Resource-Limited Country Perspective.***F. Zeeshan\** (Karachi, Pakistan), A. Naeem, F. Uddin

EF0109

**Discrepancy between clinical-radiological diagnosis and surgical confirmation in 62 patients undergoing fasciotomy for suspected necrotizing fasciitis: a 11-year retrospective study.***F. Romani\** (Modena, Italy), A. Bedini, A. Spadoni, G. Manzini, G. Franceschi, B. Fontana, M. Sarti, C. Mussini

# ESCMID Global 2025 - Programme

EF016

11:00 – 12:00

Arena 4

AMR

CLN

PHEI

ePoster Flash Session

## Rising threats: antimicrobial resistance in STIs

Chair

Marcos Rust (Feldkirch, Austria)

- E0110
- Important rise of antibiotic resistance of *Mycoplasma genitalium*, a sexually transmitted pathogen, in a French University hospital *F. Doucet Populaire\** (Clamart, France), *W. Ben Nejma, C. Benet, M. Grimaldi, I. Kansau, S. Pozzi-Gaudin, C. Guillet-Caruba, N. Bourgeois-Nicolaos*
- E0111
- Molecular characterization of antimicrobial resistance and genotyping of *Mycoplasma genitalium* positive samples of the Lisbon area, Portugal *M. Barros\** (Lisbon, Portugal), *F. Pereira, L. Rodrigues*
- E0112
- Antimicrobial Resistance in *Mycoplasma genitalium*: Surveillance and Management in São Paulo, Brazil *V. Passarelli\** (São Paulo, Brazil), *F. Goldemberg, A. Freitas, C. Picone, C. Lazari, G. Carnevale, M. Thomazella, S. Chamarelli, D. Gennari, C. Pedrozo, G. Hughes, S. Costa*
- E0113
- Impact of genotypic substitutions on treatment failure for *Mycoplasma genitalium* infection *N.B. Bana\** (Milan, Italy), *A. Nava, D. Fanti, C. Vismara, G. Cavazza, E. Di Gennaro, F. Peracchi, L. Rezzonico, A. Mulè, L. Denti, M. Puoti, R. Rossotti*
- E0114
- Macrolide-resistant *Mycoplasma genitalium*: an emerging threat to public health? *J. Ciscar Soriano\** (València, Spain), *J. Ciscar-Soriano, M.D. Gómez-Ruiz, A. Valentín-Martín, A. Hernández-Cabezas, J.L. Lopez-Hontangas*
- E0115
- Comparison of carbapenem MIC in wild-type, MDR and XDR *Neisseria gonorrhoeae* isolates *J. Brousseau\** (Paris, France), *A. Braille, M. Mainardis, F. Meunier, M. Mérimèche, F. Caméléna, B. Berçot*
- E0116
- Unsettling surge in antimicrobial resistance patterns of *Neisseria gonorrhoeae* - A study from national reference centre in India. *D. Sharma\** (Delhi, India), *S. Muralidhar, N. Joshi*
- E0117
- Surveillance of *Neisseria gonorrhoeae* antimicrobial resistance rate and treatment regimes in Singapore from 2014 to 2024 *M. Giovanni\** (Singapore, Singapore), *A.L. Tan, B.K.W. Yeo, M.T.W. Chio, S.S. Goh, S.T. Koh, Y.E. Tan*
- E0118
- Molecular surveillance results of *N. gonorrhoeae* in Korea *K.H. Roh\** (Goyang, Korea, Republic of), *C. Liu, Y.H. Suh, H. Lee, K. Lee*

KN044

11:00 – 12:00

Hall 1

AMR

PHEI

Keynote Lecture

## Asia: an AMR Hot Zone

Chairs

*Giulia De Angelis (Rome, Italy)*  
*Robert Leo Skov (Copenhagen, Denmark)*

K0136

11:00

*David L. Paterson (Singapore, Singapore)*

OS010

11:00 – 12:00

Hall 10

CLN

1-hour Case Session

## Antimicrobial drugs in action

Chairs

*Katy Jeannot (Besançon, France)*  
*Timothy R. Walsh (Oxford, United Kingdom)*

- O0072
- In vivo* cefiderocol resistance due to *cirA* modification during treatment *E. Carretto\** (Reggio Emilia, Italy), *P. Pini, R. Farzana, C. Bedogni, R. Marrollo, P. Nardini, M. Bardaro, N.C. Faccioloongo, S. Mezzadri, T. Walsh*
- O0073
- Long-term outcomes in dalbavancin-treated patients with vascular graft infection. *A. Specklin\** (Reims,



		France), T. Noël, M. Bonnet, A. Duprey, M. Hentzien
O0074		<b>Aztreonam, ceftazidime/avibactam, and tigecycline combination for the management of multi-drug resistant <i>E.coli</i> on peritonitis in a pediatric liver transplant recipient</b> <i>R. Morales Junior*</i> (Cincinnati, United States), V. Juodinis, C. Donini, J. Sampaio
O0075		<b>Early oral antibiotic treatment in patients with post-neurosurgical brain abscesses caused by <i>Cutibacterium acnes</i> – a case series</b> <i>M. Karolyi*</i> (Vienna, Austria), D. Stahl, E. Pawelka, S. Omid, A. Kuran, M. Naegeli, A. Zoufaly, C. Well, S. Fiscoeder, M. Ortler, C. Wenisch
O0076		<b>Meropenem-vaborbactam as intrathecal-sparing therapy for the treatment of carbapenem-resistant <i>K. pneumoniae</i> shunt-related ventriculitis: two case reports</b> <i>G. Giuliano*</i> (Siena, Italy), M. Sambo, P. Castellani, S. Benedetti, F. Tarantino, M. Tumbarello

SY047	11:00 – 12:00	Hall 11
	1-hour Symposium	

How long should contact isolation precautions be continued?		
Chairs	Cansu Cimen (Oldenburg, Germany) Kyriaki Tryfinopoulou (Heraklion, Greece)	

S0141	11:00	<b>Contact isolation in patients with MDR organisms: Why, when, where?</b> <i>Gabriel Birgand</i> (Nantes, France)
S0142	11:30	<b>Is discontinuation of contact precautions associated with an increase in infections?</b> <i>Daniel Diekema</i> (Harpeswell, United States)

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee, Multidisciplinary Joint Committee Infection Control UEMS

ME048	11:00 – 12:00	Hall 12
	Meet-the-Expert	

Cut a long story short: choosing NGS platforms		
--	--	--

M0143	11:00	Etienne Ruppe (Paris, France)
M0144	11:12	Stefan Green (Chicago, United States)

OS011	11:00 – 12:00	Hall 13
	1-hour Oral Session	

Around the lab in 80 ways: a journey through innovative therapeutics		
Chairs	Zuzanna Drulis-Kawa (Wroclaw, Poland) Helena Zemlickova (Prague, Czech Republic)	

O0077		<b>In vivo expression of an mRNA encoded multi-mechanistic mAb combination against <i>Staphylococcus aureus</i> and protection in a disease model</b> <i>C. Tkaczyk*</i> (Gaithersburg, United States), N. Michael, P. Mun Mun, T. George, S. Martin, G. Adam, M. Andal, D. Julie, S. Oleg, B. Elin, Y. Haitao, E. Mark, L. Ashley, D. Antonio, S. Bret
O0078		<b>Hijacking intrinsic resistance in <i>Mycobacterium abscessus</i></b> <i>G. Phelps*</i> (Memphis, United States), S. Kurt, A. Jenner, S. Anderson, T. Jayasinghe, E. Griffith, C. Thompson, L. Yang, B. Wicki, F. Bright, L. Boeck, V. Loudon, R. Lee, A. Wright, W. Wright, O. Grant-Chapman, J. Ochoado, D. Conner, B. Troyer, A. Iverson, J.W. Rosch, B. Schulthess, P. Geeleher, S. Hobbie, B. Meibohm, A. Obregon-Henao, P. Sander, R. Lee
O0079		<b>Tripartite bacteriophage-based strategy to combat human clinical pathogens</b> <i>P. Kalatzis*</i> (Copenhagen, Denmark), R. Ibarra-Chávez, H. Sampson, S. Michniewski, A. Shen, M. Ford, B. Petersen, P. Worning, P. Klement, H.P. Calum, U.M. Singh, A. Millard, M. Clokie, T. Sicheritz-Pontén



# ESCMID Global 2025 - Programme

00080	<b>Eosin Y and Ceragenin combinations for enhanced antimicrobial photodynamic therapy</b> <i>Y. Tekintas*</i> (Cigli, Türkiye), P.B. Savage, M. Ucuncu
00081	<b>Identification of compounds capable of removing established bacterial biofilms</b> <i>T. Inzana*</i> (Brookville, United States), A. Gates, W. Weng, J. Cusumano, Y.J. Lee, N. Vogelaar

ME049	11:00 – 12:00	Hall 14
	Meet-the-Expert	

PRO

## How to perform clinical trials in mycoses?

M0145	11:00	Monica Slavin (Melbourne, Australia)
M0146	11:12	Nkechi Azie (Barrington, United States)
Co-organised with: ESCMID Fungal Infection Study Group (EFISG)		

OS012	11:00 – 12:00	Hall 15
	1-hour Oral Session	

PHEI

## Climate Impact and One Health Approaches Against Infectious Diseases

Chair	Chadia Wannous (Paris, France)
-------	--------------------------------

00082	<b>Airborne Threats: Pollution, Climate, and Respiratory Infections in a Pyrenean setting: The Andorran hospital based respiratory perspective</b> <i>C. Royo-Cebrecos*</i> (Andorra, Andorra), N. Duran Torralbo, D. Vilanova Gonzalez, M. Clusas Antolin, L. Trapero
00083	<b>Effects of climate change on Aedes aegypti abundance and dengue transmission</b> <i>L. Geng*</i> (Singapore, Singapore)
00084	<b>Impact of climate variables on Crimean-Congo hemorrhagic fever in Iran, Iraq, Kazakhstan, and Russia</b> <i>M. Fereidouni*</i> (Jahrom, Iran, Islamic Republic of), D. Bisanzio, I. Lizinfeld, N. Pshenichnaya, G. Abuova, M.R. Shirzadi, H. Abdulghafoor Khaleel, R. Alhilfi, M. Keshtkar-Jahromi
00085	<b>Successful public health and one health response to a high pathogenicity avian influenza outbreak in poultry farms in Victoria, Australia: implications for future planning</b> <i>E. Athan*</i> (Geelong, Australia), A. Hussain, K. Blaney, L. Cardamone, N. Clarke, M. Hayes, M. Muleme, B. Mcnamara, E. Jalil, S. Holwill, C.K. Lim, H. O'brien, E. Layton, A. Fidao, S. Salmon, R. Kinnear
00086	<b>Turning disease surveillance into reality: Using metagenomic sequencing with piggery wastewater</b> <i>M. Muralidhar*</i> (St Lucia, Australia), L. Omaleki, M.N. Naseem, J.R.B. Mesa, C. Turni

OS013	11:00 – 12:00	Hall 16
	1-hour Oral Session	

CLN

DX

## Viral challenges in organ transplantation

Chairs	Ghady Haidar (Pittsburgh, United States) Cristiana Oprea (Bucharest, Romania)
--------	--

00087	<b>Evaluation of an individualized CMV prevention strategy guided by post-transplant CMV-specific cell-mediated immunity in intermediate-risk kidney transplant recipients</b> <i>I. Rodríguez-Goncer*</i> (Madrid, Spain), J.M. Caso, M. Fernández-Ruiz, E. González, N. Polanco, N. Redondo, T. Ruiz-Merlo, R. San-Juan, L.M. Allende, E. Paz-Artal, A. Andrés, F. López-Medrano, J.M. Aguado, I. Rodríguez-Goncer
00088	<b>Real-world Use of Letermovir Prophylaxis for Cytomegalovirus (CMV) Prevention in Non-kidney Transplant Recipients</b> <i>A. Mughrabi*</i> (Rochester, Minnesota, United States), B. Bisoño-Garcia, S. Chesdachai, N. Ranganath, R. Razonable
00089	<b>Real-world administration of maribavir beyond the eight weeks established in the clinical trial</b> <i>D.</i>

*Martínez-Simón\* (Barcelona, Spain), C. Ribera-Puig, M. Bodro, D. Campany, J. Esperalba, I. Los Arcos, P. Clèries-Rovira, A. Padullés, N. Sabé Fernández, M. Tuset, O. Len*

**O0090** **Prediction of BK Polyomavirus nephropathy in kidney transplantation by measuring neutralizing responses in a large cohort of donor and recipients***M. Solís\* (Strasbourg, France), W. Fardi, I. Benotmane, F. Gallais, S. Caillard, S. Fafi-Kremer*

**O0091** **Dengue in solid organ transplant recipients***S.I. Galian\* (Buenos Aires, Argentina), N. Pujato, N.S. Nolis, R. Del Grosso, P. Lopez, G. Aballay, M. Agustin, G. Werber*

---

**SY045** **11:00 – 12:00** **Hall 2**  
 1-hour Symposium

CLN

### What happens following TB infection?

*Chairs Catherine Ong (Singapore, Singapore)  
 Sean Wasserman (London, United Kingdom)*

**S0137** **11:00** **Post-TB disease: burden and treatment strategies***Deborah Chong (London, United Kingdom)*

**S0138** **11:30** **TB sequelae and fungal infection***Helmut Salzer (Linz, Austria)*

**Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), CPAnet**

---

**YIA** **11:00 – 12:00** **Hall 3**  
 Awards

PRO

### Young Investigator Award Session

**A001** **11:00** **Deciphering the pathogenic traits and epidemiological identities of *Staphylococcus pseudintermedius*: an emerging and underestimated zoonotic pathogen***Ikechukwu Benjamin Moses (Abakaliki, Nigeria)*

**A002** **11:12** **Drugs for Vector-borne Infections: Facts and Fibrillations***Xin Hui Chan (Oxford, United Kingdom)*

**A003** **11:24** **Duke criteria for the diagnosis of infective endocarditis in clinical practice: are we there yet?***Matthaios Papadimitriou Olivgeris (Sion, Switzerland)*

**A004** **11:36** **Finding a place for observational studies in infectious diseases research***Anthony Bai (Kingston, Canada)*

**A005** **11:48** **Clearing fungal fog in viral storms: deciphering influenza- and COVID-19-associated pulmonary aspergillosis***Simon Feys (Leuven, Belgium)*

---

**SY046** **11:00 – 12:00** **Hall 5**  
 1-hour Symposium

TRN VAX

### New frontiers in bacterial pathogenesis

*Chairs Silvio Daniel Brugger (Zurich, Switzerland)  
 Abdou Hachani (Melbourne, Australia)*

**S0139** **11:00** **Bacterial infections and cellular immunity***Charlotte Odendall (London, United Kingdom)*

**S0140** **11:20** **Immuno-metabolism in bacterial diseases***Tania Wong (New York, United States)*

---

**OS007** **11:00 – 12:00** **Hall 6**  
 1-hour Oral Session

ANT CLN VAX

### New developments in prophylaxis and treatment of COVID-19

*Chairs Gülsen Özkaya Sahin (Lund, Sweden)  
 Snjezana Zidovec Lepej (Zagreb, Croatia)*

# ESCMID Global 2025 - Programme

O0057	<b>Ensirelvir for the prevention of COVID-19 among household contacts: key subgroup analyses of a randomized, double-blinded, placebo controlled post-exposure prophylaxis study, SCORPIO-PEP</b> <i>F. Hayden* (Virginia, United States), N. Ohmagari, T.W. Clark, M. Shinkai, A.F. Luetkemeyer, P. Sax, W.P. Hanage, K.A. Gebo, H. Ikematsu, K. Izumikawa, C.C. Butler, A. Fukushi, S. Kezbor, H. Sakaguchi, S. Lacey, G. Ichihashi, T. Uehara</i>
O0058	<b>Efficacy of nirmatrelvir/ritonavir on overall COVID-19 related symptoms in immunocompromised adult participants from the EPIC-IC trial</b> <i>R. Mokgokong* (Tadworth, United Kingdom), P. Cislo, E. Tudone, E. Weinstein, J.C. Cappelleri</i>
O0059	<b>COVID-19 patients benefitting from remdesivir for improved survival: a neural network-based approach.</b> <i>T.F. Aiello* (Barcelona, Spain), C. Teijón-Lumbreras, C. Garcia-Vidal, M. Chumbita, M. Rosario, A. Mateu Subirà, O. Peyrony, P. Monzó-Gallo, A. Gallardo-Pizarro, A. Martinez-Urrea, R. Méndez, E. Calbo, M. Ballesterro-Tellez, G. Cuesta-Chasco, M. Marcos, A. Soriano</i>
O0060	<b>Efficacy and safety of sotrovimab vs oral antivirals in omicron waves: a retrospective analysis</b> <i>C. Cacace* (Napoli, Italy), A. Russo, M. Pisaturo, P. Grimaldi, F. Ambrisi, G. Granata, F.G. Numis, N. Coppola</i>
O0061	<b>Pharmacokinetics and immunogenicity of AZD7442 (Tixagevimab/Cilgavimab) in hospitalised COVID-19 patients: results from the DisCoVeRy trial</b> <i>C. Massonnaud* (Paris, France), M. Hites, N. Peiffer-Smadja, T.H.L. Han, G. Carcelain, F. Mentré, F. Ader</i>

OS008	11:00 – 12:00	Hall 7
	1-hour Oral Session	

CLN TRN

## Advancing Malaria Research: From Molecular Insights to Clinical Challenges

<i>Chairs</i>	<i>Kamruddin Ahmed (Kota Kinabalu, Malaysia)</i> <i>Giri Shan Rajahram (Kota Kinabalu, Malaysia)</i>
---------------	---

O0062	<b>Influence of second blood meals on <i>Plasmodium vivax</i> development and infectivity in mosquitoes</b> <i>S. Bantuchai* (Bangkok, Thailand), W. Nguitragool, J. Sattabongkot, C. Kumpitak</i>
O0064	<b>Severe imported <i>Plasmodium falciparum</i> malaria with hyperparasitaemia: evaluation of predictors for critical disease</b> <i>T. Lingscheid* (Berlin, Germany), J. Jochum, P. Tober-Lau, J. Schöllgen, T. Zoller, L.E. Sander, M. Ramharter, F. Kurth</i>
O0065	<b>The current status of <i>Plasmodium falciparum</i> chloroquine resistance transporter gene (K76T) and <i>Plasmodium falciparum</i> multi-drug resistance gene 1 (N86Y) in Cameroon</b> <i>M. Fru* (Buea, Cameroon)</i>
O0066	<b>SOFA score vs WHO severity criteria to guide antimalarial treatment - 10 years of imported malaria cases in a UK tertiary centre reviewed</b> <i>E. Savory* (Cambridge, United Kingdom), M. Routledge, B. Warne, E. Moore, D. Sparkes</i>

OS009	11:00 – 12:00	Hall 8
	1-hour Case Session	

CLN

## Osteoarticular uninvited guests

<i>Chairs</i>	<i>Tiziana Ascione (Naples, Italy)</i> <i>Jaime Esteban (Madrid, Spain)</i>
---------------	--

O0067	<b>Antibiotic-refractory oligoarthritis in an adolescent caused by <i>Borrelia bavariensis</i> in Croatia</b> <i>N. Krajcar* (Zagreb, Croatia), L. Stemberger Marić, M. Vrdoljak Pažur, S. Roglić, R. Beck, G. Tešović</i>
O0068	<b>Progression of vertebral echinococcosis despite radiotherapy treatment</b> <i>M. González-Sanz* (Madrid, Spain), O. Martín, A. Romero-Alegría, M. Belhassen, S. Chamorro Tojeiro, D. Gayoso Cantero, F. Norman, B. Monge Maillo, C. Crespillo-Andújar, M.D.</i>

Corbacho-Loarte, S. De La Fuente-Herranz, J. Cobo Soriano, J. Urbano, M. Martín Martín, J.A. Pérez-Molina

- O0069** **Two cases of septic osteoarthritis of *Cutibacterium acnes* detected by 16S rRNA gene sequencing in immunocompetent adolescents***H. Okuno\** (Osaka, Japan), *K. Shiota, K. Amo*
- O0070** **A UK case of Melioidosis with osteomyelitis two years after geographical exposure***C. Darlow\** (Liverpool, United Kingdom), *L. Swithenbank, R. Taggart, V. Owen, N. Wong, S. Woolley, W.D. Harrison, L. Ratcliffe, J. Lewis*
- O0071** **When Infection Masquerades as Malignancy: A Case of Disseminated *Mycobacterium fortuitum* complex infection with Mixed Osteoblastic and Osteolytic Lesions and Lymphadenopathy in Anti-IFN- $\gamma$  Immunodeficiency Syndrome***N. Hiranburana\** (Bangkok, Thailand), *S. Khahakaew, K. Meesilpavikkai, M. Satja, G. Suwanpimolkul*

**LB001** **11:00 – 12:00** **Hall 9**  
1-hour Oral Session

**Advances in vaccine effectiveness for viral respiratory infections**

*Chair* *Jean Paul Stahl (Corenc, France)*

- L0001** **Immunogenicity of JN.1- and KP.2-encoding mRNA COVID-19 vaccines against JN.1 SARS-CoV-2 sublineages in adult participants***A. Figueroa\** (Cambridge, United States), *D. Edwards, K. Johnson, D. Motefiori, B. Girard, S. Hack, X. Cao, E. De Windt*
- L0002** **JN.1-adapted vaccine effectiveness against COVID-19 hospitalisation in Europe: a test-negative case-control study using id.DRIVE***H.R. Volkman\** (New York, United States), *L. De Munter, J.L. Nguyen, T.M.P. Tran, C. Marques, E. Mesfun-Kap, L. Choi, L. Drikite, S. Valluri, J.V. Hernandez-Villena, J. Yang, I. Casas, E. Martro, B. Gruner, G. Icardi, A. Mira-Iglesias, C.M. Oñoro López, O. Pares-Badell, A. Orrico-Sanchez, S. Otero-Romero, A. Riva, A. Torres, F. Martinon Torres, L. Jodar, J.M. McLaughlin, K. Bollaerts*
- L0003** **Real-world effectiveness of 20-valent pneumococcal conjugate vaccine among adults  $\geq 65$  years of age in the United States***A. Miles\** (New York, United States), *J.T. Vietri, S. Rosenstock, H. Li, J. Vojcic, L.R. Grant, A. Randall, B.D. Gessner, P. Balmer, A. Cane, P. Peyrani*
- L0004** **Safety and immunogenicity of the MERS vaccine, ChAdOx1 MERS, in older adults with and without prior ChAdOx1 exposure***D. Jenkin\** (Oxford, United Kingdom), *E. Sheehan, R. Huq, T. Lambe, S. Gilbert, A.M. Collins, M.N. Ramasamy, A. Mujati, R. Kenneil, N. Marchevsky, I. Haeusler, E. Vannaxay, N. Ebrahimi, S. Batawi, F. Cappuccini, R. White, L.S. Ortega, O. Mazur, H.T. Belhadeh, B. Stoilova, D. Pulido-Gomez, H. Zhang, K. Conlin, M. Voysey, A. Hyder-Wright, L. Mclellan, O. Hamilton, V. Simpson, J. Court, N. Murphy, M. Farrar, P. Saunderson*
- L0005** **Vaccination in pregnancy with RSVpreF elicits IgG, IgA and total secretory antibody responses in milk of lactating individuals***J. Atwell\** (New York, United States), *R. Powell, X. Yang, C. Decarlo, A. Fox, R. Fan, S. Uppal, J. Deese, M. Vichnin, E. Gonzalez, B. Gessner*

**SY051** **13:30 – 14:30** **Hall 1**  
1-hour Symposium

CLN

**Year in infectious diseases**

*Chairs* *Nur Benzonana (Istanbul, Türkiye)*  
*Evelina Tacconelli (Verona, Italy)*

- S0151** **13:30** *Yoav Keynan (Winnipeg, Canada)*
- S0152** **14:00** *Elisa Cordero Matia (Seville, Spain)*

# ESCMID Global 2025 - Programme

SY053

13:30 – 14:30

Hall 16

PRO

1-hour Symposium

## Developing guidelines with AI tools: are they ready for prime time?

*Chairs*

*Miranda Langendam (Amsterdam, Netherlands)*  
*Blin Nagavci (Gjakove, Kosovo)*

**S0155**      **13:30**      **The PROs and CONs of using AI tools for developing guidelines***Holger Schuenemann (Milano, Italy)*

**S0156**      **14:00**      **AI in action: validated tools for speeding up your systematic reviews and how to use them***Sara Fernandez (Oslo, Norway)*

Co-organised with: ESCMID Guidelines Subcommittee

SY052

13:30 – 14:30

Hall 2

IPC

PHEI

1-hour Symposium

## Exploring children's role in infection spread

*Chairs*

*Angelika Berger*  
*Sanjay Patel (Winchester, United Kingdom)*

**S0153**      **13:30**      **Are children really super-spreaders of respiratory viruses?***Emmanuel André (Leuven, Belgium)*

**S0154**      **14:00**      **Should schools be closed at the start of the next pandemic?***Vittoria Colizza (Paris, France)*

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

EF021

13:30 – 14:30

Arena 1

AMR

CLN

DX

ePoster Flash Session

## Infections in hemato-oncological hosts: from bacterial to viral

*Chair*

*Genovefa Papanicolaou (New York, United States)*

**E0139**      **Vancomycin-resistant *Enterococcus faecium* bloodstream infection in patients with hematological malignancy and stem cell transplant: a case-control study***J. Fung\* (Vancouver, Canada), K. Aldhaferi, C. Nishi, J. Lau, A. Mah, A. Wright, R. Stubbins, M. Charles, S. Belga*

**E0140**      **Bacteremia secondary to urinary tract infection in oncology patients: risk factors and impact of multidrug-resistant Gram-negative bacilli.***I. Grafia\* (Barcelona, Spain), A. Moll, S.J. Santillá, C. Rodrigo, E. Lillo, M. Garcia De Herreros, N. López, A. Soriano, M. Espasa, D. Marco, S. Fernández, J. Marco-Hernández, C. Zamora, J. Padrosa, L. Llavata, M. Viladot, A. Tuca, P. Puerta-Alcalde*

**E0141**      **Rectal carriage of multidrug-resistant organisms and subsequent bloodstream infections in hematologic patients undergoing hematopoietic stem cell transplantation or chimeric antigen receptor T-cell therapy***C. Charalampidis\* (Athens, Greece), I. Konstantellos, P. Kazakou, K. Gkirkas, I. Lazana, C. Chatzidimitriou, A. Zormpa, E. Mastrostamati, I. Grigoropoulos, D. Kavatha, S. Tsiodras, P. Tsirigotis, K. Thomas*

**E0143**      **The RUSTIC Study: Respiratory Virus Infection in a Contemporary Longitudinal Cohort of Patients with Haematological Malignancy***B. Teh\* (Melbourne, Australia), V.G. Hall, A. Liu, K.Y. Yong, Z. Andrews, P. Kinsella, N. Laundy, J. Wolfe, L. Cooley, M.K. Yong, M.A. Slavin*

**E0144**      **Viral respiratory infections in patients with hematological diseases over 10 years: epidemiology and impact on disease severity***P. Bono\* (Milan, Italy), A. Parisi, E. Tagliaferri, R. Ungaro, G. Saporiti, F. Cavallaro, G. Bozzi, M.C. Goldaniga, G. Galli, N. Hejazifar, C. Biassoni, G. Giacomel, A. Valzano, M.R. Sciumè, N. Fracchiolla, A. Bandera, F. Passamonti, A. Callegaro, C. Alteri*

**E0145**      **Safety and tolerability of SYN-004 in allogeneic**

	hematopoietic cell transplant (HCT) recipients receiving meropenem (MER) or piperacillin/tazobactam (P/T) <i>E. Dubberke* (Saint Louis, United States), M. Schroeder, H. Sappington, G. Lampen, K. Reske, T. Hink, V. Joachimstaler, E. Jeremy, M. Keller, A. Bristol, C. Le, S. Connelly, M. Moenk, V. Wacher, M. Kaleko, J. Kutj, M. Olsen</i>
E0146	<b>Standardized gastrointestinal cytomegalovirus (CMV) tissue quantitative-nucleic-acid testing (QNAT) compared to immunohistochemistry in allogeneic hematopoietic cell transplant (HCT) recipients</b> <i>S. De Aragón De La Cruz* (Basel, Switzerland), C.S. Walti, N. Khanna, K. Leuzinger, J.P. Halter, H.H. Hirsch, K. Nägele, J. Passweg, J. Vosbeck</i>
E0147	<b>Real-life experience with maribavir for the treatment of cytomegalovirus infection in hematological patients.</b> <i>J. Boan Perez* (Madrid, Spain), J.M. Sánchez-Pina, C. Aizpurúa, I. Rodríguez-Goncer, F. López-Medrano, R. San-Juan, M. Fernández-Ruiz, E. Aparicio, M. Lizasoain, J.M. Caro-Teller, J. Martínez, M. Calbacho, J.M. Aguado</i>

EF022	13:30 – 14:30	Arena 2
	ePoster Flash Session	

**DX**

## Syndromic testing is still coming of age

*Chair Tommaso Giani (Florence, Italy)*

E0148	<b>Bacterial infections of the central nervous system: addressing the diagnostic gap in non- community-acquired meningitis</b> <i>G. Menchinelli* (Rome, Italy), M. Cacaci, D. Squitieri, B. Fiori, T. D'inzeo, G. De Angelis, B. Posteraro, M. Sanguinetti</i>
E0149	<b>Epidemiological surveillance of central nervous system infections through a rapid syndromic testing platform</b> <i>M. Rey* (Barcelona, Spain), L. Pau, C. Miravet, A. Molins, G. Hansen, M. Juanola-Falgarona</i>
E0150	<b>Impact of Syndromic Panel Implementation on Meningitis/Encephalitis Diagnosis, Antimicrobial Use, Costs, and Hospital Stay in a Regional Australian Hospital</b> <i>S. Subedi* (Brisbane, Australia), P. Harris, D. Paterson</i>
E0151	<b>Performance evaluation of the NxTAG® GPP Panel for the detection of gastrointestinal pathogens by comparison with current routine methods in Nantes University Hospital.</b> <i>S. Gibaud* (Nantes, France), L. Castain, S. Hartuis, C. Hervochon, B.M. Imbert, P. Lepape, S. Corvec</i>
E0152	<b>Correct discrimination of Monkeypox virus clades by fast syndromic testing</b> <i>S. Reister* (Hilden, Germany), L. Peñarrubia, M. Juanola-Falgarona, G. Pueyo, S. Jiménez-Guzmán, R. Diaz-Hernández, E. Padilla-Cámara, J. Michel, A. Puyskens, F. Van Deursen, D. Lueerssen</i>
E0153	<b>Managing a <i>Mycoplasma pneumoniae</i> Outbreak: Impact of Syndromic Panels on Antimicrobial Prescriptions in Pediatric Emergencies</b> <i>L. Brusca* (Barcelona, Spain), L. Brusca-Vidao, M. Pallarés-Borrás, G. Santillana-Cernuda, M. Ballesterio-Tellez, A. Boronat, J. Perez</i>
E0154	<b>Performance of BIOFIRE® FILMARRAY® Pneumonia plus in general population, solid organ transplant recipients and patients with hematologic malignancies – Interim analysis</b> <i>R. Riccardi* (Bologna, Italy), M. Rinaldi, G. Ceccarelli, C. Campoli, C. Tondi, M. Casarini, B. Miani, G. Nigrisoli, S. Ambretti, P. Viale, M. Giannella</i>
E0155	<b>Impact of the molecular rapid diagnostic panel testing in adjustment of antimicrobial therapy in febrile neutropenic patients with bacteremia.</b> <i>S. Chantharasut* (Bangkok, Thailand), M. Chayakulkeeree, W. Kamolvit, A. Jitmuang, I. Thaisuttikul</i>
E0156	<b>BacteREVEAL: Analytical performance and contribution of BioFire® BCID2 and Vitek® REVEAL™ in intensive care patients with Gram-negative bloodstream infections</b> <i>C. Roger* (Nîmes, France), L. Oudiane, M. Benyahia, F. Salipante, A.</i>

# ESCMID Global 2025 - Programme

Dubois, L. Muller, J.P. Lavigne, A. Pantel

EF023

13:30 – 14:30

Arena 3

ePoster Flash Session

DX

## Effective microbiology for the management of sepsis

Chair Maurizio Sanguinetti (Rome, Italy)

- E0157

**Molecular epidemiology of *Klebsiella* bloodstream infection-causing isolates across England using Nanopore longread-only sequencing: An interim analysis of the NEKSUS study***D. Nagy\** (Oxford, United Kingdom), *N. Stoesser, S. Lipworth, V. Pennetta, K. Hopkins, G. Rodger, R. Moran, C. Jones, T. Neksus Study Group, S. Hopkins, D. Crook, A.S. Walker, J. Robotham, K.L. Hopkins, A. Ledda, D. Williams, R. Hope, C.S. Brown*
- E0158

**Investigating seasonality of antibiotic resistance associated with *E. coli* and *Klebsiella pneumoniae* bloodstream infections***S. Lipworth\** (Oxford, United Kingdom), *L. Gorman, A. Dowsey, K. Pouwels, K. Sanderson, C. Beck, R. Hope, C. Brown, K. Turner*
- E0159

**Sensitivity of a host-protein test for microbiologically confirmed bacterial infections***R. Navon\** (Tirat Carmel, Israel), *E. Reiner, O. Shaham, A. Neuberger, S. Shiber, S. Halabi, A. Epstein, T. Zalut, S. Motov, T.P. Aufderheide*
- E0160

**Comparative genomics of *Klebsiella pneumoniae* from gut colonisation and bloodstream infections reveal novel genetic associations***M. Hetland\** (Stavanger, Norway), *K.L. Wyres, H.B. Cooper, A. Correia, M.A. Winkler, A. Fostervold, N. Raffelsberger, A. Sundsfjord, Ø. Samuelsen, K.E. Holt, I.H. Löhr*
- E0161

**Conventional microbiology vs. conventional microbiology + nucleic acid-based multiplex real-time polymerase chain reaction (MPCR) test kit in septic shock: results of a matched cohort study***G. Sanlıdag İsbilen\** (Izmir, Türkiye), *G. Şanlıdağ İşbilen, B. Akkul, C. Tol, D. Akyol Seyhan, H. Sipahi, Ş. Aydemir, F. Çilli, B. Arda, O.R. Sipahi*
- E0162

**Contribution of *Escherichia coli* microbiological factors to the presentation as sepsis/septic shock in patients with bacteraemia: a matched case-control study***N. Maldonado\** (Seville, Spain), *I. López-Hernández, L.E. López-Cortes, P.M. Martínez Pérez-Crespo, A. García-Montaner, M. Alcade-Rico, A. Sousa-Dominguez, A. Jover-Sáenz, J. Goikoetxea, Á. Pulido-Navazo, C. Labayru Echeverría, A.I. Aller-García, L. Boix-Palop, A. Del Arco-Jiménez, A. Smithson-Amat, J.M. Sánchez-Calvo, C. Natera-Kindelán, J.M. Reguera Iglesias, C. Armiñanzas-Castillo, F. Galán-Sánchez, A. Bahamonde, I. Gea-Lázaro, J. Fernández-Suárez, I. Pérez-Camacho, T. Marrodán-Ciordia, B. Becerril-Carral, Á. Pascual-Hernández, J. Rodríguez-Baño*
- E0163

**Simplified and rapid bacterial identification with antimicrobial resistance detection in bacteremia by on-chip multiplexed LAMP***C. Treille\** (Saclay, France), *K. Perez-Toralla, H. Boutal, X. Garcia Velasquez, L. Pommies, S. Simon, H. Volland*
- E0164

**Community-onset bloodstream infection among people with opioid use disorders: A twenty-year population-based cohort study in Queensland, Australia***K. Laupland\** (Herston, Australia), *A. Stewart, F. Edwards, P. Harris, S. Coulter*
- E0165

**Microbiological diagnosis tools for primary and secondary abdominal aortic infections requiring surgery***S. Soueges\** (Lyon, France), *A. Blanco, A. Souche, C. Triffault-Fillit, M. Arsicot, M. Wan, N. Della-Schiava, U. Huvelle, A. Millon, F. Valour*

EF024

13:30 – 14:30

Arena 4

ePoster Flash Session

AMR TRN

## A never-ending evolution of antimicrobial resistance

Chair Antonio Oliver (Palma De Mallorca, Spain)



E0166	<b>Gfa, a novel integron-born fosfomycin resistance mechanism</b> <i>N. Kieffer* (Madrid, Spain), L. Ortiz-Miravalles, A. Hipolito, J.A. Escudero</i>
E0167	<b>Regulons of RamA, RarA and SoxS mediated tigecycline resistance and oxidative stress among <i>in vitro</i> tigecycline resistant evolution trajectory of <i>Klebsiella pneumoniae</i>.</b> <i>X. Wang* (Beijing, China), J. Kuai, Y. Zhao</i>
E0168	<b>Assessing the impact of altered penicillin binding proteins on susceptibility to novel antimicrobials among clinical isolates of carbapenemase-producing <i>Escherichia coli</i>.</b> <i>C. Tellapragada* (Stockholm, Sweden), P. Jonsson, C. Giske</i>
E0170	<b><i>Enterococcus faecalis</i> penicillin-binding protein-4 sequence differences based on penicillin minimum inhibitory concentration</b> <i>O. Funk* (Brooklyn, United States), A. Kozlenkov, C. Toro Chacon, J. Azzouzi, S. Brown, J. Cusumano</i>
E0171	<b>Uncommon genomic rearrangements drive vancomycin resistance in <i>vanB</i>-positive <i>Enterococcus faecium</i></b> <i>K. Xanthopoulou* (Cologne, Germany), J. Mellüh, R. Arazo Del Pino, L. Casselmann, V. Persy, T. Burgwinkel, E. Gieraths, L. Maus, A. Klimka, P.G. Higgins</i>
E0172	<b>Heteroresistance in <i>Enterococcus faecalis</i>: prevalence and mechanistic insights across clinically relevant antibiotics</b> <i>S. Heidarian* (Uppsala, Sweden), S. Lohsen, A. Guliaev, K. Hjort, S. Satola, D. I. Andersson</i>
E0173	<b>Side effects of rifampicin resistance: transcriptome modulation by <i>rpoB</i> mutations in <i>Staphylococcus aureus</i></b> <i>M. Roch* (Geneva, Switzerland), R. Sierra, C. Colomer Winter, F. Bezrukov, O. Panasenko, A. Guisolon, U. Von Ah, M. Villanueva, P. Redder, K. Kline, J. Prados, W.L. Kelley</i>
E0174	<b>Novel continuous experimental evolution methodology revealing rapid resistance development and cross-resistance</b> <i>T. Echelmeyer* (Greifswald, Germany), M. Ellmann, S.E. Heiden, M. Schwabe, H. Fickenscher, G. Maschkowitz, D. Nurjadi, R. Podschun, K. Schaufler, E. Eger</i>

OS018	13:30 – 14:30	Hall 11
	1-hour Oral Session	



## Battling the Spore: *C. difficile* epidemiology and management

<i>Chairs</i>	<i>Nicolas Benech (Lyon, France)</i> <i>Fidelma Fitzpatrick (Dublin, Ireland)</i>
---------------	--

O0124	<b>Molecular epidemiology and antimicrobial resistome of <i>Clostridioides difficile</i> from private and public healthcare settings in three provinces in South Africa</b> <i>H. Shirinda* (Pretoria, South Africa), A.M. Smith, B. Prinsloo, M. Kock, M. Moodley, M. Said, M. Ehlers</i>
O0125	<b>Screening for <i>Clostridioides difficile</i> colonization at admission and during hospitalization</b> <i>N. Khanafer* (Lyon, France), S. Bennia, G. Martin-Gaujard, L. Juillard, T. Rimmelé, L. Argaud, P. Cassier, O. Martin, P. Vanhems</i>
O0126	<b>Revolutionizing CDI treatment: Are shorter antibiotic regimens the future</b> <i>M. Duricek* (Prague, Czech Republic), J. Benes, K. Halmova</i>
O0127	<b>Extended-pulsed fidaxomicin versus conventional dosing in patients at high risk of recurrence of <i>Clostridioides difficile</i> infection</b> <i>E. Rubio-Martín* (Seville, Spain), R. Escudero-Sánchez, Á. Gutiérrez Liarte, A. Ibañez Zurriaga, C. Saez Bejar, B. Díaz Pollán, C. Marcelo Calvo, G. Ruiz Carrasco, G. Pérez Caballero, A.M. Rodríguez Benavente, S. De La Villa, J.D. Ruiz-Mesa, L.F. Caballero Martínez, I. Márquez Gómez, E. Calabuig, M. Tacias, R. Blanes, M.Á. López Zúñiga, J. Rodríguez Granger, P. Merino Amador, A. Salinas, D. Rodríguez-Pardo, M. Villamarín Merlo, G. Maestro De La Calle, J. Mateo Flores, J.B. Pérez Gilaberte, R.M. Martínez Álvarez, F. Martínez García, N. Cobos-Trigueros, J. Llenas-García, M. Solivella-Rodríguez, L. Ramos Merino, B. Castelo López, M.M.</i>

# ESCMID Global 2025 - Programme

Montero, D. Echeverría-EsnaI, J. López-Contreras, P. Duch Llorach, M.R. Oltra-Sempere, C. Pinto-Pla, Í. Pineda, J.L. Del Pozo, J. Rodríguez-Baño, A. Halperin, A. Muriel García, S. Moreno Guillén, J. Cobo

00128 Gut phageome profiling in *Clostridioides difficile* infection and faecal microbiota transplantation C. Chen\* (Lausanne, Switzerland), T. Pillonel, J. Schaer, G. Greub, G. Resch, B. Guery, C. Bertelli, T. Galpérine

OS019 13:30 – 14:30 Hall 12  
1-hour Oral Session

TRN

## Microbiome Dynamics and Health: From Pathogenesis to Therapeutic Potential

Chairs Mauricio Farfan (Santiago, Chile)  
Eija Inkeri Könönen (Turku, Finland)

00129 Multi-omics integrated analysis revealed the key role of *Fusobacterium periodonticum* in colorectal tumorigenesis by decanoic acid promoting neutrophil chemotaxis. X. Chu\* (Beijing, China), Q. Yang

00130 Exploring the respiratory microbiome in COPD patients: The role of *Haemophilus* spp. in disease pathogenesis P. Camps-Massa\* (Barcelona, Spain), L. Saiz-Escobedo, J. Guerrero, E. Cuevas, D. Guevara-Núñez, F. Tubau, J. Burgos, M. Lopez, A. González-Díaz, C. Ardanuy, M. Domínguez, S. Santos, S. Martí

00131 Using the in vitro MiGut system to simulate the ulcerative colitis microbiome and post-antibiotic recovery supported by a pre-defined consortium of microbes I. Moura\* (Leeds, United Kingdom), W. Davis Birch, N. Beauchemin, M. Vulic, K. Bentley, P. Culmer, M. Mayol, C. Ford, M. Henn, E. Halvorsen, M. Wilcox, N. Kapur, A. Buckley

00132 Functional characterization of the Brazilian Yanomami microbiome along an urbanization gradient: Insights into the impacts of Westernization on human health M. Thorp\* (Gent, Belgium), C. Callewaert, B. De Pessemier, D. Good, E. Allen-Vercoe, L. Paulino, L. Vereecke

00133 Colonization resistance of the intestinal microbiota to multidrug-resistant bacteria? K. Villageois-Tran\* (Bobigny, France), C. Emavivie, H. Skerdi, E.N. Saad, M. Julie, E. Ruppé

ME055 13:30 – 14:30 Hall 14  
Meet-the-Expert

CLN

## Long acting injectables to treat and prevent infections: an example from HIV field

M0159 13:30 Monica Gandhi (Salt Lake City, United States)  
M0160 13:42 Pedro Cahn (Buenos Aires, Argentina)

OS020 13:30 – 14:30 Hall 15  
1-hour Oral Session

ANT

## How to evaluate AMS programs

Chairs Esther Calbo (Terrassa, Spain)  
Sabiha Essack (Durban, South Africa)

00134 Preference-based instrumental variables for estimating the causal effects of antibiotic prescribing decisions in common infections: Assessing potential validity using CPRD data N. Nguyen\* (Oxford, United Kingdom), K. Pouwels, J.V. Robotham, S. Yu, S. Wordsworth

00135 Novel antibiotic spectrum metrics to quantify the impact of antimicrobial stewardship: a multicentre study B. Moshy\* (London, United Kingdom), R. Llewellyn, R. Lester, G. Pollara, T. Samuels, J. Sarah, B. Gemma, I. Balakrishnan

O0136		<b>Utilizing a weighted-incidence syndromic antibiogram to evaluate antimicrobial therapies and resistance trends in community-acquired infections in a community teaching hospital</b> <i>V. Huang*</i> (Glendale, United States), <i>T. Pham, A. Vogler, H. Chhen, C. Vandenberg</i>
O0137		<b>Capturing days of therapy per days of service as a stewardship tool to identify outliers in prescribing broad-spectrum antimicrobials in the hospital setting</b> <i>A. Hopkins*</i> (Livingston, United States), <i>A. Farkas, S. Tamirisa, G. Severance, A. Yassin, E. Jaime</i>
O0138		<b>Timing of Novel <math>\beta</math>-Lactams vs. Alternatives in Hospitalized Patients with Gram-Negative Infections: Line of Therapy (LoT) Analysis Preliminary findings</b> <i>E. Yucel*</i> (Rahway, United States), <i>J. Min, Y. Wang, M. Vendetti, Y. Emre, R.K. Shields</i>

ME054	13:30 – 14:30	Hall 3
	Meet-the-Expert	
	AMR	TRN
How antimicrobial tolerance impacts polymicrobial biofilm-associated infections		
M0157	13:30	<i>Hans Steenackers (Leuven, Belgium)</i>
M0158	13:42	<i>Brian Conlon (Chapel Hill, United States)</i>

OS017	13:30 – 14:30	Hall 5
	1-hour Case Session	
	CLN	
Bad bacteria		
<i>Chairs</i>	<i>Maristela P. Freire (Sao Paulo, Brazil)</i> <i>Siegbert Rieg (Freiburg, Germany)</i>	

O0119		<b>Vancomycin Dependent Enterococci: An evolutionary dead end or the ultimate evolution of a superbug</b> <i>R. Gupta (bagga)*</i> (London, Canada), <i>R. Gupta, A. Cabrera, A. Kanyua, F. Almutawa, J. Delpont, K. Kavanoor Sridhar</i>
O0120		<b>Whipple’s disease: one of medicine’s great imitators</b> <i>S. Kesavan*</i> (Nottingham, United Kingdom), <i>F. Heard, S. Kesevan, E. Hart, V. Fleming, C. Santos, R. Thomson</i>
O0121		<b>Phage Therapy as a Rescue Treatment for Recurrent <i>Pseudomonas aeruginosa</i> Bentall Infection</b> <i>V. Eiferman*</i> (Paris, France), <i>P.A. Vion, B. Rached, C. Granger, N. Hammoudi, A. Bleibtreu</i>
O0122		<b>A clinical case of <i>Legionella longbeachae</i> pneumonia featuring unique epidemiological features in a major italian hospital</b> <i>S. Guerriero*</i> (Rome, Italy), <i>M. La Sorda, F. De Maio, S. Cardinali, M. Di Donato, P. Del Vecchio, C. Tarli, M. Fantoni, R. Murri, M. Sanguinetti, C. Torti</i>
O0123		<b><i>Francisella tularensis</i> – First autochthonous case in the UK</b> <i>G. Vanstone*</i> (Truro, United Kingdom), <i>A. Belfield, L. Vincent, V. Perks, D. Wadham, B. Marques Silva, A. Evans, O. Lloyd, N.C. Gordon, C. Arumugam, A. Ainarozidou</i>

ME061	14:45 – 15:45	Hall 3
	Meet-the-Expert	
	PHEI	TRN
How to use large language models and machine learning for improving One Health		
M0170	14:45	<i>Javier Fernández (Oviedo, Spain)</i>
M0171	14:57	<i>Nicolas Radomski (Teramo, Italy)</i>

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Epidemiological Markers (ESGEM), Portuguese Society of Microbiology (SPM)

# ESCMID Global 2025 - Programme

FO063

14:45 – 15:45

Arena 1

Open Forum

PRO

## Science communication in a noisy world: podcasting and social media in ID/CM

Chair

Emily G. McDonald (Montreal, Canada)

- FO174

14:45

The ID:IOTS guide to creating a successful CM/ID podcast" Callum Mutch (Edinburgh, United Kingdom)
- FO175

14:55

Using social media for CM/ID educationScott Jake (Oakland, United States)
- FO176

15:05

Podcasting and social media for antimicrobial stewardship and pharmacyErin McCreary (Pittsburgh, United States)

Co-organised with: CMI Communications Board of Editors

EF029

14:45 – 15:45

Arena 2

ePoster Flash Session

VAX

## Vaccination uptake-challenges and opportunities

Chair

Joanne M. Langley (Halifax, Canada)

- E0195

Electronic nudges to increase influenza vaccination uptake among patients with heart failure: insights from 3 nationwide randomized trials enrolling >2 million patientsN.D. Johansen\* (Hellerup, Denmark), M. Vaduganathan, A.S. Bhatt, D. Modin, B.L. Claggett, K.H. Janstrup, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, E.L. Dueger, S. Samson, M.M. Loiacono, R.C. Harris, L. Køber, S.D. Solomon, P. Sivapalan, J.U.S. Jensen, T. Biering-Sørensen
- E0196

Psychological Predictors of *Influenza* Vaccination Intent Among Healthcare Workers in BulgariaP. Velikov\* (Sofia, Bulgaria), V. Rangelova, Y. Axentieva, Y. Tcholakov, V. Borisova-Nenov[], D. Ivanov, A. Zasheva, A. Hori
- E0197

Determinants of COVID-19 vaccine uptake in patients with hematologic malignancies: a nationwide cohort studyQ. Hofsink\* (Amsterdam, Netherlands), T. Osmenaj, B.I. Lissenberg-Witte, S. Hahné, J. Heijmans, I.S. Nijhof, A. Goorhuis, M.D. Hazenberg, C.E. Rutten, S. Haggenburg, P. Den Tex, A. Dinmohamed, J. Kemmeren, H. De Melker, S. Van Den Hof
- E0199

Inequality in vaccine uptake among children in Denmark in the national childhood vaccination programmeA.C.M. Breschel\* (Copenhagen, Denmark), A.V. Søndergaard, S.K. Nørgaard, B. Søborg, P.H. Andersend
- E0200

Prevalence and associated factors of parental refusal rates for routine immunisation: A cross-sectional study in Peshawar, Khyber Pakhtunkhwa, Pakistan-2024M. Hakim\* (Hayat Abad Peshawar Kp Pakistan, Pakistan)
- E0201

Shingles Prevalence, Vaccine Awareness, and Acceptance in People Living with HIVD. Yaman\* (Izmir, Türkiye), D. Akdağ, M. Taşbakan, H. Pullukçu, D. Gökengin
- E0202

Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden, 2018–2022A. Palmborg\* (Stockholm, Sweden), F. Angulo, P. Zhang, A. Pilz, J. Stark, M. Jennifer, L. Jodar
- E0203

Monkeypox (mpox) vaccination willingness and determinants among people living with HIV (PLWH) in turkeyC. Boşnak\* (Altındağ, Türkiye), T.K. Şahin, E. Erul, M.Ç. Sönmezer, A.Ç. Inkaya, S. Ünal

EF030

14:45 – 15:45

Arena 3

ePoster Flash Session

CLN DX PHEI

## Viruses crossing the blood-brain barrier

E0204	<b>Clinical characteristics and outcome of Herpes simplex virus type 1 and varicella zoster virus encephalitis: A prospective population-based cohort study</b> <i>L. Duerlund*</i> (Aarhus, Denmark), L. Larsen, M. Storgaard, H. Mens, L. Weise, M.P.G. Jepsen, B.R. Hansen, H.R. Von Lüttichau, C.Ø. Andersen, H. Nielsen, J. Bodilsen
E0205	<b>Arbovirus associated neurological disease in adults and children in Brazil: a multicentre case-control study</b> <i>S. Lant*</i> (Liverpool, United Kingdom), R. Mehta, M.L. Brito Ferreira, C. Soares, R. Medialdea Carrera, M. Tullius, P. Brasil, C. Miguelote, A. Henriques Souza, M. Ellul, M. Griffiths, M.M. Jardim Rodrigues, R. Braga, L. Pamplona, C. Spitz, F. Militao, A. Rosala Hallas, G. Burnside, R. Vivancos, S. Leonhard, L. Rodrigues De Mendonça-Vieira, B. Jacobs, C. Brito, P. Sequiera, D. Brown, L. Turtle, R. Franca, A. Bispo, T. Solomon
E0206	<b>Challenges in managing Central nervous system infections: Battling the Unknown Enemy, West Nile virus vs unknown etiology</b> <i>C. Marin*</i> (Bucharest, Romania), A. Paun, E. Nedu, S. Tetrarov, S. Lazar, M. Nica, G. Tardei, I.A. Condurache, S.A. Florescu, S.M. Ruta, C.P. Popescu
E0207	<b>Spatial and temporal profiling of the immune responses induced by Japanese encephalitis virus in a mouse model</b> <i>Z. Ou*</i> (Shenzhen, China), Z. Wang, Q. Chen, X. He, P. Ren, J. Li, G. Cheng
E0208	<b>Intrathecal immunoglobulin synthesis in tick-borne encephalitis</b> <i>S. Grygorczuk*</i> (Bialystok, Poland), P. Czupryna, D. Martonik, J. Dunaj-Małyszko, J. Adamczuk, A. Parfieniuk-Kowerda, J. Osada, A. Moniuszko-Malinowska
E0209	<b>B and T cell responses to Tick-borne Encephalitis Virus</b> <i>N. Mayola Danes*</i> (Stockholm, Sweden), R. Varnaité, N. Mayola Danés, K. Blom, H.G. Ljunggren, S. Gredmark-Russ
E0210	<b>Enterovirus infections in pediatric central nervous system (CNS) diseases: molecular epidemiology and neuroimaging insights</b> <i>D. Sharma*</i> (Chandigarh, India), R. Pathania, P. Bhattacharya, M. Gautam, A. Bansal, S. Vyas, A. Ghosh, K. Goyal, M. P Singh
E0211	<b>Neuroimaging findings and their correlation with autopsy findings: Prospective study on Rabies encephalitis</b> <i>M. Mohata*</i> (New Delhi, India), V. Suri, P. Singh, G.K. Mohi, A. Bhalla, R. Mohindra, R.K. Soni, K. Gupta
E0212	<b><i>Toxoplasma gondii</i> IgG Screening and Central Nervous System Complications among People with HIV in the Combination Antiretroviral Therapy Era</b> <i>T. Ou*</i> (New Taipei City, Taiwan, China), T.Y. Tsai, S.H. Huang, T.Y. Wu, W.D. Liu, H.Y. Sun, K.Y. Lin, C.C. Hung

---

EF031	14:45 – 15:45	Arena 4
-------	---------------	---------

ANT CLN

ePoster Flash Session

**AMS around the world: know your data!**

Chair	Eoghan De Barra (Dublin, Ireland)
-------	-----------------------------------


E0213	<b>Duration of antibiotic treatment for respiratory tract infections in primary care.</b> <i>C. Llor*</i> (Barcelona, Spain), M.P. Hansen, J. Lykkegaard, J.K. Olsen, B.H. Lindberg, I.K. Rebnord, R. Radzeviciene, L. Jaruseviciene, P.T. Lundgren, P. Bruno, A. Kowalczyk, C. Lionis
E0214	<b>Antibiotic prescribing for common acute infections in Pakistan - an analysis using IQVIA prescriber healthcare surveys</b> <i>N. Nguyen*</i> (Oxford, United Kingdom), K. Pouwels, M. Sharland, S. Mangla, A. Cook, M. Thorn, P. Stephens
E0215	<b>Antibiotic prescribing for common acute infections in Egypt - an analysis using IQVIA prescriber healthcare surveys</b> <i>N. Nguyen*</i> (Oxford, United Kingdom), S. Mangla, A. Cook, M. Thorn, P. Stephens, K. Pouwels, M. Sharland
E0216	<b>Population based analysis of the impact of Japan's AMR national action plan and the COVID-19 pandemic on antimicrobial prescription</b> <i>R. Koizumi*</i>

# ESCMID Global 2025 - Programme

		(Tokyo, Japan), S. Tsuzuki, Y. Asai, K. Aoyagi, N. Ohmagari
E0217		<b>Quality of antibiotic prescribing in Portuguese hospitals: a snapshot of the first National Antimicrobial Prescribing Survey.</b> C. Palos* (Lisbon, Portugal), C. Ierano, R. James, J.A. Paiva, K. Thursky, P. Sousa
E0218		<b>Evaluating the impact on 28-day mortality of different empiric AWARe antibiotic treatment strategies for hospital-acquired infections across different hospital settings.</b> C. Lim* (Oxford, United Kingdom), K.B. Pouwels, D. Limmathurotsakul, Q. Gu, D.E. Eyre, A.S. Walker, M. Sharland, B.S. Cooper
E0219		<b>Update on WHO's Global antibiotic use surveillance system (GLASS-AMU)</b> B. Huttner* (Geneva, Switzerland), A. Muller, M. Escher, V. Ivanoska, D. Tong
E0220		<b>Harmonisation trajectory of Global-Point Prevalence Survey (Global-PPS) and WHO-PPS.</b> A. Versporten* (Antwerp, Belgium), A. Muller, M. Escher, I. Pauwels, D. Tong, A. Boven, V. Ivanovska, B. Huttner, E. Vlieghe
E0221		<b>Implementation of prospective audit and feedback strategy in intensive care units: Analysis of antimicrobial prescription patterns in a Guatemalan tertiary care hospital.</b> N. Sandoval* (Guatemala, Guatemala), G. Ozaeta, G. Reyes, K. Carrascosa

KN056	14:45 – 15:45	Hall 1
	Keynote Lecture	
		
<b>Defending against dengue: global epidemiology and strategies for prevention and control</b>		
Chairs	Anu Kantele (Helsinki, Finland) Carlos Seas (Lima, Peru)	

K0161	14:45	Fernanda Boulos (São Paulo, Brazil)
-------	-------	-------------------------------------

OS026	14:45 – 15:45	Hall 11
	1-hour Oral Session	
	  	
<b>Carbapenem resistance Gram-negatives, what's new in treatment?</b>		
Chair	Maria Milagro Montero (Barcelona, Spain)	

OO180		<b>Ceftriaxone sulbactam disodium EDTA combination(CSE) as a treatment option for carbapenem resistant gram negative bacilli - to be or not to be?</b> Y. Verma* (Hisar, India), K. Narang, D. Bandlish, C. Sharma
OO181		<b>Sulbactam-durlobactam as an effective alternative option against NDM-producing <i>Escherichia coli</i> including cefiderocol and aztreonam-avibactam-resistant isolates in Switzerland</b> C. Le Terrier* (Fribourg, Switzerland), P. Nordmann, A. Delaval, L. Poirel
OO182		<b>Optimising Difficult-to-treat Gram-negative Bacterial Infection Outcomes with Personalised Fosfomycin-Based Combination Therapy Guided by <i>in vitro</i> Antibiotic Combination Testing</b> T. Lim* (Singapore, Singapore), J.Q. Teo, J.J.Y. Ho, T.G. Lee, L.J. Sin, K.K.K. Goh, N. Mohamed Yusoff, W. Lee, N.G.S. Chua, J.S. Chung, A.L.H. Kwa
OO183		<b>Management of infections caused by ST308 New Delhi metallo-<math>\beta</math>-lactamase-producing <i>Pseudomonas aeruginosa</i> with <i>in vitro</i>-guided combination antibiotic therapy</b> J. Teo* (Singapore, Singapore), J.H. Toh, H.Y. Chang, S.H. Tan, W. Lee, T.P. Lim, Y.E. Tan, S.J. Chung, A.L.H. Kwa
OO184		<b><i>In vitro</i> activity of cefepime/enmetazobactam against clinical isolates of <i>Enterobacterales</i> in Portugal: A multicentre retrospective study</b> H. Cruz* (Porto, Portugal), C. Chaves, L. Carneiro

OS027	14:45 – 15:45	Hall 12
-------	---------------	---------

***Staphylococcus aureus*: colonisation, virulence, and persistence**

Chair

Stefano Giulieri (Melbourne, Australia)

- O0185**      **The nasal microbiome redefines and predicts *Staphylococcus aureus* nasal colonisation status**  
*D. Aggarwal\** (London, United Kingdom), *K.L. Bellis, B. Blane, M.C. De Goffau, J. Wagner, D.Y.K. Ng, K.E. Raven, P. Naydenova, S. Kaptoge, R. Henry, C. Perry, M.R. Walker, C. Churcher, S. Girgis, C.R. De Sousa, L. Sarkane, J. Brennan, S. Duthie, E. Johnson, M. Juhasz, S. Irvine, A. McMahon, A. Van Tonder, E. Di Angelantonio, A. Butterworth, J.A. Geoghegan, J. Danesh, J. Parkhill, S.J. Peacock, E. Harrison*
- O0186**      **Development of a *Staphylococcus aureus* human nasal colonisation model**  
*A. Hachani\** (Melbourne, Australia), *B. Tran, E. Cho, R. Guérillot, B. Howden, T. Stinear, E. Vincan*
- O0187**      **Selection-free, virulence gene promoter-controlled CRISPR interference system for *in vivo* pathogenesis study of *Staphylococcus aureus* - A proof of concept**  
*R. Miah\** (Tromsø, Norway), *M. Johannessen, M. Kjos, C. Lentz*
- O0188**      **Placebo-controlled study of competitive exclusion using *Lactococcus lactis* to reduce transmission of LA-MRSA from pigs to humans**  
*B. Duim\** (Utrecht, Netherlands), *A. Vlasblom, A. Rittscher-Fogg, R. Rattigan, L. Wajda, D. Crespo-Piazuelo, M. Broekhuizen-Stins, L. Portengen, G. Van Eijden, C. Elend, S. Patel, L. Smit, M. Claesson, P. Lawlor, A. Zomer, J. Wagenaar*
- O0189**      **Rifampicin-induced *Staphylococcus aureus* persister formation is driven by CodY and oxidative stress level**  
*N. Pordone\** (Lyon, France), *J. Guillemot, K. Rodriguez, N. Personnic, E. Botelho-Nevers, P.O. Verhoeven*

**SY059**      **14:45 – 15:45**      **Hall 13**  
 1-hour Symposium

IPC

**Value-based syndromic diagnostics in medical microbiology: Pro / Con debate**

Chairs

*Hege Vangstein Aamot* (Lørenskog, Norway)  
*Eric Claas* (Leiden, Netherlands)

- S0166**      **14:45**      **Pro: clinical benefit and potential for improved patient outcomes**  
*Kirstine K. Sogaard* (Aalborg, Denmark)
- S0167**      **15:15**      **Con: limitations, costs, and possible overuse of syndromic panels**  
*Gilbert Greub* (Lausanne, Switzerland)

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Société de Pathologie Infectieuse de Langue Française

**SY060**      **14:45 – 15:45**      **Hall 14**  
 1-hour Symposium

IPC

**We need to talk about toilets...**

Chairs

*Stephanie J. Dancer* (Glasgow, United Kingdom)  
*Juliette Severin* (Rotterdam, Netherlands)

- S0168**      **14:45**      **Infection risks from sanitation engineering**  
*Davey Jones* (Bangor, United Kingdom)
- S0169**      **15:15**      **Ventilation in toilets: how can we improve it?**  
*Michael Gormley* (Edinburgh, United Kingdom)

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Legionella Infections (ESGLI)

**OS028**      **14:45 – 15:45**      **Hall 15**  
 1-hour Oral Session

DX



# ESCMID Global 2025 - Programme

## Unlocking the potential of the human microbiome for clinical diagnostics

*Chairs* John W. A. Rossen (Groningen, Netherlands)  
Maria Vehreschild (Frankfurt Am Main, Germany)

- 00190

**Deep learning-enhanced wellness scores: Advancing gut microbiome-based health predictions***O. Nalbantoglu\* (Kayseri, Türkiye), A. Gundogdu, B.H. Ermis*
- 00191

**Comparison of Second-Generation and Third-Generation Sequencing technologies for 16S rRNA amplicon-based gut microbiome analysis***E. Rubio García\* (Barcelona, Spain), E. Rubio-García, A. Pulgarin, R. López-Aladid, L. Martínez-Priego, N. Palau, A. Mendoza, R. Isanta, A. Montalban, J.L. Villanueva-Cañas, M.M. Montero, M. Sanduzzi, M. Reig, C. Casals-Pascual*
- 00192

**Donor for fecal microbiota transplantation: a challenging research.***B.S. Orena\* (Milan, Italy), M.F. Liporace, A. Maraschini, D. Girelli, D. Pizzotti, E. Petrillo, C. Alteri, C. Amoroso, F. Caprioli, A. Callegaro, L. Cariani*
- 00193

**Antibiotic resistance genes diversity and antimicrobial effects in the vaginal microbiome during pregnancy***N. Boutouchent\* (Rouen, France), S. Kennedy*
- 00194

**Distinct gut microbiota and metabolic profiles in brain tumor patients: Bridging microbial insights to CNS oncology***A. Gundogdu\* (Kayseri, Türkiye), O.U. Nalbantoglu, M. Ulgen, M.A. Sav, G. Ekinci, H.F. Kelestimur, U. Ture*

ME062

14:45 – 15:45

Hall 16

ANTCLN

Meet-the-Expert

## Untangling the web: antimicrobial dose adjustments in renal impairment

- M0172

14:45

Claire Roger (Nimes, France)
- M0173

14:57

Isabel Spriet (Leuven, Belgium)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Critically Ill Patients (ESGCIP)

SY057

14:45 – 15:45

Hall 2

ANTCLN

1-hour Symposium

## Macrolides in community-acquired pneumonia: therapeutic necessity or path to overuse?

*Chairs* Marc J.M. Bonten (Utrecht, Netherlands)  
Karin Thursky (Carlton, Australia)

- S0162

14:45

**Pro: maximising outcomes with evidence-based use***Evangelos Giamarellos-Bourboulis (Athens, Greece)*
- S0163

15:15

**Con: the risks of routine (over)use***Aurélien Dinh (Garches, France)*

SY058

14:45 – 15:45

Hall 4

VAX

1-hour Symposium

## Top papers in transplant ID

*Chairs* Nicolas Mueller (Zurich, Switzerland)  
Alessandra Mularoni (Palermo, Italy)

- S0164

14:45

**Top 10 papers in infections in SOT***Patricia Munoz (Madrid, Spain)*
- S0165

15:15

**Top 10 paper in infections in HCT and cellular therapy***Joshua Hill (Seattle, United States)*

OS025

14:45 – 15:45

Hall 5

1-hour Oral Session

**DX** **IPC**

**Bacterial battles: a paediatric perspective on infections and interventions**

*Chairs* *Angelika Berger*  
*Julie Toubiana (Paris, France)*

- 00175

**Strong Alignment Between National Standard Treatment Guidelines and WHO AWaRe Book Recommendations for Primary Care Pediatric Infections***D. Dona\* (Padova, Italy), D. Donà, G. Brigadoi, A. Cantarutti, M. Masetti, G. Autore, S. Mathur, M. Sharland, S.M.R. Esposito*
- 00176

**Correlation between antibiotic consumption and digestive colonization with multidrug-resistant *Enterobacterales* in a paediatric haematology department***S. Frigui Ep Oueslati\* (Tunis, Tunisia), N. Fitouri, S. Frigui, Y. Chebbi, I. Fezaa, M. Ouederni, C. Drira, W. Achour*
- 00177

**Interleukin-6 as a diagnostic biomarker for sepsis in neonates, children and pregnant women – a real-world cohort study***Sean Olann Whelan (Dublin, Ireland)*
- 00178

**Impact of rapid diagnostic stewardship interventions to reduce blood culture utilization in a pediatric medical center***E. Vaugon\* (Los Angeles, United States), C. Costales, T. Barter, L. Posch, E. Orgel, J. Dien Bard*
- 00179

**Infective endocarditis: A Decade of Experience at a Tertiary Pediatric Care Centre***M. De Luca\* (Rome, Italy), R. Iacobelli, S. Samperi, S. Mercadante, L. Romani, L. Ragni, P. Bruno, G. Brancaccio, F.I. Calò Carducci, P. Bernaschi, A. Rizza, L. Lancella, L. Galletti*

EW071

16:15 – 18:15

Hall 15

Educational Session

**PRO**

**The rare art of writing scientific articles: from conception to submission**

*Chairs* *Marlieke De Kraker (Geneva, Switzerland)*  
*Mical Paul (Haifa, Israel)*

- W0205

16:15

**Expressing yourself correctly: writing tips***Angela Huttner (Geneva, Switzerland)*
- W0206

16:35

**Constructing your manuscript for an original article***Jesús Rodríguez-Baño (Seville, Spain)*
- W0207

16:55

**The use of artificial intelligence tools for writing articles: what to do and not to do***Erlangga Yusuf (Rotterdam, Netherlands)*
- W0208

17:15

**Selecting the best journal for my manuscript***Andre Kalil (Omaha, United States)*

Co-organised with: CMI Board of Editors

SY069

16:15 – 18:15

Hall 16

2-hour Symposium

**TRN**

**Controlled human infection models**

*Chairs* *Frederick Hayden (Charlottesville, United States)*  
*Nikolai Siemens (Greifswald, Germany)*

- S0197

16:15

**Updates on the dengue human infection model***Kirsten Lyke (Baltimore, United States)*
- S0198

16:45

**CHIM in endemic countries***Melissa Kapulu (Kilifi, Kenya)*
- S0199

17:15

**Controlled human infection models of parasitic infections***Meta Roestenberg (Leiden, Netherlands)*
- S0200

17:45

**Controlled human infection models of non-typhoidal *Salmonella****Malick Gibani (London, United Kingdom)*

Co-organised with: British Infection Association (BIA)

# ESCMID Global 2025 - Programme

EF033

16:15 – 17:15

Arena 2

ePoster Flash Session

AMR ANT CLN

## Current treatment options for Invasive fungal infections

Chair

Andreas H. Groll (Münster, Germany)

E0232

**The paediatric European Confederation of Clinical Mycology (ECMM) Quality (paed-EQUAL) Score for the management of candidaemia in children and neonates***Z.D. Pana\* (Nicosia, Cyprus), A.H. Groll, A. Bal, R. Sprute, F. Carlesse, S. Mellinghoff, S. Butzer, D. Ludwig-Bettin, K. Mehler, J. Stemler, D. Seidel, A. Marek, U. Ristau-Schäfer, O. Cornely*

E0233

**Prevalence rate, species distribution and antifungal susceptibility of bloodstream infections caused by rare yeasts of the Saccharomycetales order documented in 28 Brazilian medical centers***C. Palamin Buonafine\* (São Paulo, Brazil), C.P. Buonafine, A.E. Dos Santos, L.M. Favarello, R.C. Cognialli, V.R. Aquino, C.B. Agnelli, A.V. Mendes, T. Guimaraes, T.C. Sukiennik, F. Carlesse, P.T. Castro, C.C. Baqueiro, E.C. Francisco, A.L. Colombo*

E0234

**Rezafungin showed high *in vitro* activity and very low resistance rate against a collection of yeasts causing fungaemia in patients admitted to a tertiary hospital in Madrid from 2014 to 2024***J. Guinea\* (Madrid, Spain), P. Escribano, A. Gomez, A. Burillo, P. Muñoz*

E0235

**Posaconazole Drug-Drug Interaction Potential is Similar Across Bodyweight***R.E. Wrishko\* (Rahway, United States), P. Kothare, T.J. Bateman, M.G. Johnson, A. Stoch*

E0236

**Phase 2, open-label, non-comparative clinical trial evaluating the safety and efficacy of posaconazole in paediatric patients 2 to <18 years old with invasive aspergillosis***H. Kang\* (Seoul, Korea, Republic of), A.C. Arrieta, C. Dhooze, A. Kelemen, M. Macías-Parra, L. Aranda, Y.V. Dinikina, I. Kassis, S. Cesaro, T. Mackey, A. Shepherd, A.K. Shah, H. Waskin, M.G. Johnson*

E0237

**Activity of manogepix against a worldwide collection of mould isolates from 2023***M. Winkler\* (North Liberty, United States), S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira*

E0239

***Candida auris* displays an inoculum effect with multiple antifungal drug classes***R. Ben-Ami\* (Tel Aviv, Israel), R. Shadhan, A. Novikov, N. Mizrahi*

E0240

***In vitro* olorofim activity against *Aspergillus* spp clinical isolates collected as part as two national surveys on azole resistance conducted in Spain (ASPEN II and III)***J. Guinea\* (Madrid, Spain), P. Escribano, J. Moraga, A. Gomez, P. Muñoz*

EF034

16:15 – 17:15

Arena 4

ePoster Flash Session

AMR IPC

## Surgical site infections: epidemiology, risk factors, and prevention strategies

Chair

Trisha Peel (Melbourne, Australia)

E0241

**Incidence of Surgical Site Infections (SSIs) from the automated patient-based surveillance system, SPICMI, France***P. Astagneau\* (Paris, France), B. Nkoumazok, N. Benhajkassen, I. Arnaud, D. Verjat-Trannoy, J. Auraix, K. Lebascle*

E0242

**Beta-lactam versus non-beta-lactam antimicrobial prophylaxis and its association with the surgical site infection rate, a nationwide cohort study with 348 793 patients***S. Largiadèr\* (Lucerne, Switzerland), D. Berthod, A. Widmer, N. Troillet, C. Perdrieu, S. Harbarth, R. Sommerstein*

E0245

***Cutibacterium* species in Neurosurgical Infections: Not Such a "Cute" Pathogen After All***J. Donnelly\* (Dublin, Ireland), B. Dinesh, S. O'donnell*

E0246

**The polymicrobial nature of wound infections in an emergency orthopaedic ward in Northern Nigeria - implications for treatment and patient outcome***K.*

		<i>Cook* (Oxford, United Kingdom), F.S. Mohd, M.Y. Ahmad, A. Aliyu, K. Iregbu, C. Achi, T. Walsh, K. Sands</i>
E0247		<b>Efficacy of Octenidine Dihydrochloride Versus Chlorhexidine Gluconate Solutions in Reducing Surgical-Site Infections in Total Hip and Knee Arthroplasty: A Comparative Analysis</b> <i>A. Abialevich* (Beer Sheva, Israel), V. Benkovich, G. Benkovich</i>
E0249		<b>Impact on rates of surgical site infection of requiring pre-authorization of surgical antibiotic prophylaxis choice and post-operative antibiotic doses</b> <i>C.M. Villavicencio* (Taguig, Philippines), M.C. Hufano, R.R. Gabunada, Z. Alano</i>

SY067	16:15 – 18:15	Hall 11
	2-hour Symposium	

PHEI

#### STIs: an ongoing crisis

<i>Chairs</i>	<i>Dagmar Heuer (Berlin, Germany)</i> <i>Tomislav Mestrovic (Varazdin, Croatia)</i>
---------------	--

S0189	16:15	<b>STI treatment options are running out due to AMR</b> <i>Magnus Unemo (Örebro, Sweden)</i>
S0190	16:45	<b>Genomic surveillance of <i>Neisseria gonorrhoeae</i> strains</b> <i>Petra Wolffs (Maastricht, Netherlands)</i>
S0191	17:15	<b>Evolutionary insights into syphilis and <i>Treponema pallidum</i></b> <i>Mathew Beale (Hinxton, United Kingdom)</i>
S0192	17:45	<b>Challenges in chlamydial STI infections</b> <i>Cecile Bebear (Bordeaux, France)</i>

Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie

SY068	16:15 – 18:15	Hall 12
	2-hour Symposium	

CLN

DX

VAX

#### Tick-borne encephalitis: contemporary diagnosis and management

<i>Chairs</i>	<i>Joanna Maria Zajkowska (Białystok, Poland)</i> <i>Dace Zavadzka (Riga, Latvia)</i>
---------------	--

S0193	16:15	<b>Tick-borne encephalitis: immune response and clinical experience</b> <i>Sara Gredmark Russ (Stockholm, Sweden)</i>
S0194	16:45	<b>TBE immune responses and vaccine effectiveness</b> <i>Karin Stiasny (Vienna, Austria)</i>
S0195	17:15	<b>NS1 antibodies: diagnostics and screening of seroprevalence of TBE virus infection</b> <i>Gerhard Dobler (Munich, Germany)</i>
S0196	17:45	<b>Treatment for TBE: where do we stand?</b> <i>Daniel Ruzek (Brno, Czech Republic)</i>

LB006	16:15 – 18:15	Hall 13
	2-hour Oral Session	

#### The Trial Run: recent trials on *S. aureus* bacteraemia management

<i>Chairs</i>	<i>Julia Anna Bielicki (London, United Kingdom)</i> <i>Vance Fowler (Durham, United States)</i>
---------------	--

L0031	16:15	<b>Introduction</b> , <i>Julia Anna Bielicki (London, United Kingdom), Vance Fowler (Durham, United States)</i>
L0032	16:20	<b>Description of SNAP trial</b>
L0033	16:30	<b>Benzylpenicillin versus (flu)cloxacillin for the treatment of penicillin-susceptible <i>Staphylococcus aureus</i> bacteraemia: a randomised controlled trial of the <i>S. aureus</i> network adaptive platform (SNAP)</b> <i>S. Tong* (Melbourne, Australia), S. Aureus Network Adaptive Platform Trial Group</i>
L0034	16:45	<b>Cefazolin versus (flu)cloxacillin for the treatment of penicillin-resistant, methicillin-susceptible <i>Staphylococcus aureus</i> bacteraemia: a randomised controlled trial within the <i>S. aureus</i> network adaptive platform (SNAP)</b> <i>J. Davis* (Newcastle, Australia), S. Aureus Network Adaptive Platform Trial Group</i>

# ESCMID Global 2025 - Programme

L0035	17:00	<b>Cloxacillin versus cefazolin for methicillin-susceptible <i>Staphylococcus aureus</i> bacteraemia (CloCeBa): a randomised, controlled, non-inferiority trial</b> <i>X. Lescure* (Paris, France), F. Vandenesch, X. Duval, S. Tubiana, C. Burdet, N. Saïdani, A. Lemaignien, E. Canoui, L. Surgers, M. Esposito Farese, V. Le Moing, P. Tattevin</i>
L0036	17:15	<b>Trial Discussion</b> <i>Julia Anna Bielicki (London, United Kingdom)</i>
L0037	17:30	<b>Trial Discussion</b> <i>Vance Fowler (Durham, United States)</i>
L0038	17:45	<b>Open Discussion and Q&amp;A</b>

OS032	16:15 – 18:15	Hall 14
-------	---------------	---------

2-hour Oral Session



## Unravelling respiratory viruses, 2025

<i>Chairs</i>	<i>Eeva Broberg (Solna, Sweden)</i> <i>Florian Krammer (New York, United States)</i>
O0222	<b>Human metapneumovirus infections in hospitalized adults compared to respiratory syncytial virus and influenza infections over ten years in France</b> <i>P. Loubet* (Nîmes, France), S. Guitten, R. Simon, L. Lefrançois, L.B. Luong Nguyen, P. Vanhems, F. Laine, F. Galtier, X. Duval, B. Lina, M. Valette, G. Lagathu, V. Foulogne, N. Houhou-Fidhou, A.S. L'honneur, F. Carrat, L. Meyer, C. Durier, O. Launay</i>
O0223	<b>Unveiling animal susceptibility to influenza viruses (H1N1(pdm09) and H5N1 HPAIV) using animal-derived respiratory organoids</b> <i>F. Tarrés-Freixas* (Bellaterra, Spain), G. Ceada, N. Navarro, M. Pérez-Simó, N. Carmona-Vicente, L. Bonillo-Lopez, A. Moreno, C. López, J. Segalés, N. Majó, K. Kochanowski, J. Vergara-Alert</i>
O0224	<b>Exploring the impact of acute lung hypoxia on CD8 T cell phenotypes following severe influenza infection.</b> <i>B. Huckestein* (Memphis, United States), P. Thomas</i>
O0225	<b>Virological characterisation of RSV after Nirsevimab Breakthrough Infections in a Multicentre Observational Real-world Study in France</b> <i>S. Fourati* (Créteil, France), A. Reslan, J. Bourret, Y. Rahou, L. Chollet, S. Pillet, P. Tremeaux, N. Candace Dossou, E. Gault, M. Salmona, B.M. Imbert, A. Mirand, S. Larrat, A. Moisan, S. Marot, A. Schnuriger, N. Veyrenche, I. Engelmann, L. Handala, A. Henry, V. Stephan, S. Brichler, V. Avettand-Fenoel, N. Zemali, C. Lefeuvre, C. Pronier, L. Regueme, M.C. Jaffar, L. Mouna, C. François, A. Regueme, C. Hartard, S. Roger, F. Gallais, A. Ly, C. Rodriguez, G. Dos Santos, J. Buchrieser, O. Schwartz, J.M. Pawlotsky, F. Lemoine, E. Audureau, M.A. Rameix-Welti</i>
O0226	<b>Baseline immunity to highly pathogenic avian influenza viruses in a healthcare worker cohort</b> <i>C. Geurts Van Kessel* (Rotterdam, Netherlands), M. Power, W. Rijnink, L. Gommers, T. Bestebroer, W. Soochit, W. Tan, B. Verstrepen, S. Bogers, G. Van Nierop, R. Sikkema, A. Grifoni, A. Sette, M. Koopmans, R. Fouchier, M. Richard, R. De Vries, C. Geurtsvankessel</i>
O0227	<b>Impact of reinfection on post-acute sequelae of COVID-19 over multi-organ systems</b> <i>J. Tan* (Singapore, Singapore), J.T. Lim, L.E. Wee, C. Chiew, B. Ong, D. Lye</i>
O0228	<b>Clinical and economic burden of respiratory syncytial virus in adults with acute respiratory infections – a Danish nationwide cohort study</b> <i>Stanislava Bratkovic (Copenhagen, Denmark)</i>
O0229	<b>The burden of respiratory syncytial virus in children &lt;3 years old presenting to primary, secondary and tertiary care in England: report from the STOP RSV prospective surveillance study</b> <i>E. Carter* (Liverpool, United Kingdom), H. Hill, D. Ferreira, A. Collins, C. Solórzano, L. McLellan, L. Kerruish, F. Fyles, S. Drysdale, P. Gonzalez-Dias, G. Duncan, K. Davies, P. Crozier, P. Saunderson, R. Kramer, M. Bangert, N. Vassilouthis, S. Messahel, B. Caroline, S. Brearey, J.</i>

Bernatoniene, S. Bhowmik, J. Perry, P. Mottram, P. Mcnamara, D. Lewis, N. Van Kinnekan, A. Finn

O0230

**Targeted metagenomic sequencing of influenza, RSV, and symptomatic respiratory infections from UK healthcare workers** M. Knoll\* (Hinxton, United Kingdom), L. Findlater, B. Katie, J. Wagner, T. Diego, D. Rajan, S. Frances Field, S. Thurston, A. Wong, B. Hyatt, N. Thesin, J. Robinson, R. Yeadon, A. Galvin, B. Blane, Y.L. Huang, K. Howe, M. Forbes, K. Figueroa, F. Schwach, S. Stott, A. Marhino, A. Frick-Kretschmer, B. Dave, T. Maddison, S. Hopkins, S. Foulkes, J. Islam, A. Atti, V. Hall, E. Harrison

SY064

16:15 – 18:15

Hall 2

2-hour Symposium

AMR ANT

**PK/PD to avoid emergence of resistance?**

Chairs

Anne-Grete Märtsen (Leiden, Netherlands)  
Joseph Meletiadis (Athens, Greece)

S0177

16:15

**PK/PD and antibacterial therapy** Dolores Soy-Muner (Barcelona, Spain)

S0178

16:45

**PK/PD and antifungal therapy** Roger Brüggemann (Nijmegen, Netherlands)

S0179

17:15

**PK/PD and antiviral therapy** Joe Standing (London, United Kingdom)

S0180

17:45

**PK/PD considerations in anthelmintic treatment** Jennifer Keiser (Allschwil, Switzerland)

EW070

16:15 – 18:15

Hall 3

Educational Session

AMR CLN DX

**Malaria: when the drugs don't work Management of treatment failure in non-endemic countries**

Chairs

Laura Nabarro (London, United Kingdom)  
Caroline Rönnerberg (Stockholm, Sweden)

W0201

16:15

**Malaria in the non-endemic setting: who to treat as an outpatient and how to detect treatment failure** Emmanuel Bottieau (Antwerp, Belgium)

W0202

16:35

**Malaria resistance mutations in the non-endemic setting: role of genomic surveillance** Anna Rosanas Urgell (Antwerp, Belgium)

W0203

16:55

**How to manage *Plasmodium Knowlesi* infection** Giri Shan Rajahram (Kota Kinabalu, Malaysia)

W0204

17:15

**Epidemiology and control of *Plasmodium Knowlesi*** Kimberly Fornace (Singapore, Singapore)

Co-organised with: British Infection Association (BIA)

SY065

16:15 – 18:15

Hall 4

2-hour Symposium

AMR

**Gram-positives, are they still going?**

Chairs

Diederik Bathoorn (Groningen, Netherlands)  
Stefania Stefani (Catania, Italy)

S0181

16:15

**The vanco chronicles: enterococci's global journey** Guido Werner (Wernigerode, Germany)

S0182

16:45

**Pitfall in susceptibility testing of Gram-positives** Helena Zemlickova (Prague, Czech Republic)

S0183

17:15

**Drivers for daptomycin and linezolid resistance in Gram-positives** Glen Carter (Melbourne, Australia)

S0184

17:45

**What is new in treatment against MDR Gram-positives?** Alex Soriano (Barcelona, Spain)

SY066

16:15 – 18:15

Hall 5

2-hour Symposium

CLN DX

# ESCMID Global 2025 - Programme

## Biomarker testing to manage respiratory infections in primary care in low resource settings

<i>Chairs</i>		<i>Sonia Lewycka (Hanoi, Vietnam)</i> <i>Heiman Wertheim (Nijmegen, Netherlands)</i>
S0185	16:15	<b>The Vietnamese experience with CRP testing in the community setting</b> <i>Thi Thuy Nga Do (Ha Noi, Vietnam)</i>
S0186	16:45	<b>The Nigerian experience with CRP testing in the community setting</b> <i>Augustine Onwunduba (Awka, Nigeria)</i>
S0187	17:15	<b>CRP testing in diagnosing tuberculosis in Zambia and South Africa</b> <i>Helen Ayles (Lusaka, Zambia)</i>
S0188	17:45	<b>The health economics of CRP testing in LMICs</b> <i>Yoel Lubell (Bangkok, Thailand)</i>

EF035	17:15 – 18:15	Arena 1
ePoster Flash Session		

**DX** **PHEI**

## Genomics in pathogen surveillance

<i>Chair</i>		<i>Vitor Borges (Lisbon, Portugal)</i>
E0250	<b>Genomic Surveillance of Invasive Group A Streptococcus in Argentina's 2023 Epidemic: Unveiling Hypervirulent emm1 Lineages and Pediatric emm12 Burden</b> <i>L. Cipolla* (Buenos Aires, Argentina), A. Gianecini, T. Poklepovich, C. Giovacchini, M. Prieto</i>	
E0251	<b>Understanding the population structure of <i>Moraxella catarrhalis</i> using core-genome multilocus sequence typing</b> <i>I. Yassine* (Oxford, United Kingdom), K.A. Jolley, J.E. Bray, M.J. Jansen Van Rensburg, F. Patel, A. Sheppard, H.J. Zar, V. Allen, L. Ah Tow, M.C.J. Maiden, M.P. Nicol, A.B. Brueggemann</i>	
E0252	<b>Impact of the COVID-19 pandemic on the <i>Streptococcus pyogenes</i> clones causing adult invasive infections</b> <i>M. Ramirez* (Lisbon, Portugal), A. Friães, J. Vermeiren, R. Mamede, C.R. Bettencourt, M.P. Bajanca-Lavado, J. Melo-Cristino, P. Group For The Study Of Streptococcal Infections</i>	
E0253	<b>Unveiling the Hidden Complexity of <i>Providencia</i>: Genomic Insights into Species Reclassification and Antibiotic Resistance</b> <i>X. Dong* (Hangzhou, China)</i>	
E0254	<b>Genomic description of outbreak of VIM-1 carrying <i>Enterobacter</i> in Switzerland suggests plasmid transmission between sequence types</b> <i>H. Seth-Smith* (Zurich, Switzerland), M. Greutmann, C. Beckmann, E. Gruner, R. Capaul, G. Greub, P.M. Keller, S. Tschudin-Sutter, L. Berlinger, S.D. Brugger, T. Roloff, O. Nolte, L. Poirel, P. Nordmann, A. Egli</i>	
E0255	<b>Genomic epidemiology of <i>Klebsiella pneumoniae</i> bloodstream infections in a german tertiary centre: increased virulence in carbapenem-resistant strains</b> <i>L. Kneigendorf* (Hannover, Germany), M. Lindenberg, C. Baier, J. Erdmann, S. Häußler, D. Schlüter</i>	
E0256	<b>Phylogenetic mixing and undetected circulation of multiple <i>Candida auris</i> lineages following recognition of imported cases in Italy</b> <i>V. Di Pilato* (Genoa, Italy), E. Willison, L. Calabrese, L. Magnasco, C. Elisa, G. Daniele Roberto, M. Mikulska, B. Matteo, M. Anna</i>	
E0257	<b>Using Long-Read Sequencing for Core Plasmid Multilocus Sequence Typing to Investigate Plasmid Relationships Among Bacterial Species in German Hospital Wastewater</b> <i>A.K. Bari* (Groningen, Netherlands), B. Sinha, J.W.A. Rossen, B.B. Xavier, T.T. Severs, M.J. Cardoso, M. Savin</i>	
E0258	<b>Screening for rectal colonization with multidrug-resistant pathogens: usage of rapid metagenomic long-read technology</b> <i>S. Purushothaman* (Zurich, Switzerland), A.M. Rooney, S. Moser, A. Egli</i>	

EF036	17:15 – 18:15	Arena 3
ePoster Flash Session		

**CLN**

## Heads up! CNS infections

<i>Chair</i>		<i>Jacob Bodilsen (Aalborg, Denmark)</i>
--------------	--	--



E0259	<b>Central Nervous System Involvement by <i>Mycobacterium avium</i> Complex in Advanced HIV: A Rare and Underdiagnosed Challenge</b> <i>E. Sienra Iracheta* (Tlalpan, Mexico), M. Aranda Aurelio, A. Camiro Zuñiga, D.H. Martínez Oliva, A. Llamas Lopez, A.P. Rodriguez Zulueta</i>
E0260	<b>Acute disseminated encephalomyelitis following bacterial meningoencephalitis – Two Case reports &amp; Review of Literature</b> <i>M. Priyadarshi* (Delhi, India), M. Salunkhe, A. Mohan, P. Gupta, A. Agarwal, V. Goel, R. Bhatia</i>
E0261	<b><i>Streptococcus equi</i> Subspecies <i>zooepidemicus</i> Endocarditis and Meningitis in a 62-Year-Old Patient: A Case Report and Literature review</b> <i>D. Chemello* (Modena, Italy), G. Franceschi, S. Alessandra, B. Andrea, S. Mario, M. Marianna, M. Cristina</i>
E0262	<b>Breaking barriers: meropenem-vaborbactam as a game-changer for KPC central nervous system infections</b> <i>F. Prataviera* (Udine, Italy), S. Giuliano, S. Flammini, J. Angelini, P.G. Cojutti, C. Tascini</i>
E0263	<b>Multidrug-Resistant <i>Klebsiella pneumoniae</i> Meningitis in the Absence of Intracranial Devices: A Case Report</b> <i>M. Chumbita* (Barcelona, Spain), E. Viñas Esmel, P. Castro, S. Herrera, C. Bastida, A. Soriano</i>
E0264	<b>Triple Threat: Sequential Meningitis Infections in an Immunosuppressed Patient with <i>Morganella morganii</i>, <i>Acinetobacter baumannii</i>, and Vancomycin-resistant <i>Enterococcus faecium</i></b> <i>Y. Çakır Kıymaz* (Sivas, Türkiye), Y. Çakır Kıymaz, E. Kıymaz, Z. Bulut, S.A. Büyüktuna, N. Elaldi</i>
E0265	<b>Invasive pulmonary <i>Arthrophagus kalrae</i> infection with cerebral abscesses in an immunocompromised child</b> <i>B. Winkel* (Utrecht, Netherlands), J. Jans, M. Luesink, R.J. Nievelstein, F. Hagen, J. Buil, T. Wolfs, T. Van Der Bruggen</i>
E0266	<b>Treatment of herpes simplex encephalitis with the helicase-primase inhibitor pritelivir in an immunocompromised patient</b> <i>A. Birkmann* (Wuppertal, Germany), C. Lueck, C. Rautenberg, S. Bonsmann, A. Marini, M. Sumner, T. Schroeder, S. Voigt</i>
E0267	<b>A case of influenza A (H1N1) encephalitis: Rare neurological implication in a healthy adult</b> <i>N.K. Midha* (Jodhpur, India), S. Bhat K S, S. Tiwari, D.S. Meena, D. Kumar, G.K. Bohra</i>

Sunday, 13 April 2025

SY075	08:30 – 10:30	Hall 15
	2-hour Symposium	
	<div>PHEI</div>	
Diphtheria: from re-emergence to vaccine strategies		
Chairs	Helena Seth-Smith (Zurich, Switzerland) Julie Toubiana (Paris, France)	
S0221	08:30	Diphtheria: from clinical picture to medical managementRegina Oladokun (Oyo, Nigeria)
S0222	09:00	The epidemiology of diphtheria worldwide over the last half-century: more than one comebackAndreas Hoefler (Solna, Sweden)
S0223	09:30	There’s more than one toxigenic <i>Corynebacterium</i> : the current genomics landscape of diphtheria-associated strainsSylvain Brisse (Paris, France)
S0224	10:00	Diphtheria vaccination: a reappraisal Gayatri Amirthalingam (London, United Kingdom)
Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Vaccine Study Group (EVASG)		

EF039	08:30 – 09:30	Arena 1
	ePoster Flash Session	
	<div>CLN PHEI TRN</div>	

# ESCMID Global 2025 - Programme

## Novel approaches to antiviral therapy

Chair

Pinyo Rattanaumpawan (Bangkok, Thailand)

- E0288

**Obeldesivir exhibits broad anti-RSV activity and a high barrier to resistance in vitro and is efficacious in a non-human primate challenge model of RSV infection.***J. Pitts\* (Foster City, United States), J.L.R. Zamora, S. Manhas, T. Aeschbacher, J. Chan, V. Cutillas, V. Nair, N. Riola, A. Vijjapurapu, M. Vermillion, S. Eng, C. Richards, D. Han, J. Perry, S. Chaudhuri, I. Liu, C. Martinez, N. Peinovich, K.H. Sun, A. Cai, R. Martin, J. Moshiri, C. Hedskog, V. Avadhanula, P. Piedra, K. Stobbelaar, P. Delputte, T. Cihlar, S. Fletcher, J. Bilello*
- E0289

**EDP-323, a first-in-class, oral, RSV L-protein inhibitor reduces disease severity (respiratory mucus production) and accelerates viral clearance in a human viral challenge study.***J. Devincenzo\* (Watertown, United States), A. Ahmad, S. Chen, B. Löndt, A. Mann, J. Mori, A. Catchpole, S. Rottinghaus*
- E0290

**A Combined *In Silico* and *In Vitro* Pipeline for Optimizing Nanobodies Targeting Surface Proteins of Pathogens: Applications to SARS-CoV-2, WNV, and Influenza A Virus.***C.L. Pierri\* (Bari, Italy), G.C.M. Perrone, A.L. Francavilla, S. Todisco, M.N. Sgobba, V. Scaglione, D.I. De Luca, F. Mastropirro, S. Spadone, L. Guerra, M. Volpicella, A. De Grassi*
- E0291

**Bernifosbuvir and Remdesivir exhibit potent antiviral activity against tick-borne encephalitis virus *in vitro*.***D. Grandgirard\* (Bern, Switzerland), S. Leoni, R. Dijkman, L. Eyer, D. Ruzek, S.L. Leib*
- E0292

**Combinations of antiviral drugs demonstrating synergistic inhibition of multiple respiratory RNA viruses.***S. Ellis\* (London, United Kingdom), A.I. Jacobs, M. Woodall, S. Zhang, J.F. Standing, J. Breuer*
- E0293

**The safety and pharmacokinetics of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor: Interim results from a Phase 1a/1b study in healthy participants.***A. Gagar\* (South San Francisco, United States), E. Gane, C. Schwabe, G. Wang, J. Liu, S. Knox, K. Kitrinos, K. Zomorodi*
- E0294

**Efficacy of ganciclovir against CMV infection is dependent on treatment initiation time.***L. Sudarsono\* (Leiden, Netherlands), X. Liu, J.G.C. Van Hasselt, A.G. Märtson*
- E0295

**Efficacy of molnupiravir and baloxavir against Influenza A H1N1 infection *in vitro* and *in vivo*.***D. Liu\* (Hong Kong, Hong-Kong SAR, China), K.Y. Leung, R. Zhang, Y. Fan, K.H. Chan, F.N.I. Hung*
- E0296

**Human defensin derived peptide showing broad antiviral activity against human adenoviruses.***X. Wang\* (Hongkong, China), H. Zhao*

EF040

08:30 – 09:30

Arena 3

ePoster Flash Session

CLN TRN

## New frontiers in parasitic disease and migrant health research

- E0298

**Targeting metabolic bioenergetics: the 'Achilles' heel' of *Leishmania*.***D. Sarkar\* (Kolkata, India)*
- E0299

**Leishmaniasis in Southern Alicante (Spain): what is the new patient profile?***M.D. Hernández Rabadán\* (Orihuela, Spain), C. Bernal Alcaraz, M.B. Martínez López, D. López Parra, J. Llenas García*
- E0300

***Schistosoma haematobium* infection is associated with oncogenic gene expression in cervical mucosa, with enhanced effects following treatment.***Anna Mertelsmann (Zürich, Switzerland)*
- E0301

**Associations between water and sanitation service, risk of intestinal schistosomiasis, infection intensity, and liver fibrosis in selected households living near Lake Albert: a descriptive cross-sectional study?***G. Lam\* (London, United Kingdom), D. Dee, A. Edielu, E. Ohuma, V. Anguajibi, E. Webb, A. Wamboko, P.*

	<i>Mawa, J. Friedman, A. Bustinduy</i>	
E0302		<b>Schistosomiasis detected by Screening of sub-Saharan African Unaccompanied Minor Refugees in Berlin between 2023 and 2024</b> <i>G. Equihua Martinez* (Berlin, Germany), A.K. Lindner, M.C. Moreno-Del Castillo, J. Hammer, M. Nürnberg, P. Pitzinger, T. Geppert, F. Mockenhaupt, B. Kampmann, F. Olgemöller</i>
E0303		<b>NADPH oxidase of the mosquitoes and the antioxidant genes repertoire of the bacteria coordinate mosquito-bacteria interaction in midgut</b> <i>B. Song* (Kowloon, Hong-Kong SAR, China), J. Zeb, N. Buchon, O. Sparagano, P. Butaye</i>
E0304		<b>Molecular detection and sequencing of the genes encoding the predicted enzymes; Amidase, NADH ubiquinone oxidoreductase, and sodium neurotransmitter symporter in <i>Onchocerca volvulus</i></b> <i>A. Acheampong* (Sunyani, Ghana), J. Larbi, P.C. Kudzordzi, P. Nyarko, K.B. Otabil</i>
E0305		<b>Tuberculosis outcomes among international migrants living in Europe compared to the non-migrant population: a systematic review and meta-analysis</b> <i>G. Guido* (Bari, Italy), S. Cotugno, L. Frallonardo, R. Papagni, V. Giliberti, F.V. Segala, C. Polizzotto, G. Di Franco, M. Affronti, E. Piccione, G. Gualano, F. Palmieri, M. Barbagallo, N. Veronese, A. Saracino, F. Di Gennaro</i>

EW079	08:30 – 10:30	Hall 11
	Educational Session	

CLN DX		
New guidelienes for management of brain Infections		
Chairs	<i>Jacob Bodilsen (Aalborg, Denmark)</i> <i>Kartika Maharani (Jakarta, Indonesia)</i>	

W0237	08:30	<b>Tuberculous meningitis: what can we learn from the first global guidelines?</b> <i>Joseph Donovan (Ho Chi Minh City, Vietnam)</i>
W0238	08:50	<b>WHO guidelines on bacterial meningitis: change of clinical practice?</b> <i>Matthijs Brouwer (Amsterdam, Netherlands)</i>
W0239	09:10	<b>ESCMID encephalitis guidelines 2024: what's new?</b> <i>Tom Solomon (Liverpool, United Kingdom)</i>
W0240	09:30	<b>WHO guidelines for cryptococcal meningitis: success stories and barriers to implementation</b> <i>Nelesh Govender (Johannesburg, South Africa)</i>

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

SY073	08:30 – 10:30	Hall 12
	2-hour Symposium	

AMR ANT		
Proxy indicators: bridging the gap between surveillance and antimicrobial stewardship		
Chairs	<i>Bhanu Sinha (Groningen, Netherlands)</i> <i>Annelies Verbon (Bosch En Duin, Netherlands)</i>	

S0213	08:30	<b>A broad spectrum of possibilities: spectrum scores as a unifying metric</b> <i>Céline Pulcini (Nancy, France)</i>
S0214	09:00	<b>Proxy indicators to estimate appropriateness of antibiotic prescriptions</b> <i>Diane Ashiru-Oredope (London, United Kingdom)</i>
S0215	09:30	<b>How to bridge the gap between surveillance and antimicrobial stewardship</b> <i>Mark G. J. De Boer (Leiden, Netherlands)</i>
S0216	10:00	<b>Health economics, surveillance and antimicrobial stewardship</b> <i>Zhu Nina Jiayue (London, United Kingdom)</i>

Co-organised with: Dutch Committee on Antimicrobial Policy, ESCMID Education Subcommittee, International Society for Infectious Diseases (ISID)

SY074	08:30 – 10:30	Hall 13
-------	---------------	---------

# ESCMID Global 2025 - Programme

CLN IPC

2-hour Symposium

## Difficile to treat: advanced management strategies in difficult to treat CDI

Chairs *Frédéric Barbut (Paris, France)*  
*Kerrie Davies (Leeds, United Kingdom)*

S0217	08:30	<b>Severe CDI: when standard protocols fail</b> <i>Hynek Bartos (Prague, Czech Republic)</i>
S0218	09:00	<b>Therapies for complicated CDI</b> <i>Emma Bishop (Clayton Vic, Australia)</i>
S0219	09:30	<b>Recurrent CDI: Breaking the cycle</b> <i>Andrea Marino (Catania, Italy)</i>
S0220	10:00	<b>Live biotherapeutic products for <i>Clostridioides difficile</i> infection</b> <i>Simon Goldenberg (London, United Kingdom)</i>

Co-organised with: ESCMID Study Group for *Clostridioides difficile* (ESGCD)

OS038 08:30 – 10:30 Hall 14

AMR DX

2-hour Oral Session

## Making fast for making better: AMR rapid diagnostics

Chairs *Giulia De Angelis (Rome, Italy)*  
*Onur Karatuna (Växjö, Sweden)*

00278	<b>Point of care rapid lateral flow antibiotic resistance test to detect carbapenem resistance in lower respiratory tract infections.</b> <i>J. Rogers* (Bedford, United Kingdom), A. Gregg, Q. Liu, S. Owen, C. Chen, M. Edward, S. Jiang, W. Lu, L. Mynheer, W. Finch</i>
00279	<b>Evaluation of a new rapid Lateral flow immunoassay for the detection of DHA-producing Gram-negative bacteria</b> <i>C. Moguet* (Guipry, France), S. Oueslati, A. Vogel, S. Gelhaye, A. Chalin, H. Volland, T. Naas</i>
00280	<b>The NitroSpeed Taniborbactam NP test; easy detection of <math>\beta</math>-lactamase sensitivity to taniborbactam</b> <i>O. Raro* (Fribourg, Switzerland), S. Herrera-Espejo, M. Bouvier, A. Kerbol, L. Poiriel, P. Nordmann</i>
00281	<b>Rapid detection of <math>\beta</math>-lactamase-mediated resistance to aminopenicillins from urines.</b> <i>P. Nordmann* (Fribourg, Switzerland), N. Helsens, C. Duployez, L. Poiriel, R. Dessein</i>
00282	<b>Rapid detection of antibiotic resistance in direct urine samples</b> <i>M. Bot* (Arnhem, Netherlands), J. Flipse, S. Bongers, J. Hoogerwerf, J. Ten Oever, H. Wertheim, M. Van Meer</i>
00283	<b>Next-Generation Utilizer Dipsticks for direct-from-sample phenotypic Antibiotic Susceptibility Testing in UTIs</b> <i>E. Iseri* (Stockholm, Sweden), W. Van Der Wijngaart, V. Özenci, R. Santini, A. Nakama, O. Ekelund, A. Van Belkum</i>
00284	<b>Screening for ceftriaxone-resistant <i>Neisseria gonorrhoeae</i> with the Urogenital and Resistance kit (AusDiagnostic)</b> <i>A. Braille* (Paris, France), M. Mainardis, F. Meunier, M. Mathar, M. Mérimèche, B. Condamine, F. Caméléna, B. Berçot</i>
00285	<b>Comparative evaluation of rapid antimicrobial susceptibility testing assays for Gram-negative bacteria from positive blood cultures</b> <i>D. Squitieri* (Rome, Italy), G. Menchinelli, C. Magri, T. D'inzeo, M. Cacaci, B. Posteraro, G. De Angelis, M. Sanguinetti</i>
00286	<b>Rapid detection of Carbapenemases directly from positive blood culture bottle: A tool for early shifting from empirical to targeted therapy</b> <i>K. Chaudhary* (New Delhi, India), H. Gautam, P. Batra, S. Mohapatra, S. Sood, B. Dhawan, B. Das Kumar</i>

SY076 08:30 – 10:30 Hall 16

AMR

2-hour Symposium

## AMR Surveillance in low resource countries: Insights into clinical and policy translation

Chairs *Kwame Ohene Buabeng (Ho, Ghana)*  
*H. Rogier Van Doorn (Hanoi, Vietnam)*

S0225	08:30	<b>New indicators in national monitoring and evaluation of AMR supported by improved data utilisation</b> <i>Direk Limmathurotsakul (Bangkok, Thailand)</i>
S0226	09:00	<b>Interdisciplinary investigation of the drivers and burden of AMR in urinary tract infections</b> <i>Stephen Mshana (Mwanza, Tanzania, United republic of)</i>
S0227	09:30	<b>A clinically-oriented AMR surveillance network: case-based surveillance and implementation</b> <i>Paul Turner (Siem Reap, Cambodia)</i>
S0228	10:00	<b>National prescribing guidelines based on AMR surveillance data</b> <i>Vilada Chansamouth (Vientiane, Lao People's democratic republic)</i>

Co-organised with: CAESAR network, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

EW077	08:30 – 10:30	Hall 2
Educational Session		

CLN DX

**New tools in acute bacterial infections and sepsis: from machine learning to precision medicine**

*Chairs* Benjamin Mcfadden (Perth, Australia)  
Rita Murri (Rome, Italy)

W0229	08:30	<b>Differentiating acute infection, sepsis and sepsis mimics in the ED?</b> <i>Lisa Mellhammar (Lund, Sweden)</i>
W0230	08:50	<b>Machine learning for early recognition of sepsis</b> <i>Karsten Borgwardt (Martinsried, Germany)</i>
W0231	09:10	<b>How to avoid common mistakes in randomised clinical study design</b> <i>Yin Mo (Singapore, Singapore)</i>
W0232	09:30	<b>Improved clinical trials in community-acquired pneumonia using precision medicine</b> <i>Lennie Derde (Utrecht, Netherlands)</i>

Co-organised with: ESCMID Scientific Affairs Subcommittee, European Clinical Research Alliance on Infectious Diseases (ECRAID), ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), European Sepsis Alliance (ESA), ESCMID Study Group for Antimicro

SY072	08:30 – 10:30	Hall 3
2-hour Symposium		

PHEI VAX

**Tackling the emergence of dengue and other *Aedes*-borne diseases in Europe**

*Chairs* Fernanda Boulos (São Paulo, Brazil)  
Martin P. Grobusch (Amsterdam, Netherlands)

S0209	08:30	<b>How dengue, chikungunya and zika virus disease became emerging threats to Europe</b> <i>Celine Gossner (Solna, Sweden)</i>
S0210	09:00	<b>Surveillance of dengue in urbanised tropical regions</b> <i>Vincent Junxiong Pang (Singapore, Singapore)</i>
S0211	09:30	<b>Mosquito surveillance and control: opportunities and challenges</b> <i>Tba</i>
S0212	10:00	<b>Tracking autochthonous arboviral infection</b> <i>Luisa Barzon (Padua, Italy)</i>

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

EW078	08:30 – 10:30	Hall 4
Educational Session		

DX

**Implementing metagenomics in my lab and mistakes to avoid**

*Chairs* Hege Vangstein Aamot (Lørenskog, Norway)  
Claudio Neidhöfer (Bonn, Germany)

W0233	08:30	<b>Is metagenomics right for my lab?</b> <i>Paula Mölling (Örebro, Sweden)</i>
-------	-------	--

# ESCMID Global 2025 - Programme

W0234	08:50	<b>Understanding the experimental and certification aspects of metagenomics</b> <i>Mads Albertsen (Aalborg, Denmark)</i>
W0235	09:10	<b>Navigating tools, techniques, and procurement</b> <i>Basil Britto Xavier (Groningen, Netherlands)</i>
W0236	09:30	<b>Setting realistic goals and outcomes for metagenomics integration</b> <i>Claire Bertelli (Lausanne, Switzerland)</i>
Co-organised with: Danish Society for Clinical Microbiology, ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Trainee Association of ESCMID (TAE) Steering Committee		

OS037	08:30 – 10:30	Hall 5
	2-hour Oral Session	

DX

IPC

## Whole genome sequencing: tracking transmission and reservoirs in outbreaks

<i>Chairs</i>	<i>Eric Claas (Leiden, Netherlands)</i> <i>Paul G. Higgins (Cologne, Germany)</i>
---------------	--

00268	<b>From outbreaks to outcomes: Harnessing WGS for IPC in a high-risk paediatric setting</b> <i>N. Storey* (London, United Kingdom), E. Cloutman-Green, J. Hartley, H. Dunn, B. Brekle, M. Adil, S. Barua, J. Hatcher, J. Brown, J. Breuer</i>
00269	<b>Why do routine genome-oriented surveillance for <i>Pseudomonas aeruginosa</i>?</b> <i>A. Rath* (Regensburg, Germany), L. Grancicova, B. Kieninger, A. Caplunik-Pratsch, J. Fritsch, A. Eichner, W. Schneider-Brachert</i>
00270	<b>TreeTime estimation depicts transmission dynamics of clinical and environmental <i>Pseudomonas aeruginosa</i> from common reservoirs in healthcare environment through whole genome sequencing (WGS)</b> <i>Ö. Yetis* (London, United Kingdom), Ö. Yetiş, F. Dyrkell, S. Ali, P. Wilson</i>
00271	<b>Understanding <i>Serratia</i> transmission during a neonatal ICU outbreak: A combined genotyping and risk factor analysis</b> <i>K. Jaakkola* (Lyon, France), C. Dananché, A. Fischer, J.C. Picaud, P. Cassier, M. Colomb-Cotinat, S. Hayş, J.P. Rasigade</i>
00272	<b>Genomic Insights into the Regional Transmission of KPC-Producing Bacteria: Clonal and Non-Clonal Plasmid Sharing</b> <i>C. Shankar* (Ann Arbor, United States), A.M. Pirani, D.B. Narayanan, B. Brennan, S. Mcnamara, A. Miles-Jay, A. Bahr, E.S. Snitkin</i>
00273	<b>Genome-oriented analysis of the first outbreaks involving the novel <i>Serratia sarumanii</i> at a neonatal unit</b> <i>A. Rath* (Regensburg, Germany), B. Kieninger, L.J. Klages, A. Eichner, A. Keller-Wackerbauer, S.M. Wellmann, A. Ambrosch, J. Fritsch, A. Caplunik-Pratsch, M. Kabesch, J. Kalinowski, W. Schneider-Brachert</i>
00274	<b>Evaluating the Utility of Whole-Genome Sequencing to Optimise Infection Prevention and Control in a Hospital Setting: Findings from the GENOTYPE Study</b> <i>J. Price* (Brighton, United Kingdom), I. Sey, A. Yeoh, D. Wlazly, A. Davies, O. Makanjuola, J. Leach, S. Mookerjee, M. Krutikov</i>
00275	<b>Outbreak of Carbapenem-Resistant <i>Acinetobacter seifertii</i> in a Neonatal Intensive Care Unit: Genomic Characterization and Surveillance.</b> <i>D. Pereira* (Porto Alegre, Brazil), P. Barth, L. Konkewicz, W. Latosinski, G. De Oliveira, L. Lutz, M. Mott, C. Constante, C. Wilhelm, L. Antochervis, R. Paiva, K. Tragnago, A. Barth, A. Martins</i>
00276	<b>Unveiling the Clonal Dynamics and transmission mechanism of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> in the ICU environment</b> <i>X. Han* (Hangzhou, China), J. Zhou, Y. Jiang, Y. Yu</i>
00277	<b>Survey of Infection Prevention staff perception of WGS integration into routine IPC practice</b> <i>D. Ling* (Melbourne, Australia), B. Baral, V. Madigan</i>

EF041	09:30 – 10:30	Arena 2
	ePoster Flash Session	

# ESCMID Global 2025 - Programme

		<b>treatment of a cerebrospinal fluid drain infection caused by a multidrug-resistant <i>Staphylococcus epidermidis</i> strain</b> <i>M.D. Di Trapani* (Bozen, Italy), T. Kamal Eldin, G. Spoladore, D. Drusiani, B. Ladinser, R. Aschbacher</i>
E0318		<b>Timeline of early infections post porcine xenothymokidney transplant</b> <i>H. Neumann* (New York, United States), M. Ringer, R. Alpizar-Rivas, J. Stern, F. Zervou, V. Halpern-Cohen, J. Hogan, A. Griesemer, R. Montgomery, S. Williams, S. Mehta</i>
E0319		<b>Invasive Non-tuberculous mycobacteria Infection in children undergoing Cardiac Surgery at the specialized Cardiology Hospital of Peshawar</b> <i>M. Khan* (Peshawar, Pakistan)</i>
E0320		<b>Use of multiplex PCR assay analysis in patients with suspected implant-based breast reconstruction infection: a single center experience</b> <i>A. Pagotto* (Udine, Italy), G.G. Caputo, A. Scarabosio, A. Sartor, A. Colombo, P.C. Parodi, C. Tascini</i>
E0321		<b>PET CT controls and Dalbavancin therapeutic drug monitoring can help guiding Dalbavancin treatment duration of complicated cardiovascular infections</b> <i>C. Kujat* (Kiel, Germany), M. Jüptner, D. Pape, J. Frank, A.T.D. Thiem, B. Panholzer, B. Steinborn, S. Ewering, A. Friedrichs</i>
E0322		<b>A complex case of pelvic bone infection caused by carbapenem-resistant <i>Acinetobacter baumannii</i> successfully treated with eravacycline</b> <i>M. Zagarrigo* (Bologna, Italy), S. Tedeschi, M. De Paolis, G. Fornaro, A. Pozzi, E. Zamparini, P. Viale</i>
E0323		<b>Oritavancin in a patient with recurrent endocarditis by <i>Enterococcus faecalis</i>: a new therapeutic option?</b> <i>M. Bongiovanni* (Lugano, Switzerland), B. Barda, E. Bernasconi</i>

KN080	09:30 – 10:30	Hall 1
	Keynote Lecture	

VAX

## Infections after solid organ transplantation: past, present and future

<i>Chairs</i>	<i>Nina Khanna (Basel, Switzerland)</i> <i>Priscilla Rupali (Vellore, India)</i>
---------------	---

K0241	09:30	Jay Fishman (Boston, United States)
-------	-------	-------------------------------------

SY082	11:00 – 12:00	Hall 6
	1-hour Symposium	

PRO

PHEI

## How to address anti-science in our community?

<i>Chairs</i>	<i>Tuba Dal (Ankara, Türkiye)</i> <i>Tyra Grove Krause (Copenhagen, Denmark)</i>
---------------	---

S0243	11:00	<b>The rise of anti-science: lessons for the future scientist</b> <i>Marion Koopmans (Rotterdam, Netherlands)</i>
S0244	11:30	<b>Open science for public trust</b> <i>Lisa Hansen (Ottawa, Canada)</i>

FO090	11:00 – 12:00	Arena 1
	Open Forum	

PRO

## European CM/ID exam: going forward

<i>Chair</i>	<i>Siri Goepel (Tuebingen, Germany)</i>
--------------	---

F0259	11:00	<b>View from medical microbiology</b> <i>Maeve Doyle (Waterford, Ireland)</i>
F0260	11:10	<b>view from infectious diseases</b> <i>Eoghan De Barra (Dublin, Ireland)</i>
F0261	11:20	<b>view from trainees (TAE)</b> <i>Christian Kraef (Copenhagen, Denmark)</i>
F0262	11:30	<b>European exam - how to prepare?</b> <i>Annelies Verbon (Bosch En Duin, Netherlands)</i>



# ESCMID Global 2025 - Programme

E0367	<b>Optimizing pretreatment for MALDI-TOF MS: Evaluating the dispersion method for filamentous fungal identification</b> <i>R. Huang*</i> (Shenzhen, China), <i>Y. Li, Y. He, T. Ma, F. Lu</i>
E0368	<b>Rapid detection of colistin resistance in <i>Acinetobacter baumannii</i> by a MALDI-TOF MS-based assay</b> <i>E. Kırbaş*</i> (Van, Türkiye), <i>I.D. Nix, K. Sparbier, O. Drews, B. Oberheitmann, M. Kostrzewa, G. Haşçelik, B. Sancak</i>
E0369	<b>Discrimination of clinical <i>Pseudomonas</i> strains at the species level using a large-scale genomically predicted protein mass database with MALDI-MSK.</b> <i>Teramoto*</i> (Kyoto, Japan), <i>Y. Sekiguchi, L. Sellami, M. Tohya, T. Kirikae</i>
E0370	<b>Automatic differentiation of <i>Clostridioides difficile</i> ribotypes using MALDI-TOF MS and web-based classification models</b> <i>M. Blazquez Sanchez*</i> (Madrid, Spain), <i>M.C. Blazquez-Sanchez, J.M. Moreno, A. Guerrero-López, G.P. Mark, V. Gómez-Verdejo, P. Muñoz, M. Marín, L. Alcalá, D. Rodríguez-Temporal, B. Rodríguez-Sanchez</i>
E0371	<b>Identification of sepsis-causing bacteria using shotgun proteomics</b> <i>L. Meekes*</i> (Rotterdam, Netherlands), <i>D. Rustad, C. Güzel, T.K. Jenssen, H. Hauge, C. Klaassen, M. Bexkens, N. Strepis, T. Luider, W. Goessens</i>

EF051	11:00 – 12:00	Arena 4
	ePoster Flash Session	

ANT TRN

## The enemy of my enemy: From Jumbo phages to cocktails for difficult to treat infections

*Chair* *Paul G. Higgins (Cologne, Germany)*

E0372	<b>Anti-K2 recombinant phage depolymerases as anti-virulence agents against hypervirulent <i>Klebsiella pneumoniae</i></b> <i>M. Roch*</i> (Geneva, Switzerland), <i>R. Sierra, D. Andrey</i>
E0373	<b>Jumbo <i>Klebsiella</i> bacteriophage demonstrates efficient multidrug-resistant <i>Klebsiella pneumoniae</i> killing and significant clinical potential</b> <i>Y. Liu*</i> (Singapore, Singapore), <i>Y. Zhong, S. Thong, L.H.A. Kwa</i>
E0374	<b>A new phage cocktail targeting at <i>Klebsiella pneumoniae</i></b> <i>X. Yin*</i> (Chengdu, China), <i>Y. Feng, H. Luo, Z. Zong</i>
E0375	<b>Bacteriophages against pulmonary infection and colonization of the gut by multidrug-resistant <i>Klebsiella pneumoniae</i> in murine models</b> <i>A.M. Örmälä-Tiznado*</i> (Stockholm, Sweden), <i>S. Patpatia, J. Bengoechea, C. Frantzen, A. Garcia Navarro, C. Giske</i>
E0376	<b>A novel broad-spectrum phage cocktail effective for carbapenem resistant <i>Acinetobacter baumannii</i> of capsular type 104/2/7 in vitro</b> <i>L. Wei*</i> (Chengdu, China), <i>Y. Feng, Z. Zong</i>
E0377	<b>Proteomic and Genomic Characterization of a Novel Bacteriophage of a New Genus Infecting <i>Pseudomonas aeruginosa</i></b> <i>S. Unlu*</i> (Ankara, Türkiye), <i>A. Uskudar Guclu</i>
E0378	<b>Phages as innovative adjuvants of antibiotics therapy against <i>S. aureus</i> and <i>P. aeruginosa</i> in the context of Cystic Fibrosis</b> <i>A. Glorieux*</i> (Brussels, Belgium), <i>S. De Soir, M. Merabishvili, J.P. Pirnay, D. De Vos, F. Van Bambeke</i>
E0379	<b>Evaluation of bacteriophages against <i>Staphylococcus aureus</i> strains isolated from orthopaedic infections</b> <i>S. Patpatia*</i> (Helsinki, Finland), <i>A. Camporeale, S. Kiljunen, C. Giske, A.M. Örmälä-Tiznado</i>
E0380	<b>Anti-<i>Staphylococcus aureus</i> phages: assessing the risk of bacterial resistance emergence through selective pressure</b> <i>M. Degreze*</i> (Lyon, France), <i>M. Medina, F. Laumay, L. Blazère, E. Helluin, F. Laurent, C. Kolenda</i>

KN081	11:00 – 12:00	Hall 1
	Keynote Lecture	

AMR ANT

# ESCMID Global 2025 - Programme

*Curatolo, P. Giordani, F. D'andrea, M. Campanella, E. Conoscenti, S. Caruso, G. Mulè, D. Lo Porto, F. Monaco, F. Cardinale, G. Di Martino, D. Di Carlo, N. Coppola, A. Mularoni*

O0350	<b>Risk factors for carbapenem-resistant Enterobacteriaceae infection after orthotopic liver transplant in a large cohort of pre-transplant CRE carriers</b> <i>M. Rinaldi* (Bologna, Italy), B. Miani, M. Freire, E. Girão, D. Yahav, M. Valerio, L.M. Parra, L. Alagna, E. Franceschini, P. Burra, A. Mularoni, M. Halpern, L. Camargo, R. Romagnoli, E. Graziano, N. Caroccia, M. Di Chiara, P. Viale, M. Giannella</i>
O0351	<b>Serologic follow up of solid organ transplant recipients who receive organs from syphilis seropositive donors.</b> <i>O. Fernandez Garcia* (Edmonton, Canada), D. You, J. Gratrix, A. Singh, K. Doucette</i>
O0352	<b>Prophylaxis strategies and risk of cytomegalovirus in solid organ transplant recipients</b> <i>A. Dahl* (København V, Denmark), M. Koller, O.J. Manuel, K.S. Moestrup, J. Reekie, E. Tusch, C.G. Crone, M. Perch, F. Gustafsson, S.S. Sorensen, N. Schultz, K. Schønning, J. Lundgren, N. Mueller, M. Helleberg</i>
O0353	<b>Burden of non-microbiologically confirmed infections in solid organ transplant recipients</b> <i>M. Zou* (Basel, Switzerland), M. Koller, O.J. Manuel, N. Mueller, K. Boggian, C. Hirzel, C. Garzoni, N. Khanna, C. Van Delden, D. Neofytos</i>

SY085	11:00 – 12:00	Hall 13
	1-hour Symposium	

## Diagnosing the undiagnosed fraction: the final step towards viral hepatitis elimination

<i>Chairs</i>	<i>Mojca Maticic (Ljubljana, Slovenia)</i> <i>Snjezana Zidovec Lepej (Zagreb, Croatia)</i>
---------------	---

S0249	11:00	<b>Role of reflex testing strategies in identifying patients with chronic viral hepatitis</b> <i>Oana Sandulescu (Bucharest, Romania)</i>
S0250	11:30	<b>Management and elimination of hepatitis in hard-to-reach persons</b> <i>Suda Tekin (Istanbul, Türkiye)</i>

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), Romanian Society for Infectious Diseases and HIV/AIDS

SY086	11:00 – 12:00	Hall 14
	1-hour Symposium	

## Impact on including a measure of viability in molecular diagnostic tests

<i>Chairs</i>	<i>Fusun Can (Istanbul, Türkiye)</i> <i>Denise O'sullivan (Teddington, United Kingdom)</i>
---------------	---

S0251	11:00	<b>Viability markers in support of development of <i>Chlamydia</i> screening recommendations</b> <i>Petra Wolffs (Maastricht, Netherlands)</i>
S0252	11:30	<b>Measuring viability to improve the correlation of AMR markers and clinical outcomes in <i>Neisseria gonorrhoeae</i></b> <i>Tatum Mortimer (Athens, United States)</i>

Co-organised with: ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC)

ME089	11:00 – 12:00	Hall 15
	Meet-the-Expert	

## How to teach Medical Mycology

M0257	11:00	<i>Katrien Lagrou (Leuven, Belgium)</i>
M0258	11:12	<i>Mihai Mares (Iasi, Romania)</i>
Co-organised with: European Confederation of Medical Mycology (ECMM)		

# ESCMID Global 2025 - Programme

	<i>Putoto, F. Di Gennaro, C. Severini, A. Saracino</i>
L0007	<b>Investigation of an international pseudo-outbreak involving <i>Paraburkholderia fungorum</i> blood culture contamination</b> <i>J. Moran-Gilad* (Jerusalem, Israel), J.L. Dale, A. Michael-Gayego, A. Gross, V. Temper, S. Lim, C. Lees, K. Knowles, J. Strahilevitz, Y. Oster, D. Grupel, D. Reshef, B.A. Smith, B. Warren, E.L. Palavecino, P. Snippes Vagnone</i>
L0008	<b>Evolving cluster of severe infective endocarditis with non-toxigenic <i>C. diphtheriae</i> amongst people experiencing homelessness and substance misuse in the UK</b> <i>R. Cordery* (London, United Kingdom), T. Patel, T. Anwar, N. Utjesanovic, A. Aryee, E. Mavrogiorgou, N. Karogiannis, D.J. Litt, J. D'aeth, C. Primus, S. Das, K. Paranthaman, G. Amirthalingham</i>
L0009	<b>AI-driven live cough rate tracking for public health surveillance</b> <i>M. Kågeback* (Göteborg, Sweden), E. Carlsson</i>

OS044	11:00 – 12:00	Hall 5
	1-hour Case Session	

CLN

## Unusual presentations of unusual parasites

<i>Chairs</i>	<i>Emmanuel Bottieau (Antwerp, Belgium)</i> <i>Marcelo Victor Radisic (Buenos Aires, Argentina)</i>
---------------	--

O0329	<b>Atypical neonatal cutaneous myiasis: a diagnostic challenge mimicking pustular rash in a resource-limited setting</b> <i>D. Ekwem Amarachi* (Gulu, Uganda), E. Namara, E. Ssenuni, A. Amuge, V. Omona, R. Okidi, R. Olum</i>
O0330	<b>An Itchy awakening due to <i>Dermanyssus</i> infestation</b> <i>J. Sevestre* (Marseille, France), A.Z. Diarra, J.P. Dales, J.M. Bérenegr, S. Ranque</i>
O0331	<b>Uterine Myiasis: A Rare Case of External Genitourinary Myiasis</b> <i>R.L. Johnson* (Birmingham, United States), J.C.F. Nakazaki, P. Legua</i>
O0332	<b>Neurognathostomiasis Presenting with Cerebral Venous Sinus Thrombosis: A case report of rare clinical manifestation</b> <i>C. Norsungnarn* (Bangkok, Thailand), J. Vinichanan, L. Paitoonpong</i>
O0333	<b>If at first, you don't succeed... Treatment-resistant Fascioliasis: case report</b> <i>W. Garr* (Leeds, United Kingdom), K. Woods, L. Nabarro</i>

SY083	11:00 – 12:00	Hall 7
	1-hour Symposium	

CLN

DX

## Lyme neuroborreliosis: challenges in diagnosis and treatment

<i>Chairs</i>	<i>Alexandra Mailles (Paris, France)</i> <i>Joanna Maria Zajkowska (Białystok, Poland)</i>
---------------	---

S0245	11:00	<b>Challenges in diagnosis of Lyme neuroborreliosis</b> <i>Rick Dersch (Freiburg, Germany)</i>
S0246	11:30	<b>Challenges in treatment of Lyme neuroborreliosis</b> <i>Anne Marit Solheim (Kristiansand, Norway)</i>

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), ESCMID Study Group for Lyme Borreliosis (ESGBOR)

OS045	11:00 – 12:00	Hall 8
	1-hour Oral Session	

AMR

## Social behavioural dynamics of antibiotic use and AMR

<i>Chairs</i>	<i>Sonia Lewycka (Hanoi, Vietnam)</i> <i>Filippo Mediolì (Milan, Italy)</i>
---------------	--

O0334	<b>Investigating the Knowledge, Attitudes, and Practices around Antimicrobial Resistance and Stewardship Among Syrian Healthcare Professionals: A Cross-Sectional Survey</b> <i>A. Abbara* (London, United Kingdom)</i>
-------	---

# ESCMID Global 2025 - Programme

SY093

13:30 – 14:30

Hall 11

TRN

VAX

1-hour Symposium

## Immunosenescence and immune response to vaccination

Chairs

Petar Velikov (Sofia, Bulgaria)

Dafna Yahav (Ramat-Gan, Israel)

- S0267

13:30

How immunosenescence impacts vaccine responseAndrea Cossarizza (Modena, Italy)
- S0268

14:00

Strategies to tackle immunosenescence and improve immune response to vaccination in the elderlyInna Ovsyannikova (Rochester, United States)

Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), ESCMID Vaccine Study Group (EVASG)

EW096

13:30 – 15:30

Hall 15

PRO

Educational Session

## Tools for successful development as a medical educator

Chairs

Giorgia Caruana (Sion, Switzerland)

Yoav Keynan (Winnipeg, Canada)

- W0273

13:30

Developing your educator professional identityTodd Cassese (Bronx, United States)
- W0274

13:50

What do IPC doctors need to learn to be preparedSimone Scheithauer (Göttingen, Germany)
- W0275

14:10

Communities of practice: successful experience of a transformative collaboration and roadmapErin Bonura (Portland, United States)
- W0276

14:30

The critical need for ongoing innovations in medical educationClémentine Schilte (Paris, France)

Co-organised with: Infectious Diseases Society of America (IDSA), ESCMID Professional Affairs Subcommittee, Trainee Association of ESCMID (TAE) Steering Committee, British Infection Association (BIA), Young Leader Circle of the American Society of Microbiology

FO097

13:30 – 14:30

Arena 1

DX

Open Forum

## Essential diagnostics in Low-Resource Settings: why are we still talking?

Chair

Truls Michael Leegaard (Lørenskog, Norway)

- F0277

13:30

Training skilled personnel in LMIC and brain drain: is the solution the problem?Sipho Kenneth Dlamini (Observatory, South Africa)
- F0278

13:40

Leveraging surveillance networks to strengthen basic bacteriologyDissou Affolabi (Cotonou, Benin)
- F0279

13:50

Clinical bacteriology laboratories in low-resource settings: considerations for sustainabilityMakeda Semret (Montreal, Canada)

Co-organised with: ESCMID Professional Affairs Subcommittee, Dutch Society for Medical Microbiology (NVMM), ESCMID Parity Commission, Federation of European Microbiological Societies (FEMS), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Société belge d'Infectiolo

FO098

13:30 – 14:30

Arena 2

PRO

Open Forum

## Best of ID Week

Chair

Tina Tan (Chicago, United States)

- F0280

, Seth Cohen (Seattle, United States), Erin McCreary (Pittsburgh, United States), Ilan Youngster (Beer Yaakov, Israel)

# ESCMID Global 2025 - Programme

	<b>using whole genome analysis.</b> <i>M. Mansfield*</i> (Dublin, Ireland), <i>E. Roycroft, S. Mok, P. Flanagan, M. Mc Elroy, B. Byrne, H. Cameron, D. Farrell, S.V. Gordon, J. Wagener, M.M. Fitzgibbon, T.R. Rogers</i>
E0403	<b>Distinguishing relapse from reinfection in tuberculosis patients from Lithuania</b> <i>L. Vasiliauskaite*</i> (Vilnius, Lithuania), <i>L. Vasiliauskaitė, A. Zinola, F. Di Marco, V.E. Davidavičienė, B. Nakčerienė, A. Vaitulionytė, D.M. Cirillo, T. Kačergius</i>
E0404	<b>Rapid Resistance Profiling of Mycobacterium tuberculosis from Clinical Specimens using Targeted Next-Generation Sequencing: A Pilot Validation Study</b> <i>P. Chheda*</i> (Mumbai, India), <i>S. Shivaprakash, T. Dama, G. Thandassery</i>
E0405	<b>Inflammation precedes early respiratory worsening in HIV-negative tuberculosis patients during antituberculosis treatment</b> <i>A. Van Laarhoven*</i> (Nijmegen, Netherlands), <i>L. Kurver, E. Klein Teeselink, A. Lemson, C. Bosteels, N. Carpaij, J. Van Ingen, E. Ardiansyah, C. Van Arkel, R. Vullingsh, C. Magis Escurra, W. Hoefsloot, R. Van Crevel</i>
E0406	<b>Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis</b> <i>C. Kim*</i> (London, United Kingdom), <i>S. Sweeney, H. Sohn, G.M. Knight, C.F. Mcquaid</i>
E0407	<b>A longitudinal study on the evolution of drug resistance during tuberculosis treatment</b> <i>E. Danso*</i> (Accra, Ghana), <i>P. Asare, P. Tetteh, A. Tetteh, A.A. Boadu, S. Osei-Wusu, A. Asante-Poku, Y. Klinogo, A. Sylverken, J. Afriyie-Mensah, A. Adjei, D. Yeboah-Manu</i>
E0408	<b>Phase 1, randomized, double-blind, parallel-group, dose-escalation safety and tolerability of PLGA encapsulated first line antitubercular drugs nanoparticles in healthy volunteers</b> <i>A.K. Pandey*</i> (Chandigarh, India), <i>N. Shafiq, S. Malhotra, C. Mothsara, G. Khuller, J. Verma, L. Verma</i>

SEL	13:30 – 15:30	Hall 1
	Special Session	

PRO

## Selective Pressure

<i>Chairs</i>	<i>Jacob Moran-Gilad (Beer Sheva, Israel)</i> <i>Joshua Nosanchuk (Bronx, United States)</i> <i>Jose Ramon Pano-Pardo (Zaragoza, Spain)</i> <i>Jesús Rodríguez-Baño (Seville, Spain)</i> <i>Anja Šterbenc (Ljubljana, Slovenia)</i> <i>Suzanne Van Asten (Nijmegen, Netherlands)</i> <i>David Van Duin (Chapel Hill, Nc, United States)</i>
---------------	---

JS1	13:30 – 14:30	Hall 12
	Journal Session	

## Late-breaker research from CMI and CMI Communications

J001	13:30	<b>Measuring the impact of hospitalization for infectious diseases on the quality of life of older patients in four European countries: the AEQUI longitudinal matched cohort study (2020–2023)</b> <i>Gaetan Gavazzi (Grenoble, France)</i>
J002	13:45	<b>Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial</b> <i>Thomas Holland (Durham, United States)</i>
J003	14:00	<b>The long-term sustainability of a pharmacist-led antimicrobial stewardship penicillin allergy delabelling ward round: A prospective cohort study</b> <i>Elise Mitri (Heidelberg, Australia)</i>
J004	14:15	<b>Efficacy and safety of mechanical thrombectomy in acute ischemic stroke secondary to infective endocarditis</b> <i>Tba</i>

# ESCMID Global 2025 - Programme

O0382	<b>CarbaDetector: An Artificial Intelligence-Driven Prediction Model for Detecting Carbapenemase-Producing Enterobacterales Using Disk-Diffusion</b> <i>L.K. Muhsal* (Oldenburg, Germany), C. Cimen, J. Sattler, O. Nolte, L. Dortet, R. Bonnin, A. Egli, A. Hamprecht</i>
O0383	<b>AI-Driven Early Infectious Disease Detection in Dutch Primary Care: leveraging Bidirectional Encoder Representations from Transformers (BERT) and Early Recognition using Neural Information Encoding (ERNIE)</b> <i>G. Danoe* (Groningen, Netherlands), M. Homburg, M.Y. Berger, T. Olde Hartman, A. Voss, A. Hamprecht, M. Brilman, L.L. Peters, M.S. Berends</i>
O0384	<b>Predicting potentially infection-related findings in structured radiology reports</b> <i>J. Xu* (Oxford, United Kingdom), J.B. Delbrouck, J. Wei, A.S. Walker, C.P. Langlotz, D. Eyre</i>
O0385	<b>Application of Artificial Intelligence in Assisting X-ray Diagnosis of Pediatric Pulmonary Infections</b> <i>H. Zhang* (Shanghai, China), X. Xu, J. Ai</i>

OS053	13:30 – 14:30	Hall 3
	1-hour Oral Session	

TRN

## Immune evasion and intracellular survival strategies

<i>Chairs</i>	<i>Juliane Bubeck Wardenburg (St. Louis, United States) Giovanni Delogu (Rome, Italy)</i>
---------------	---

O0386	<b>Capsule-Dependent Modulation of Cell Death Pathways and Immune Evasion in <i>Acinetobacter baumannii</i></b> <i>H. Wang* (Beijing, China), C. Jiang</i>
O0387	<b>Intracellular lifestyle of <i>Acinetobacter baumannii</i>. Role of phospholipase A2 and transcriptional factor EB (TFEB)</b> <i>Y. Smani* (Seville, Spain), C. Atalaya Rey, I. Molina Panadero, A. Lora González, A. Hmadcha</i>
O0388	<b>The role of peg344 of hypervirulent <i>Klebsiella pneumoniae</i> on suppressing autophagy responses of macrophages</b> <i>Z.E. Kuloğlu* (Istanbul, Türkiye), Ö. Albayrak, D. Güllü, G. Ekinci, F. Can</i>
O0389	<b>c-Myc Inhibits Macrophage Antimycobacterial Response in Mycobacterium tuberculosis Infection</b> <i>C. Dollé* (Zurich, Switzerland), E. Sarti, R. Wolfensberger, K. Kusjeko, S. Bredl, R.A. Speck, M. Greter, J.H. Rueschoff, D. Mai, A. Diercks, P. Sander, G.S. Olson, J. Nemeth</i>
O0390	<b>Targeting neutrophil extracellular traps (NETs) prevents tuberculosis immunopathology</b> <i>J. Kutschenreuter* (London, United Kingdom), D. Kirwan, R. Cusman, K.H. Skolimowska, R.H. Gilman, J.S. Friedland, D.L.W. Chong</i>

SY091	13:30 – 14:30	Hall 4
	1-hour Symposium	

PHEI

## Emerging infectious diseases: staying informed and prepared in a globalised world

<i>Chairs</i>	<i>Nitin Gupta (Manipal, India) Pikka Jokelainen (Copenhagen, Denmark)</i>
---------------	--

S0263	13:30	<b>Lessons learnt from previous outbreaks</b> <i>Tba</i>
S0264	14:00	<b>Disease X: preparedness for the next pandemic</b> <i>Yee Sin Leo (Singapore, Singapore)</i>

Co-organised with: ESCMID Emerging Infections Subcommittee, Deutsche Gesellschaft für Infektiologie, Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.

SY092	13:30 – 14:30	Hall 5
	1-hour Symposium	

CLN

## Sex differences in management and outcome of patients with serious bacterial infections

<i>Chairs</i>	<i>Michele Bartoletti (Milan, Italy) Merel Lambregts (Leiden, Netherlands)</i>
---------------	--

# ESCMID Global 2025 - Programme

- E0428** **Invasive group A streptococcus infections is often preceded by seasonal influenza.***J. Westin\** (Gothenburg, Sweden), *M. Nygren, U. Snygg-Martin, L. Gustavsson, N. Sundell*
- E0429** **Impact of the COVID-19 Pandemic on Tuberculosis Transmission Rates.***A. Cannas\** (Rome, Italy), *V. Antonelli, A. Navarra, O. Butera, A. Mazzarelli, C. Nisii, E. Girardi, C. Fontana*
- E0430** **Treatment outcomes of bedaquiline-based longer oral regimens in Indian children above 5-years of age.***D. Gandhi\** (Mumbai, India), *I. Shah, R. Ansari, H. Warse, S. Kalawadia, T. Yangchen, D. Shah, V. Puri, S. Mattoo, M. Bodhanwala*
- E0431** **Incidence of Invasive *Escherichia coli* Disease in the Northwestern United States (2002–2022): Insights from Electronic Health Records***M. Blum\** (Leuven, Belgium), *C. Onwuchekwa, M.A. Schmidt, J. Poolman, T. Verstraeten, J. Geurtsen*
- E0432** **A prospective controlled cross-sectional study demonstrates significantly higher IgG seroprevalence of leptospirosis among Munich's Eisbach river surfers.***F. Voit\** (München, Germany), *D. Schult-Hannemann, M.H. Richter, L. Wagner, J. Ostermaier, K. Stollberg, E. Luge, P. Bahn, M. Lee, J. Ten-Pas, J. Erber, M. Kosch, M. Mayr, C.D. Spinner, J. Schneider*

---

**EF060** **14:45 – 15:45** **Arena 3**

ePoster Flash Session

AMR CLN

## AMR in the community

*Chair* *Camilla Wiuff Coia (Copenhagen, Denmark)*

- E0433** **Socio-demographic factors associated with community-acquired extended spectrum  $\beta$ -lactamase producing *E. coli*/urinary tract infections at intermunicipal level in France***M. Prime\** (Nantes, France), *O. Lemenand, S. Thibaut, T. Coeffic, B. Perrot, J. Caillon, D. Boutoille, E. Batard, G. Birgand*
- E0434** **Prolonged community outbreak of OXA-48-producing *Escherichia coli*/linked to a food premises: Lower Hutt, New Zealand, 2018-2022***C. Thornley\** (Lower Hutt, New Zealand), *M. Kelly, M. Bloomfield, A. Nesdale, R. White*
- E0435** **Low rates of macrolide resistance found in *Mycoplasma pneumoniae* cases in Australia***R. Rockett\** (Westmead, Australia), *J. Kok, K.G. Tam, T. Golubchik, C. Suster, W. Fong, V. Sivalingam, M.C. Wehrhahn, A. Ginn, J. Robson, I. Gardner, L. Papanicolas, K. Kennedy, M. Graham, T. Tran, D. Speers, L. Cooley, J. Harbidge, S. Campbell, K. Basile, V. Sintchenko, S.C.A. Chen*
- E0436** **Epidemiology of antibiotic resistance associated with *E. coli*/Klebsiella pneumoniae bloodstream infections in England 2012-2023***S. Lipworth\** (Oxford, United Kingdom), *L. Gorman, A. Dowsey, K. Pouwels, K. Sanderson, C. Beck, R. Hope, C. Brown, T. Katy*
- E0437** **The effect of long-term fluoroquinolone prophylaxis on carriage of antimicrobial resistant organisms in children.***C. Brand\** (Cape Town, South Africa), *R. Ocloo, D. Wilck, P. Dube, A. Hesseling, J. Seddon, A. Demers, M. Newton-Foot, A. Whitelaw*
- E0438** **Risk factors and prevalence of AntiMicrobial Resistant microbes In the English Community (AMRIC)***D. Lecky\** (Gloucester, United Kingdom), *Z. Aiken, M. Joyce, A. Hawker, N. Zhu, L. Eastwood, S. Leaver, K. Hopkins, R. Hope, S. Eccles, S. Neilson, M. Neilson, G. Edwards, S. Hopkins, C. Brown*
- E0439** **Risk factors for antimicrobial resistance in community commensal *Staphylococcus aureus* isolates, a sub-analysis of the AMRIC project.***M. Joyce\** (Manchester, United Kingdom), *Z. Aiken, N. Zhu, A. Hawker, L. Eastwood, S. Leaver, K.L. Hopkins, R. Hope, S. Eccles, S. Neilson, M. Neilson, G. Edwards, S. Hopkins, C. Brown, D.M. Lecky*
- E0440** **Prevalence and risk factors for antimicrobial resistance in invasive pneumococcal disease in southern Ontario in the late post PCV13 era (2014-2023)***A. Mcgeer\** (Toronto, Canada), *A. Shigayeva, A. Golden, I. Martin, G. Zhanel, H. Adam, K. Barker, W.*



# ESCMID Global 2025 - Programme

*Cabed, V. García-López, A. Polo, J. Laporte-Amargos, G. López De Egea, M.Á. Galán-Ladero, E. Ruiz De Gopegui-Bordes, G. Sena-Corrales, J.A. Girón, F. Galán, M. Chávez-Caballero, M.O. Mohamed-Balghata, S. Winderickx, J.M. García De Lomas, F.J. Martínez-Marcos, M. Giannella, M. Garzaro, M. Fernández, M. Freire, M.L. Pedro-Botet Montoya, S. López Cardenas, E. Cendejas, A.V. Halperin Benito, A. Romero Palacios, M. Navarro, C.A. Alonso, A. Gimeno-Gascón, S. Jiménez Jorge, J. Pachón, M.E. Pachón-Ibáñez, E. Cordero-Matía*

**SY100** **14:45 – 15:45** **Hall 12**

TRN

1-hour Symposium

## The challenge of a healthy microbiota in neonates

*Chairs Maria Vehreschild (Frankfurt Am Main, Germany)  
Walter Zingg (Zurich, Switzerland)*

- S0283

14:45

Infant gut microbiome development*Debby Bogaert (Edinburgh, United Kingdom)*
- S0284

15:15

Metagenomic signatures and antibiotic disruption of the gut microbiome in neonates*Gautam Dantas (Saint Louis, United States)*

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), European Society of Paediatric Infectious Diseases (ESPID)

**OS058** **14:45 – 15:45** **Hall 16**

CLN

1-hour Case Session

## In the field with fungi

*Chairs Beatriz L. Gomez (Bogota, Colombia)  
Leonardo Nimrichter (Rio De Janeiro, Brazil)*

- O0419

Fosmanogepix expanded access in patients with *Fusarium* infections*S. Dadwal\* (Duarte, United States), A. Baluch, J. Dickter, J.R. Newman, M.H. Nguyen, R. Weihe, H. Schlamm, L. Ostrosky-Zeichner*
- O0420

Voriconazole's hidden toll: unveiling periostitis in a heart transplant recipient and a hematologic patient.*G. Motoa\* (Boston, United States), A. Woolley, N. Issa*
- O0421

Unveiling the Uncommon: Managing *Geotrichum candidum* in Pancreatic Necrosis*L. Kriegl\* (Graz, Austria), C. Geiger, I. Zollner-Schwetz, T. Valentin, H. Schlager, G. Zollner, K. Dichtl, R. Krause*
- O0422

Detection of siderophores as a superior non-invasive diagnostic tool in unravelling mixed fungal infections*V. Havlicek\* (Prague, Czech Republic), R. Dobias, M. Navrátil, R. Patil, D. Luptakova, D.A. Stevens*
- O0423

Efficacy of novel antifungal therapies in refractory *Candida* and *Aspergillus* infections: insights from compassionate use and clinical trials*S. Sedik\* (Graz, Austria), R. Krause, C. Zurl, I. Zollner-Schwetz, M. Linhofer, C. Hoegenauer, G. Gorkiewicz, M. Hoenigl, J. Prattes*

**OS056** **14:45 – 15:45** **Hall 2**

PHEI

1-hour Oral Session

## Emerging trends in viral hepatitis across Europe

*Chairs Federico Garcia (Granada, Spain)  
Neven Papic (Zagreb, Croatia)*

- O0409

One of the largest outbreak of hepatitis A in the 21<sup>st</sup> century in Europe*I. Hockickova\* (Košice, Slovakia), I. Hockicková, J. Hockicko, D. Javorská, Š. Zamba, A. Vasilová, M. Ševčík, A. Cehelská, D. Hudáčková, P. Kristian*
- O0410

Higher prevalence of Cytomegalovirus and Epstein–

# ESCMID Global 2025 - Programme

Movie Session	15:00 – 18:30	Hall 5
	Special Session	

## Behind the scenes: Contagion

Chairs	William Hanage (Boston, United States) Luigia Scudeller (Pavia, Italy)
--------	---

SY107	16:15 – 17:15	Hall 15
	1-hour Symposium	

PRO PHEI

## Communicating (your) ID science for policy and societal impact

Chairs	Leonard Leibovici (Petah-Tiqva, Israel) Ines Steffens (Solna, Sweden)
--------	--

S0297	16:15	Communicating to policy makers and for societal impact <i>Balázs Babarczy (Budapest, Hungary)</i>
S0298	16:45	Influencing behaviour through the media and a multichannel communications strategy <i>Charlotte Hutchinson (London, United Kingdom)</i>

Co-organised with: CMI Board of Editors

EW109	16:15 – 18:15	Hall 2
	Educational Session	

CLN VAX

## Infections in cancer patients: tips for daily practice

Chairs	José Molina Gil-Bermejo (Seville, Spain) Stefan Schwartz (Berlin, Germany)
--------	---

W0301	16:15	Tailoring pharmacologic prophylaxis in patients with non-haematologic cancer: from viruses to fungi <i>Janne Vehreschild (Frankfurt, Germany)</i>
W0302	16:35	Pneumonitis or pneumonia? A practical approach to lung infiltrates in patients with solid tumours <i>Tba</i>
W0303	16:55	The diagnostic dilemmas and treatment challenges of mycobacteria in cancer patients <i>Şiran Keske (Istanbul, Türkiye)</i>
W0304	17:15	HTLV-1 and T-cell lymphoma - predict & prevent <i>Lucy Cook (London, United Kingdom)</i>

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)

EF065	16:15 – 17:15	Arena 1
	ePoster Flash Session	

ANT TRN

## The Antibiotic bakery: Novel compounds in the pipeline

Chair	Susanne Haeussler (Braunschweig, Germany)
-------	---

E0471	<i>In vitro</i> activity and <i>in vivo</i> proof-of-efficacy of epimutillin derivatives AR-7732, AR-7731, AR-9842 and AR-10058 against AMR bacterial pathogens <i>S. Paukner* (Vienna, Austria), W.W. Wicha</i>
E0472	SC5005 and DHA: A Novel, Rapid-Acting Combination Therapy for Biofilm Eradication in Catheter-Associated Infections <i>Y. Hui Hui* (Taipei, Taiwan, China), H.H. Yeo, H.N. Huang, Y.T. Huang, Y.S. Lu, H.C. Chiu</i>
E0473	<i>In vitro</i> potency of ceftibuten with xerubor bactam against $\beta$ -lactamase-producing isolates of Enterobacterales (ENT) from the SENTRY global surveillance programme <i>O. Lomovskaya* (San Diego, California, United States), M. Castanheira, J. Lindley</i>
E0474	Effect of novel antimicrobial peptides SET-M33L and SET-M33L-PEG on <i>Pseudomonas aeruginosa</i> biofilm formation <i>A. Fontanot* (Rotterdam, Netherlands), W. Unger, J. Hays, P. Croughs, A. De Bruijn, C. Falciani, A. Pini, R. Ecker, I. Ellinger</i>

# ESCMID Global 2025 - Programme

ePoster Flash Session

CLN

## Blood parasitology at its best

Chair *Miriam José Álvarez-Martínez (Barcelona, Spain)*

- E0489

**Unexepected P.malariae diagnosis in Italian woman with no history of travel to endemic areas***A. Busni\* (Milan, Italy), L. Tartaglione, S. Torri, A. Longhi, E.M. Zavaroni, F. Crippa, C.S. Vismara*
- E0490

**A blue-hued mystery: Primaquine-induced methemoglobinemia in mixed infection with *Plasmodium vivax* and *Plasmodium falciparum****U.A. Zainulabid\* (Pahang, Malaysia), X.K. Cheong, P. Periyasamy, A.F. Mohd Salleh, N. Ghazali, N.W. Hassan, K. Sangaran, A. Mohd Yasin, Z.M. Idris*
- E0491

**Trick or Treat? An unrelenting malaria case***C. Uhomoibhi\* (Dublin, Ireland), E. De Barra, C. Leddy, A. Brown*
- E0492

**"64% Parasitaemia in Falciparum Malaria: Challenges in Managing Severe Infection and Delayed Haemolysis"***F. Murphy\* (Dublin, Ireland), A. Albadi, P. Coakley, C. McNally*
- E0493

**Benznidazole treatment in Chagas Disease: a case series in Luigi Sacco Hospital, Milan (Italy)***F. Sabaini\* (Milan, Italy), A. Giacomelli, M. Beltrami, L.R. Galimberti, S. Antinori*
- E0494

**The Challenge of Managing Visceral Leishmaniasis in Immunocompromised Patients***S. Vita\* (Rome, Italy), A. D'abramo, A. Corpolongo, M.V. Tomassi, F. Faraglia, T. Ascoli Bartoli, A. Mariano, A. Vulcano, G. Maffongelli, E. Nicastri*
- E0495

**Diagnosis and management of visceral leishmaniasis in children in France : a national retrospective study***J. De Larminat\* (Paris, France), N. Dahane, N. Argy, M. Rifai, O. Haas Ferrua, C. Pomares, N. Rasandisona Ravonjena, D. Dupont, J.P. Lemoine, T. Cesar, O. Pineau, P. Picherit Steinbrucker, S. Azohana, S. Guilmon-Crepon, I. Allouche, C. Ravel, A. Faye*
- E0496

**Chronic cutaneous leishmaniasis following visceral leishmaniasis in a pediatric patient: a rare report of extensive facial involvement***A. Mohta\* (Bikaner, India)*
- E0497

**Therapeutic challenges in the management of Disseminated leishmaniasis in a patient with HIV co-infection***N. T R\* (Jodhpur, India), T. Kanagiri, S. Angirekula, N. Kaur, Y. Khatod, D. Kumar, A. Purohit, G.K. Bohra*

EF068 16:15 - 17:15 Arena 4

ePoster Flash Session

AMR

PHEI

## A global perspective on antimicrobial resistance surveillance

Chair *Mirfin Mpundu (Lusaka, Zambia)*

- E0498

**Global, regional and country-level prevalence of antimicrobial resistance in human bacterial infections under surveillance in WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS)***E. Van Kleef\* (Geneva, Switzerland), O. Tosas Auguet, S. Tolba, S. Eremin, D. Marcano, K.B. Pouwels, B.S. Cooper, A.S. Dean, S. Bertagnolli*
- E0499

**Comparative analysis of antimicrobial resistance (AMR) burden across european countries***A. Dörre\* (Berlin, Germany), A. Meinen, S. Haller, G. Robles Aguilar, T. Meštrović, M. Nahgavi, T. Eckmanns*
- E0500

**Setting up a regional AMR surveillance network in the Netherlands: challenges and opportunities***C. Van Rossum\* (Nijmegen, Netherlands), C. Meijer, P. Koopman, D. Van Der Vegt, T. De Groot, M. Nabuurs-Franssen, G. Heeren, M. Heuvelmans, J. Flipse, E. Bowles, A. Tostmann, C. Van Der Veer, S. Pas*
- E0501

**Bridging gaps in antimicrobial resistance surveillance: the CAESAR network's first decade***R. Janssen\* (Bilthoven, Netherlands), S. Woudt, D. Boudville, C. Ruesen, W. Van Den Reek, J. Monen, O. Karatuna, A. Tambić-Andrašević, D. Lo Fo Wong, M.*

# ESCMID Global 2025 - Programme

---

ME108 16:15 – 17:15 Hall 12  
Meet-the-Expert

CLN

Navigating travel medicine: expert tips for safe international travel

M0299 16:15 Sophie Schneitler (Homburg, Germany)

M0300 16:27 Andreas Neumayr (Basel, Switzerland)

---

OS062 16:15 – 18:15 Hall 13  
2-hour Oral Session

CLN

DX

TRN

Heterogeneity and complexity of sepsis

*Chairs* Despoina Koulenti (London, United Kingdom)  
Sylvain Meylan (Lausanne, Switzerland)

- 00451 **A consensus immune dysregulation framework for sepsis: results of the SUBSPACE consortium.**  
*Moore\* (Emerald Hills, United States), T. Sweeney, A. Rogers, P. Khatri, H. Zheng, A. Ganesan, Y. Hasin-Brumshtein, M. Maddali, J. Levitt, T. Van Der Poll, B. Scicluna, E.J. Giamarellos-Bourboulis, A. Kotsaki, I. Martin-Loeches, A. Garduno, J. Sevransky, D. Wright, R. Rothman, M. Atreya, L. Moldawer, P. Efron, M. Kralovcova, T. Karvunidis, H. Giannini, N. Meyer*
- 00452 **BLOODICU: Bloodstream infections and their outcomes in ICU patients - Insights from the PROSAFE Study**  
*C. Genovese\* (Milan, Italy), M. Offer, G. Tricella, G. Scaglione, E. Palomba, G. Montrucchio, F. Agostini, F. Dore, G. Monti, B. Viaggi, A. Gori, S. Finazzi, M. Colaneri*
- 00453 **Deciphering the Dynamics of *Klebsiella pneumoniae* Colonization and Infection: Genomic Insights and Microbiome Interactions in ICU Patients**  
*W. Yu\* (Beijing, China)*
- 00454 **Antibiotics with anti-anaerobe activity promote enteric pathobionts in ICU patients**  
*S. Taylor\* (Adelaide, Australia), S. Miller, E. Vasil, B. Reddi, L.A. Chapple, S. Bihari, M. Chapman, G. Rogers, L. Papanicolas*
- 00455 **Association between blood culture time to positivity and 30-day bacteremia mortality differs for bacterial groups**  
*M.H. Øvre\* (Herlev And Gentofte, Denmark), J.B. Boel, J.G. Holler, S. Skovgaard, D.S. Hansen, T.S. Itenov, B.J. Holzknicht*
- 00456 **Treatment patterns of patients with sepsis/SIRS/septic shock treated with ceftolozane/tazobactam – results from SPECTRA**  
*E. Yucel\* (Rahway, United States), A. Soriano, F. Thalhammer, S. Kluge, P. Viale, M. Allen, B. Akrich, J. Levy, H. Yang, S. Kaul*
- 00457 **Risk of myocardial infarction and stroke following bloodstream infection: a population-based self-controlled case series**  
*J. Underwood\* (Cardiff, United Kingdom), N. Reeve, V. Best, A. Akbari, H. Ahmed*
- 00458 **Is transthoracic echocardiography required in all patients with *Staphylococcus aureus* bacteremia? Validating the VIRSTA and VIRSTA+ scores to define the population at low risk of endocarditis**  
*M. Verdejo Gómez\* (Barcelona, Spain), D. Malano-Barletta, M.Á. Verdejo, G. Cuervo, C. Pitart, M. Hernández-Meneses, M. Bodro, S. Herrera, C. García-Vidal, P. Puerta, A. Del Rio, M. Espasa, J.A. Martínez, L. Morata, A. Soriano*
- 00459 **DNA methylation changes in Sepsis: Potential use as biomarkers**  
*I. López-Cruz\* (Valencia, Spain), J.L. García-Giménez, L. Piles, M. Madrazo, G. Judit, M. López-Torres, A. Artero*
- 00460 **Host response plasma biomarkers and transcriptomic alterations in critically ill patients with suspected aspiration pneumonia**  
*S. Doeleman\* (Amsterdam, Netherlands), D. Susanne, E. Michels, J. Butler, F. Uhel, O. Cremer, T. Van Der Poll*

# ESCMID Global 2025 - Programme

## Novel beta-lactams and beta-lactamase inhibitors: a diagnostic and therapeutic approach

*Chairs* Robert A. Bonomo (Cleveland, United States)  
Arjana Tambic Andrasevic (Zagreb, Croatia)

**S0293 16:15 Novel beta-lactams and beta-lactamase inhibitors: challenges for laboratory diagnostics** Anna Sramkova (Pilsen, Czech Republic)

**S0294 16:45 Clinical perspectives of novel beta-lactams and beta-lactamase inhibitors** Parikshit Prayag (Pune, India)

Co-organised with: EUCAST Steering Committee

**LB004 16:15 – 18:15 Hall 9**  
2-hour Oral Session

## Trials in severe infections

*Chair* Steven Tong (Melbourne, Australia)

**L0016 16:15 Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): a randomised, pragmatic trial** F. Cogliati Dezza\* (Seville, Spain), L. Barrera Pulido, I. Borreguero Borreguero, F. Docobo Pérez, V. Palomo Jiménez, S. De La Rosa Riestra, J. Bravo-Ferrer Acosta, M.A. Lopez Zuñiga, F. Cobo, J. Gómez-Junyent, J.P. Horcajada, E. Merino, M. Parra, J. López-Contreras, A. Rivera, D. Sousa Regueiro, M. Pampin Garcia, S. Lopez Cardenas, M.C. Goméz Sanchez, I. Peréz Camacho, S.M. Martín Ramos, E. Leon Jimenez, A.I. Aller García, M.T. Pérez-Rodríguez, A. Sousa, M.C. Fariñas, A.D.L.R.A. Fracisco, L. Gisbert Pérez, J. Goikoetxea Agirre, A. Cano, F.J. Martínez-Marcos, M.J. García País, R. Escudero Sanchez, S. De La Villa, J.R. Yuste Ara, M.A. Esteban-Moreno, A. Ruiz-Sancho, M. Pedrosa Aragón, J. Alba Fernandez, A. Barrios Blandino, H.H. Vilchez Rueda, R. Álvarez-Marín, A. Romero Palacios, A.E. Roura Piloto, E. Nuño Álvarez, Z.R. Palacios Baena, L. López Cerero, J. Rodríguez-Baño

**L0017 16:27 HRS-8427 versus imipenem-cilastatin for complicated urinary tract infections: a randomised, double-blind phase 2 study** M. Ju\* (Shanghai, China), M. Wang, J. Yuan, H. Huang, G. Bi, J. Lyv, X. Lyv, L. Xue, H. Yang, D. Fan, H. Wu, X. Wang, J. Xu, X. Li, Q. Zhang

**L0018 16:39 Efficacy and safety in a Phase 2 study of intravenous BV100 combined with polymyxin B versus best available therapy in adult subjects with ventilator-associated bacterial pneumonia suspected or confirmed to be due to carbapenem resistant *Acinetobacter baumannii*** G. Dale\* (Basel, Switzerland), F. Fratzeskaki, I. Tsagkaris, A. Armaganidis, M. Katsiashvili, D. Kazaishvili, T. Gaphrindashvili, K. Japaridze, E. Mouloudi, M. Kapanadze, T. Kachibaia, A. Sarkany, E. Zakyntinos, P. Delique, M. Davila, L. Husband, P. Timofeev, F. Jung, C. Kemmer

**L0019 16:51 Neutralising plasma versus placebo for hospitalised patients with West Nile fever: a double-blind randomised controlled trial** M. Canetti\* (Tel Aviv, Israel), G. Regev-Yochay, N. Barda, Y. Shusterman, E. Magiel, N. Baharav, A. Belkin, I. Margalit, V. Indenbaum, E. Tomer, Y. Lustig, Y. Ottolenghi, G. Joseph, H. Yonath, E. Leshem, I. Levy, Y. Peretz, S. Amit, L. Miller, M. Misgav, N. Landa, M. Brod, A. Wieder-Finesod, N. Maggio, D. Yahav

**L0020 17:03 Randomised placebo controlled trial of faecal microbiota transplantation to tackle antimicrobial resistance: inducing bacteriophage network remodelling and enteric pathogen reduction** L.A. Edwards\* (London, United Kingdom), B. Auch, T. Portlock, B.H. Mullish, B. Merrick, C. Woodhouse, T. Tranah, J.M. Blanco, L. Meoli, A. Clavé Llavall, V.T. Kronsten, A. Zamalloa, V.C. Patel, J.R. Marchesi, I. Liachko, S. Goldenberg, D.L. Shawcross

**L0021 17:15 Double-dose dolutegravir and lamivudine versus efavirenz-based antiretroviral therapy for patients**

# ESCMID Global 2025 - Programme

- mutations in *Enterococcus* spp. by using High Resolution Melting-qPCR-typing analysis *R. Musumeci\** (Monza, Italy), *E. Giordano, M. Martinelli, M. Oggioni, D. Oggioni, V. Marano, E. Arighi, C. Villa, C. Giubbi, G. Mannarà, F. Perdoni, S. Frugoni, P. Congedo, C.E. Cocuzza*
- E0539** **An automated pipeline to genotype bacteriophages using third generation sequencing** *Z. Halász\** (Debrecen, Hungary), *E. Szoták, L. Dr. Laczkó, G. Dr. Kardos*
- E0540** **Novel approach for fast, automated strain typing and source tracking by Fourier-transform infrared spectroscopy** *N. Mauder\** (Bremen, Germany), *M. Cordovana, M. Kostrzewa*

**EF075** **17:30 – 18:30** **Arena 2**



ePoster Flash Session

## Healthcare (workers') safety revisited

*Chair* *Daniel Diekema (Harpswell, United States)*

- E0541** **Preparedness and cooperation throughout the chain of care during regional-level outbreaks with multidrug resistant organisms: a network analysis and interview study** *B. Beishuizen\** (Bilthoven, Netherlands), *M. Stein, A. Tostmann, C. Rovers, A. Timen*
- E0542** **Preparing First-Line health care workers for 'Virus X' through targeted training (FILI-VI-X)** *A. Mondelaers\** (Antwerp, Belgium), *Y. Somers, K. Vanden Driessche, I. Brosius, L. Liesenborghs, C. Rovers, L. Zweers, M. Wieland, E. Vlieghe*
- E0543** **Analysis of the current situation of hospital inspection practices by German health authorities** *A. Schwabe\** (Bonn, Germany), *J. Dannenberg, A.D. Wollkopf, F. Droop, S. Engelhart, N.T. Mutters*
- E0544** **A nationwide survey on the status and implementation of infection prevention and control practice on behalf of INSIEME Project (Italian National project for contrast antibiotic resistance a cooperation between Simit (Italian society of infectious diseases) E (&) Ministry of hEalth)** *M. Meschiari\** (Modena, Italy), *F.V. Segala, E. Ricchizzi, A. Gallerani, V. Scaglione, R. Castoldi, F. Almerigogna, I. Spalliera, A. Parente, S. Coladonato, P. Grimaldi, C. Camaioni, M. Abbott, A. Carretta, S. Audagnotto, A. Pan, C. Fanelli, S. Cicalini, P. Tanzili, E. Ponatali, I. Gentile, R.F. Del Vecchio, A. Oliva, A. Mularoni, M. Lichtner, F. Di Gennaro, A. Marino, R. Murri, C. Mussini*
- E0545** **High level of measles immunity among Dutch healthcare workers with self-reported "unknown" measles immunity status** *C. Meijer\** (Nijmegen, Netherlands), *J. Leijser, M. McCall, C. Rovers, E. Bowles, N. Van Der Geest, A. Tostmann*
- E0546** **Factors associated with positive latent TB screening results in healthcare workers at two tertiary referral hospitals in Ireland** *C. Anderson\** (Dublin, Ireland), *D. McGee, M. Coleman, A. Hehir, L. Dolan, N. Noonan, V. Tormey, C. Bergin, C. Fleming, L. Townsend*
- E0547** **Systematic review of determinants of vaccine hesitancy among healthcare workers** *V. Gabellone\** (Lecce, Italy), *F. Nuccetelli, R. Prato, E. Gabrielli, P.L. Lopalco*
- E0548** **Post-pandemic questions on vaccine usage: Two qualitative analyses of open-ended responses comparing hypothetical and novel vaccines** *P. Shamsrizi\** (Hamburg, Germany), *S. Eitze, D. Heinemeier, A. Tänzer, M.A. Jenny*
- E0549** **Do healthcare professionals working in acute healthcare settings identify infection prevention and control related knowledge deficits?** *A. Kearney\** (Dublin, Ireland), *H. Humphreys, D. Fitzgerald Hughes*

**EF076** **17:30 – 18:30** **Arena 3**

# ESCMID Global 2025 - Programme

	<b>from a multicenter questionnaire study in Western Japan</b> <i>R.M. Sada* (Osaka, Japan), S. Yamamoto, T. Toyokawa, T. Takahashi, A. Yamanaka, M. Kawamura, K. Yokota, Y. Fukumori, T. Taniguchi, R. Tanizaki, K. Iwata, S. Kutsuna</i>
E0563	<b>Post-Acute Sequelae and Excess Healthcare Utilization Following Dengue Infection: A Population-Based Cohort Study</b> <i>J.T. Lim* (Singapore, Singapore), I. Wee, W.Z. Tan</i>
E0564	<b>Challenges of dengue in haematological malignancy patients: Analysis from the DANGO registry during the 2023-2024 outbreak in Argentina</b> <i>G.A. Méndez* (Posadas, Argentina), J. Salmanton-García, C. Niveyro, P.A. Villalba Apestegui, V.I. Martín, L.M. Compañy Kec, M.C. Tomasino, M.D.C. Marull, H.I. Bernard, C.P.L. Fernández, M.F. Tosin, M.F. Hobecker, K.B. Duranona, A.D. Jara, O.A. Cornely</i>
E0565	<b>Key predictors of critical illness and mortality in Crimean-Congo haemorrhagic fever</b> <i>D. Yigci* (Istanbul, Türkiye), D. Güllü, N. Baykam, A. Kocagül Çelikbaş, D. Yapar, Ö. Akdoğan, K. Özden, R. İnan Sarıkaya, İ. Hasanoğlu, H.R. Güner, E. Doğan, F. Karakeçili, H. Alay, Z. Türe Yüce, E. Eryılmaz Eren, A. Erbay, Ş.E. Gök, Ç. Kader, G. Ünüvar Kalın, A. Yetişgen, M. Özgüler, A. Şenol, Ö. Gündag, M. Çağlar Özer, F. Soyak, B. Tanır, I.D. Alıracı, G. Çınar, B. Öztürk, E. Gürbüz, F. Pınarlık, M. Kuşkucu, Ö. Ergönül</i>
E0566	<b>Kyasanur Forest Disease in 2024: A Retrospective Cohort Study from a tertiary care centre in South India</b> <i>P. Venkata Swathi Kiran* (Udupi, India), P.K. Tirlangi, N. Gupta, R. Bhat, P. Ravindra, S.K. Pothumarthu</i>
E0567	<b>Unravelling the aetiology of summer flu-like illness in Czechia</b> <i>M.F. Křihá* (Ceske Budejovice, Czech Republic), V. Hönig, J. Kamiš, M. Dvořáková, L. Tardy, D. Teislerová, A. Chrdle, M. Palus, D. Růžek</i>

SY112	17:30 – 18:30	Hall 1
	1-hour Symposium	

PHEI

## Year in public health

Chairs	<i>Ziad A. Memish (Riyadh, Saudi Arabia)</i> <i>Catherine Moore (Cardiff, United Kingdom)</i>
--------	--

S0309	17:30	<i>Li Yang Hsu (Singapore, Singapore)</i>
S0310	18:00	<i>Rita Oladele (Lagos, Nigeria)</i>

SY111	17:30 – 18:30	Hall 11
	1-hour Symposium	

ANT

## PK/PD in drug development: what's in it for me?

Chairs	<i>Sandrine Marchand (Poitiers, France)</i> <i>Sebastian Wicha (Hamburg, Germany)</i>
--------	--

S0307	17:30	<b>PK/PD from the EUCAST/regulatory perspective: what tools do we need?</b> <i>Joseph Meletiadis (Athens, Greece)</i>
S0308	18:00	<b>PK/PD for new anti-TB drugs</b> <i>Elin Svensson (Uppsala, Sweden)</i>

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

OS070	17:30 – 18:30	Hall 12
	1-hour Oral Session	

CLN

DX

## What's new in antifungal guidelines and management

Chairs	<i>Sharon Chen (Sydney, Australia)</i> <i>Helmut Salzer (Linz, Austria)</i>
--------	--

O0512	<b>Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in</b>
-------	---



# ESCMID Global 2025 - Programme

	<i>Khider, L. Maisonobe, J. Mesnier, Y. Nguyen, B. Oules, M. Sanchez, S. Voicu, N. Burnichon, A. Faye, A. Mageau, T. Mirault, A. Pellat, C.A. Hobson, D. Bouzid, M. Thy, N. Peiffer-Smadja</i>
O0523	<b>Large language model in real-world clinical infectious diseases: are we there yet?</b> <i>G. Carra*</i> (Switzerland, Switzerland), <i>M. Van Singer, A. Cancela Costa, P.A. Crisinel, L. Cobuccio, F. Desgranges, A. Filali, Y. Fougère, T. Galpérine, E. Gauthiez, B. Guery, M. Jaboyedoff, S. Meylan, A. Munting, E. Kampouri, M. Papadimitriou-Olivgeris, M. Plebani, V. Suttels, P. Valladares, M.A. Hartley, J.L. Raisaro, D. Kaufmann, N. Boillat-Blanco</i>
O0524	<b>Artificial Intelligence-Powered Transformation: Enhancing Public Health Education at Tampere University Towards Sustainable Development Goal 3</b> <i>S. Ahmad*</i> (Tampere, Finland)
O0525	<b>A Survey on Perceived Priorities for the Implementation of Artificial Intelligence in Developing ESCMID Guidelines</b> <i>J. Molina Gil-Bermejo*</i> (Seville, Spain), <i>J. Molina, J.R. Paño-Pardo, B. Nagavci, M. Paul, T. Kostyanev, M.W. Langendam, J.P. Stahl, E. Tacconelli, S. Tschudin-Sutter, M. Zervos, L. Scudeller</i>
O0526	<b>Expect the unexpected: Longitudinally extensive transverse myelitis in a healthy young adult - a rare manifestation of tuberculosis</b> <i>S. Angirekula*</i> (Jodhpur, India), <i>R. Modi, R. Bora, R. Lohiya, S.K. Shivtarkar, S. Jagennath, D. Kumar, S. Tiwari, G.K. Bohra</i>

OS073	17:30 – 18:30	Hall 16
	1-hour Case Session	

CLN

## Still going viral

<i>Chairs</i>	<i>Ursula Hofer (London, United Kingdom)</i> <i>Yee Sin Leo (Singapore, Singapore)</i>
---------------	---

O0527	<b>Clinical outcomes of adoptive cell therapy for EBV reactivation and EBV-PTLD in primary immunodeficiencies: prophylactic and therapeutic applications of post-allo-HSCT memory T cell infusions.</b> <i>A. Tessitore*</i> (Trieste, Italy), <i>N. Maximova, S. Braidotti, M. Granzotto, R. Simeone</i>
O0528	<b>Histopathological proof of herpes simplex pneumonitis in a patient with severe COVID-19 pneumonia</b> <i>J. Heylen*</i> (Leuven, Belgium), <i>B. Lopuhaa, L. Maessen, S. Feys, L. Vanderbeke, G. De Vlieger, K. Lagrou, G. Hermans, M. Peetermans, E. Van Wijngaerden, P. Meersseman, A. Wilmer, G. De Hertogh, G. Verjans, J. Von Der Thüsen, J. Van Kampen, J. Wauters</i>
O0529	<b>Transmission of dengue virus from donors to recipient after solid organ transplantation. Case series in Argentina.</b> <i>L. Barcan*</i> (Buenos Aires, Argentina), <i>S. Villamandos, R. Gago, M. Aguirre, A. Martinoia, A. Patterer, M. Uranga, C. Sarkis, E. Temporiti, N. Pujato, S. Claudia, D. Calfunao, C. Nyveyro, M. Martinez, A. Smud, P. Giorgio, L. Barcán</i>
O0530	<b>Rash without borders: waning immunity in a travelling physician</b> <i>R. Ville Benavides*</i> (Mexico City, Mexico), <i>R. Ville-Benavides, I. Avendaño-Gutiérrez</i>
O0531	<b>A handful of Orf: a case of successful management with cidofovir in a renal transplant recipient</b> <i>A. Kaya*</i> (Izmir, Türkiye), <i>G.S. İzgi, B. Yaman, Y. Tiftikçioğlu, I. Karaaslan, M. Taşbakan</i>

SY110	17:30 – 18:30	Hall 3
	1-hour Symposium	

VAX

## Immune reconstitution syndrome in infectious diseases: Who. Are. You?

<i>Chairs</i>	<i>Elisa Borghi (Milan, Italy)</i> <i>Justyna Kowalska (Warsaw, Poland)</i>
---------------	--

S0305	17:30	IRIS in HIV Immunocompromised hosts: a failure of
-------	-------	---

# ESCMID Global 2025 - Programme

	<i>Uren* (Lviv, Ukraine), N. Aliieva, O. Voitovych</i>
E0579	<b>Evaluating a Tailored Antimicrobial Stewardship Strategy to Optimise IV to Oral Conversion: A Pre and Post-intervention Study</b> <i>M. Alyazji* (Abudhabi, United Arab Emirates), A. Sadeq, J. Shamseddine, Z.O.E. Babiker, A. Almansoori, M. Alhindasi, A. Abadi, S. Alhebsi, S. Alawlaqi, F. Aljasmí, A. Aitamimi, S. Shaabani, A. Alhosani, S. Shawish, R. Ali</i>
E0580	<b>Antimicrobial stewardship program for antibiotic use in the community: impact of multidisciplinary local guidelines during the 2023-2024 influenza A H1N1 season in northern Italy</b> <i>R. Corsini* (Reggio Emilia, Italy), P. Pavone, L. Donghi, S. Filippini, A. Valcavi, S. Filippi, F. Marchi, F. Violi, A. Gandolfi, E. Casini, M. Bardaro, G. Russello, P. Nardini, G. Formoso, G. Dolci, S. Mezzadri</i>
E0581	<b>Effectiveness of Clinical Algorithms combined with Point-of-Care testing to improve Antibiotic Prescribing practices of physicians in outpatient setting of low middle-income country</b> <i>S. Qureshi* (Karachi, Pakistan), S. Ahmed, N. Nasir, F.N. Qamar</i>
E0582	<b>Antibiotic prescribing behaviour in a public Bangladeshi hospital: a snapshot from BALANCE study</b> <i>M.S. Kabir* (Dhaka, Bangladesh), R. Farzana, S.M.R. Islam, A. Monir, A. Sharmin, J.B. Joyee, F. Humayra, M. Sultana, M.N. Haque, T.R. Walsh</i>
E0583	<b>Tailored response to antimicrobial resistance emergence: remote-created stewardship program in a low/middle-income country pediatric hospital</b> <i>P. Favier* (Valencia, Spain), M.A. Aguilera, G. Rapetti Salik, M. Quipildor, M.M. Maresca, I.A. Falco</i>
E0584	<b>Weekly interdisciplinary antimicrobial stewardship rounds at two surgical wards show notable potential in optimising antimicrobial treatment</b> <i>M. Krauss* (Vienna, Austria), C. Labut, G. Brunhofer-Bolzer, G. Laml-Wallner, B. Unterkoefler, M. Andtisch, E. Presterl, H. Burgmann, B. Willinger, I. Minichmayr, P. Starzengruber, F. Loetsch, H. Lagler</i>
E0585	<b>Antimicrobial stewardship programmes may improve patients' outcome and hospitalization: a sub-analysis of the CASAS (CARbapenem Sparing Antimicrobial Stewardship) Project</b> <i>M. Bongiovanni* (Lugano, Switzerland), B. Barda, L. Elzi, P. Bellini, C. Di Benedetto, N. Ramponi, M. Mombelli, N. Centemero, A. Colombo, D. Destefani, M. Bissig, E. Bernasconi</i>
E0586	<b>"Prescribing antibiotics is a gamble...": A mixed-methods approach to current practices and implementation challenges of antimicrobial stewardship in a Ugandan tertiary care hospital</b> <i>L. Jung* (Leipzig, Germany), L. Atikoro, D. Owachi, A. Schneider, S. Schönherr, A. Von Braun, C. Kabugo</i>

EF080	08:30 – 09:30	Arena 3
-------	---------------	---------



ePoster Flash Session

## *Acinetobacter baumannii*, still a strong knight to be knocked

*Chair* Parikshit Prayag (Pune, India)

E0587	<b>Evaluation of the Antibacterial Activity of New Dermaseptin Derivatives against <i>Acinetobacter baumannii</i></b> <i>H. Haddad* (Sousse, Tunisia)</i>
E0588	<b>Clonal dissemination of highly resistant <i>Acinetobacter baumannii</i> ST2: Insights from the BALANCE study</b> <i>C. Abdellaoui* (Oxford, United Kingdom), R. Farzana, M.N. Haque, M. Sultana, A. Sharmin, R.I. Rony, T. Ahmed Rifat, Z.T. Chaity, S. Afroj, S. Parvin, M. Ea De Kraker, S. Harbarth, N. Hassoun-Kheir, M. Hamza, G. Jana, S. Jamshaid, R. Yaseen, G. Fatima, M. Nawaz, S.N.Z. Rizvi, U. Ibrahim, K. Shafique, A. Naqvi, R. Zahra, B. Hassan, E. Carretto, K. Sands, K.J. Hoog, T.R. Walsh</i>
E0589	<b>Prevalence and genomic characterization of Sulbactam-Durlobactam-resistant and Carbapenem-resistant <i>Acinetobacter baumannii</i> in ICU Patients in a tertiary hospital in Hanoi, Northern Vietnam</b> <i>D. Nurjadi* (Luebeck, Germany), S. Boutin, Q.T. Nguyen, A.M.P. Thi, N.M. Truong, T.K.P. Nguyen, T.S. Bui, V.T. Nguyen, L. Göpel, L. Huber, K. Kocer, T.K.L. Le, T.T. Tran, T.T. Nguyen, H.S. Le, T.P.</i>

# ESCMID Global 2025 - Programme

## stewardship in long-term care facilities

*Chairs* *Gaetan Gavazzi (Grenoble, France)*  
*Giusy Tiseo (Pisa, Italy)*

- S0319

08:30

**The burden of nosocomial infections in long-term facilities** *Virginie Prendki (Genève-Thônex, Switzerland)*
- S0320

09:00

**Pneumonia in the elderly: management and prevention** *Marcos Restrepo (San Antonio, United States)*
- S0321

09:30

**Challenges in the clinical diagnosis of infection in the elderly** *Maheen Abidi (Denver, United States)*
- S0322

10:00

**Challenges in implementing antimicrobial stewardship in long-term care facilities** *Elena Carrara (Verona, Italy)*

Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

SY117

08:30 – 10:30

Hall 16

2-hour Symposium

AMR CLN

## Survival of the parasites: is treatment failure due to antimicrobial resistance?

*Chairs* *Hanne Brekke (Oslo, Norway)*  
*Jaco J. Verweij (Tilburg, Netherlands)*

- S0327

08:30

**Nitroimidazole refractory *Giardia intestinalis* infection** *Pavla Tůmová (Praha, Czech Republic)*
- S0328

09:00

**Treatment failure in scabies** *Francisco Bravo (Lima, Peru)*
- S0329

09:30

**Recurrent *Enterobius* infections** *Sarah Eisen (London, United Kingdom)*
- S0330

10:00

**Recent advances in the treatment of Visceral Leishmaniasis and PKDL** *Shyam Sundar (Varanasi, India)*

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

EW118

08:30 – 10:30

Hall 2

Educational Session

DX IPC

## How can we infer and track plasmid outbreaks?

*Chairs* *Alessandra Carattoli (Rome, Italy)*  
*Jacob Moran-Gilad (Beer Sheva, Israel)*

- W0331

08:30

**Evolutionary modelling of plasmids** *Manuel Ares Arroyo (Paris, France)*
- W0332

08:50

**How plasmids shape the emergence of nosocomial pathogens** *Jukka Corander (Oslo, Norway)*
- W0333

09:10

**Understanding the complexity of plasmid outbreaks using bioinformatics** *Torsten Seemann (Melbourne VIC), Australia)*
- W0334

09:30

**Plasmid transmission at the One Health interface** *Nicole Stoesser (Oxford, United Kingdom)*

Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Veterinary Microbiology (ESGVM)

SY113

08:30 – 10:30

Hall 3

2-hour Symposium

PHEI

## Haemorrhagic viral infections

*Chairs* *Önder Ergönül (Istanbul, Türkiye)*  
*Catherine Houlihan (Porton Down, United Kingdom)*

- S0311

08:30

**Filovirus disease: evolving therapeutic strategies** *Ian Crozier (Frederick, United States)*
- S0312

09:00

**Jack in the box: Re-emergence of Kyasanur Forest Disease in India** *Kavitha Saravu (Manipal, India)*

# ESCMID Global 2025 - Programme

EF081

09:30 – 10:30

Arena 2

ePoster Flash Session

ANT DX

## Clinical features and outcome of invasive fungal infections

Chair

Marcus De Melo Teixeira (Brasília, Brazil)

E0596

**Management, outcomes and predictors of mortality of *Cryptococcus* infection in patients without HIV: a multicentre study in 46 hospitals from Australia and New Zealand**J. Coussement\* (Melbourne, Australia), C.H. Heath, M.B. Roberts, R.J. Lane, T. Spelman, O.C. Smibert, A. Longhitano, C.O. Morrissey, B. Nield, M. Tripathy, J.S. Davis, K.J. Kennedy, S.A. Lynar, L.C. Crawford, S.J. Crawford, B.J. Smith, A.P. Gador-Whyte, R. Haywood, A.A. Mahony, J.C. Howard, G.B. Walls, G.M. O'kane, M.T. Broom, C.L. Keighley, O. Bupha-Intr, L. Cooley, J.A. O'hern, J.D. Jackson, A.J. Morris, C. Bartolo, A.R. Tramontana, K.C. Grimwade, V. Au Yeung, R. Chean, E. Woolnough, B.W. Teh, M.A. Slavin, S.C.A. Chen

E0597

**Incidence of invasive fungal infections in hospitalised paediatric patients in England**A. Warris\* (Exeter, United Kingdom), L. Ferreras-Antolin, G. Kiely, Z. Riaz, M. Czachorowski, M. Gerino, K.K. Rai, Z. Akhter, J. Owczarek, C. Castillo, I. Jimenez

E0598

**Invasive fungal disease in critically ill patients with cirrhosis: an autopsy study**L. Maessen\* (Leuven, Belgium), A. Wilmer, P. Meersseman, J. Wauters, J. Heylen, S. Feys, C. Jacobs, H.M. Lauwers, K. Lagrou, M. Peetermans, G. Hermans, Y. Debaveye, E. Van Wijngaerden, S. Van Der Merwe, G. De Hertogh

E0599

**Non-*Aspergillus* mould infections in Australia and New Zealand: a multi-centre study on epidemiology and clinical outcomes**C.F. Neoh\* (Melbourne, Australia), S.C.A. Chen, A.J. Morris, C.H. Heath, S.J. Tan, R. Lane, S.Y. Tio, M.B. Roberts, S.Y. Tay, K. Kennedy, S. Van Hal, H. Murray, R. Pickles, A. Douglas, K. Urbancic, M. Menon, A. Stewart, P. Simos, N.M. Vaselli, J. Howard, C. Keighley, S. Miyakis, R. Beresford, L. Cooley, O. Smibert, M. Sehu, K.Y. Yong, A. Crowe, M. England, O. Robinson, S. Lynar, K. Daveson, C. Halliday, S. Kidd, D.C.M. Kong, T. Spelman, L. Worth, M. Slavin

E0600

**Leveraging natural language processing (NLP) for early detection of aspergillosis: A retrospective study**L. Nwankwo\* (London, United Kingdom), N. Pinnock, A. Shek, C. Hemsley, J. Periselnieris, S. Schelenz, D. Armstrong-James

E0601

**How often does Mucormycosis (MCM) contribute to mortality in Hematologic Malignancy (HM) patients? Analysis of 103 patients over 20 years**S. Wurster\* (Houston, United States), T.M. John, J. Ying, D.P. Kontoyiannis

E0602

**Emergence of *Wickerhamomyces anomalus* invasive infections in injecting drug users**M. Lefranc\* (Bordeaux, France), M. Desnos-Ollivier, P. Baudino, K. Boukris-Sitbon, C. Plaisant, F. Dalle, F. Lanternier, S. Imbert

E0603

**Prevalence and risk-factors for secondary localizations during candidemia in intensive care unit patients: the French Candida ICU multicenter study**J.P. Gangneux\* (Rennes, France), F. Reizine, J. Henry, L. Desmedt, C. Camus, V. Coirier, F. Arrive, E. Burban, G. Eustache, T. Belleville, A. Marc, J. Malherbe, P. Bouju, P. Jaubert, O. Lesieur, M. Leclerc, P. Fillâtre, A. Frérou, R. Prével, A. Cady, F. Morio, M. Pihet, G. Nevez, L. Delhaes, S. Imbert, H. Guegan, J. Bonhomme, E. Perraud, C. Dupin, D. Du Cheyron, Y. Launey, C. Aubron

E0604

**Population-based longitudinal study over two decades of *Candida* and *Candida*-like species bloodstream infection reveals gender and species differences in mortality, recurrence and resistance**A. Stewart\* (Boston, United States), K. Laupland, F. Edwards, S. Koo, S. Hammond, P. Harris, D. Paterson, M. Slavin, S. Chen

# ESCMID Global 2025 - Programme

EF090

11:00 – 12:00

Arena 3

DX

ePoster Flash Session

## Addressing the need for speed: advances in point-of-care testing

Chair

Jennifer Dien Bard (Los Angeles, United States)

- E0649

**Rapid respiratory microbiological POCTs and antibiotic use in primary care: the RAPID-TEST RCT***E. Brown\** (Bristol, United Kingdom), *A.D. Hay, S. Abbs, M. Ridd, S. Granier, A. Lane, P. Muir, J. Taylor, G. Young, K. Eastwood, H. Dash, L. Bradshaw, R. Clarke, M. Lui, E. Bridgeman, R. Brierley, H. Thornton, P. Mitchell, L. Zhu, L. Yardley, C. Metcalfe*
- E0650

**Evaluation of the prototype BIOFIRE® nasal HR panel (nHRP) in children with acute respiratory illness, a nasal swab-based rapid hoSt gene expression test***G. Storch\** (Saint Louis, Missouri, United States), *M. Wallendorf, C. Rindlisbacher, J. Jackson, M. Hockin*
- E0651

**Evaluation of the analytical performance of the Biosynex AMPLIQUICK Fecal Bacteriology kit in the diagnosis of bacterial intestinal infections***P. Lehours\** (Bordeaux, France), *Q. Beaufils, L. Benejat, A. Ducournau, J. Aptel, A. Chevalier, M. Jauvain*
- E0652

**Development and Validation of a Novel Rapid Antigen Test for Norovirus Detection: A Comparative Performance Analysis***N. Younes\** (Doha, Qatar), *G. Nasrallah*
- E0653

**A Rapid Molecular POCT System for Detection of Carbapenem-Resistant Enterobacterales (CRE)***S. Y. Choi\** (Daejeon, Korea, Republic of), *C. Lee, H.O. Park*
- E0654

**Validation of an ultra-rapid, point-of-care, antibiotic susceptibility testing device***A. Van Der Linden\** (Eindhoven, Netherlands), *Y. Deurloo, N. Doomen, D. Kreft, J. Hays, H. Stapert, A. Van Belkum, S. Shanko*
- E0655

**Development of a frugal multiplexed paper sensor for rapid detection of sepsis-causing pathogens***C. Singhal\** (Faridabad, India), *S. Chatterjee, S. Gupta, M. Yadav, C. Sharma, S. Pandey, D. Kumar, P. Joshi, J. Jaya, R. Dwivedi, S. Tanwar, S. Sharma, S. Shamsi, A. Tyagi, N. Kumar, S. Chaudhuri*
- E0656

**Multianalyte POCT device for a sample-to-result detection of nucleic acid and protein***L. Pommiers\** (Gif Sur Yvette, France), *H. Boutal, D. Fras, H. Volland*
- E0657

**A smartphone app for point-of-care quantification of lateral flow assays***R. Armiger\** (London, United Kingdom), *R. Reid, P. Georgiou, A. Holmes, J. Herberg*

KN121

11:00 – 12:00

Hall 1

PHEI

Keynote Lecture

## HIV: from needle parks to injectables

Chairs

Mary Horgan (Dublin, Ireland)  
Gölsen Özkaya Sahin (Lund, Sweden)

K0341

11:00

Huldrych Günthard (Zürich, Switzerland)

OS085

11:00 – 12:00

Hall 10

CLN PHEI

1-hour Oral Session

## Planes, Pains, and Pathogens: The Perils of Travel Medicine

Chairs

Anu Kantele (Helsinki, Finland)  
Carlos Seas (Lima, Peru)

O0620

**Fever in returning travelers from tropical regions: what not to miss in an evolving epidemiology***S. Caronni\** (Milan, Italy), *M. Pieruzzi, A. Rizzo, A.H. Behring, A. Poloni, A. Giacomelli, F. Salari, S. Grosso, A. Mancon, D. Mileto, S. Antinori*

O0621

**Tracing the Itch: A spatiotemporal analysis of scabies rates and its risk factors using the Global Burden of Disease data***S. Gupta\** (Auckland, New Zealand), *S. Thornley, G. Sundborn, C. Grant*

# ESCMID Global 2025 - Programme

SY126

11:00 – 12:00

Hall 13

CLN

1-hour Symposium

## Why is the concept of complicated UTI so complicated?

Chairs

Gernot Bonkat (Basel, Switzerland)  
Maeve Doyle (Waterford, Ireland)

S0350

11:00

The concept of complicated UTI: underlying conditions matter  
Suzanne Geerlings (Amsterdam, Netherlands)

S0351

11:30

The concept of complicated UTI: the site of infection matters most  
Jesús Rodríguez-Baño (Seville, Spain)

Co-organised with: ESCMID Education Subcommittee

ME128

11:00 – 12:00

Hall 14

TRN

Meet-the-Expert

## How to apply organoid models to study infectious disease

M0354

11:00

Jennifer Rohn (London, United Kingdom)

M0355

11:12

Nathalie Sauvonnnet (Paris, France)

OS087

11:00 – 12:00

Hall 15

AMR TRN

1-hour Oral Session

## Antimicrobial resistance around birth

Chairs

Julia Anna Bielicki (London, United Kingdom)  
Surbhi Malhotra-Kumar (Antwerp, Belgium)

O0630

Prevalence and risk factors of antibiotic resistance genes in breastmilk and neonatal oral cavity of preterm mother-infant pairs  
A. Sharma\* (Chandigarh, India), S. Dutta, M. Biswal, A. Chakraborty, V. Suri, P. Ray

O0631

Effect of maternal peripartum antibiotic exposure on the microbial diversity, relative abundance of taxa, and resistome in breastmilk  
A. Chakraborty\* (Chandigarh, India), S. Dutta, P. Sikka, D. Puri, A. Kumar, P. Kumar, A. Pal, A. Arora

O0632

Dynamics of gastrointestinal colonisation by antibiotic-resistant bacteria in high-risk infants in Swiss and Greek neonatal intensive care units  
A. Braspenning\* (Antwerp, Belgium), L. Timbermont, L. Van Heirstraeten, M. Berkell, A. Cook, E. Sieswerda, C.H. Van Werkhoven, J. Bielicki, S. Malhotra-Kumar

O0633

Harnessing functional omics to decipher how probiotics reduce antibiotic resistance gene carriage in infants' gut  
V. Pettersen\* (Tromsø, Norway), A. Bargheet, G.H. Bø, C. Klingenberg

O0634

Dynamics of gut resistome and mobilome in early life: A meta-analysis  
V. Pettersen\* (Tromsø, Norway), A. Bargheet, H.T. Noordzij, A.J. Ponsero, C. Jian, K. Korpela, M. Valles-Colomer, J. Debelius, A. Kurilshikov

OS088

11:00 – 12:00

Hall 16

CLN DX VAX

1-hour Oral Session

## Advancing diagnostics and preventive measures in hemato-oncological patients

Chairs

Dina Averbuch (Jerusalem, Israel)  
Malgorzata Mikulska (Genoa, Italy)

O0635

Prediction of bacterial and fungal bloodstream infections using machine learning in patients undergoing chemotherapy  
M. Freire\* (Sao Paulo, Brazil), A. Villani, Jr, M. P. Freire, F. Lazzar Neto, L.A. De Padua Covas Lages, M. Salaroli De Oliveira, E. Abdala, F. L.S. Nunes, A.S. S. Levin

# ESCMID Global 2025 - Programme

S0342	11:00	The lung microbiome of people with cystic fibrosis receiving modulator therapy <i>Sebastien Boutin (Lübeck, Germany)</i>
S0343	11:30	Tackling chronic infections in people with cystic fibrosis receiving modulator therapy: is it still necessary? <i>Alessandra Bragonzi (Milano, Italy)</i>
Co-organised with: ESCMID Study Group for Biofilms (ESGB), Czech Society for Medical Microbiology		

SY123	11:00 – 12:00	Hall 4
	1-hour Symposium	

IPC

Infection prevention and control and intensive care: challenges and solutions		
Chairs	<i>Antonios Katsounas (Bochum, Germany)</i> <i>Claire Roger (Nimes, France)</i>	

S0344	11:00	Intensive care unit (ICU) and infection: two sides of a coin <i>Reto Schuepbach (Zurich, Switzerland)</i>
S0345	11:20	Ventilator- associated pneumonia (VAP) and ICU enviroment: how can we improve practices? <i>Despoina Koulenti (London, United Kingdom)</i>
Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIP), EUCIC Steering Committee		

OS083	11:00 – 12:00	Hall 5
	1-hour Oral Session	

CLN

DX

PHEI

Don't 'rash' it		
Chairs	<i>Heli Harvala (Turku, Finland)</i> <i>Catherine Moore (Cardiff, United Kingdom)</i>	

O0610	<b>Current Prevalence of Parvovirus B 19 Infections: Ankara Bilkent City Hospital Experience 2019-2024</b> <i>B. Dinc* (Ankara, Türkiye), F.G. Aslan, F. Kırca, A. Toyran, S. Aydoğan, B. Dinç</i>	
O0611	<b>Managing an outbreak of parvovirus B19 infection in pregnancy: clinical outcomes from a single-centre study</b> <i>M. Melchio* (Genoa, Italy), E. Ricci, E. Cristina, E. Di Marco, P. Caligiuri, F. Prefumo, S. Mangini, A. Mesini, M. Mariani, C. Russo Artimagnella, C. Saffioti</i>	
O0612	<b>The dark side of the „fifth disease” endemic: human parvovirus B19 infections transmitted through blood transfusions in adults with malignant hematological diseases</b> <i>B.G. Szabo* (Budapest, Hungary), D. Korozs, P. Remenyi, J. Sinko</i>	
O0613	<b>Key learnings from a measles outbreak with multiple hospital exposures in Ireland, May-July 2024</b> <i>A.M. Murray* (Dublin, Ireland), G. Larkin, D. Hickey</i>	
O0614	<b>Measles virus in the context of subacute sclerosing panencephalitis (SSPE)</b> <i>J. Dina* (Caen, France), S. Medragh, J. Adnet, T. Belveyre, C. Vauloup-Fellous</i>	

SY124	11:00 – 12:00	Hall 6
	1-hour Symposium	

CLN

Antimicrobial prescribing: myths or pearls?		
Chairs	<i>Massimo Fantoni (Roma, Italy)</i> <i>Spyros Pournaras (Athens, Greece)</i>	

S0346	11:00	Why treat IV when PO is possible? <i>Bradley Spellberg (Los Angeles, United States)</i>
S0347	11:30	De-escalation of antibiotic therapy to narrow-spectrum IV drugs <i>Flaminia Olearo (Hamburg, Germany)</i>
Co-organised with: CMI Communications Board of Editors, ESCMID AMR Action Subcommittee, ESCMID Study Group for Antimicrobial stewardship (ESGAP), Trainee Association of ESCMID (TAE) Steering Committee, ESCMID Scientific Affairs Subcommittee		



# ESCMID Global 2025 - Programme

M0367 13:30 Maheen Abidi (Denver, United States)  
M0368 13:42 Alaa Atamna (Petah-Tikva, Israel)

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Study Group for Infections in the Elderly (ESGIE)

SY131 13:30 – 14:30 Hall 2  
1-hour Symposium

AMR PHEI VAX

## Vaccines and antimicrobial resistance

Chairs Iva Butic (Zagreb, Croatia)  
Zitta Barrella Harboe (Hillerød, Denmark)

S0361 13:30 The impact of current and future vaccines on AMR: from pneumococcal to COVID-19 Mateusz Hasso-Agopsowicz (Geneva, Switzerland)  
S0362 14:00 Can vaccines against AMR be translated into policy? William Hausdorff (Washington DC, United States)

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Vaccine Study Group (EVASG)

EW135 13:30 – 15:30 Hall 3  
Educational Session

PRO

## Transforming your research idea into an appropriate study design

Chairs Casandra Bulescu (Bucharest, Romania)  
Mary Horgan (Dublin, Ireland)

W0369 13:30 Designing high-quality research studies: methodological skills and knowledge Mical Paul (Haifa, Israel)  
W0370 13:50 How to design and run scientific studies using AI agents as research assistants Alyssa Bilinski (Cambridge, United States)  
W0371 14:10 Designing your first study: how to construct a workable project when your work environment may not help Thomas Tängdén (Uppsala, Sweden)  
W0372 14:30 Bridging early-career professionals with partners and seniors Giorgia Caruana (Sion, Switzerland)

Co-organised with: CMI Board of Editors, CMI Communications Board of Editors, Trainee Association of ESCMID (TAE) Steering Committee

FO136 13:30 – 14:30 Arena 1  
Open Forum

PRO

## Diversity in CM and ID: gender gaps and policy traps

Chair Andre Fuchs (Augsburg, Germany)

F0373 13:30 How to avoid parity traps in ID/CM research? Muge Cevik (St Andrews, United Kingdom)  
F0374 13:40 Gender gaps in visibility at scientific conferences Sarah Delliére (Paris, France)  
F0375 13:50 Psychological determinants of empowerment at individual and societal level Tba

Co-organised with: ESCMID Education Subcommittee, ESCMID Parity Commission

EF093 13:30 – 14:30 Arena 2  
ePoster Flash Session

CLN DX

## Real world experience with modern HIV treatment: the art of ART

E0668 Use of long-acting cabotegravir/rilpivirine in HIV-viraemic individuals: a metanalysis M. Bongiovanni\* (Lugano, Switzerland), B. Barda, G. Barilaro, E.

# ESCMID Global 2025 - Programme

E0681	<b>Pathobiome characterization and role in disease severity in children under 5-years with respiratory infection symptoms</b> <i>L. Terranova* (Milan, Italy), L. Corneo, G. Di Pietro, R. Pinzani, M. Bolis, L. Alagna, M. Caruso, F. Giorgetti, N. Hejazifar, E. Furchi, M. Carnevale Schianca, P. Bono, C. Tagliabue, F.B.A. Blasi, A. Callegaro, A. Bandera, S. Bosis, C. Alteri</i>
E0682	<b>Viral viability markers of SARS-CoV-2: A Comparison of cell culture genomic RNA RT-PCR and subgenomic RNA RT-PCR</b> <i>C. Cuesta Chasco* (Barcelona, Spain), S. Alex, M. M<sup>a</sup> Ángeles, C.C. Genoveva, A. Francesco, R. Cristina, V. Anna, H. Juan Carlos, F.A. Francesc, R.L. Luis Gerardo, N. Mireia, G. Ignacio, B. Marta, G.V. Carolina</i>
E0683	<b>Diagnostic performance of Hepatitis B virus surface antigens in the Netherlands using type-specific external quality assessment</b> <i>E. Vanhulle* (Bilthoven, Netherlands), M. Simões, H. Ten Bruin, G. Boland, A. Brandenburg, K. Bens chop</i>
E0684	<b>Low utility of parallel testing by multiplex and individual real-time PCR assays for the diagnosis of viral meningitis and encephalitis at a large public hospital in the United States</b> <i>A. Cuber* (Los Angeles, United States), S. Butler-Wu</i>
E0685	<b>Plasma Separation Card as an alternative sampling method for quantitative HCV RNA testing with high comparability to EDTA plasma</b> <i>F. Garcia* (Granada, Spain), A. Fuentes López, A. Rando Segura, R. Carracedo, A. Kessler, A. De Salazar González, S.Z. Gebreab, E. Molina, N. Parajó, S. Pereira, J. Romero Vico, E. Ruiz Escolano, M. Vila, L. Viñuela González, A. Carrasco Durán, A. Aguilera, F. García, M. Buti Ferret</i>

KN130	13:30 – 14:30	Hall 1
	Keynote Lecture	

## Infectious disease challenges in an ever-changing environment

<i>Chairs</i>	<i>Jacob Moran-Gilad (Beer Sheva, Israel)</i> <i>Annelies Zinkernagel (Zurich, Switzerland)</i>
---------------	--

K0360	13:30	<i>Pamela Rendi Wagner (Stockholm, Sweden)</i>
-------	-------	--

PM3	13:30 – 14:30	Hall 12
	Meet-the-Innovators	

## Future prospects of electronic clinical decision support systems in stewardship programs

L007	13:30	<b>Opportunities for clinical decision support systems in infectious disease management</b> <i>Nathan Peiffer-Smadja (Paris, France)</i>
L008	14:00	<b>CDSS and AMS programs: the Lumed example</b> <i>Valiquette Louis (Sherbrooke, Canada)</i>

SY132	13:30 – 14:30	Hall 13
	1-hour Symposium	

AMR DX

## Predicting antibiotic susceptibility profiles from whole genome sequences: state-of-the-art

<i>Chairs</i>	<i>Werner Ruppitsch (Vienna, Austria)</i> <i>Balaji Veeraraghavan (Vellore, India)</i>
---------------	---

S0363	13:30	<b>Impact of the WHO's developed catalogue of mutations on rapid TB diagnosis and treatment</b> <i>Thomas Schön (Kalmar, Sweden)</i>
S0364	14:00	<b>Antimicrobial resistance prediction using whole genome sequencing</b> <i>Patricia Simner (Rochester, United States)</i>

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Epidemiological Markers (ESGEM), EUCAST Steering Committee

# ESCMID Global 2025 - Programme

		Türkiye), S. Unlu
O0662	<b>Genome-wide association study (GWAS) reveals importance of vaginal epithelium associated genes in case of recurrent vaginitis</b> <i>R. Mändar* (Tartu, Estonia), E. Mutli, K. Koort, A. Salumets, T. Laisk</i>	
<hr/>		
EF099	14:45 – 15:45	Arena 1
		ePoster Flash Session
		AMR IPC
Infection Prevention in Action: Innovations, Insights, and Global Intervention		
Chair	Allison Mcgeer (Toronto, Canada)	
<hr/>		
E0706	<b>A <i>Candida auris</i> cgMLST Scheme for Enhanced Outbreak Surveillance and Global Epidemiological Tracking</b> <i>C. Harless* (Silver Spring, United States), J. Stam, B. Corey, E. Horishny, A. Ong, Y. Kwak, J. Bennett, P. McGann, F. Lebreton</i>	
E0707	<b>Machine Learning-Augmented Clinical Scoring System for Predicting KPC Infections in Healthcare Crisis Scenarios</b> <i>A. Rearte* (Buenos Aires, Argentina), F. Herrera, E. Temporiti, J. Smayevski, P. Bonvehi</i>	
E0708	<b>Incident infections with respiratory syncytial virus in a hospital-based healthcare worker cohort, 2023-2024 winter season</b> <i>C. Savulescu* (Paris, France), M. Rojas, K. Brolin, A. Uusküla, C. Bergin, C. Fleming, V. Zvirbulis, D. Zavadska, V. Gaio, C.P. Popescu, R.M. Hrisca, M. Cisneros, M. Latorre-Millán, J. Mcgrath, L. Lohur, L. Ferguson, I. Abolina, D. Gravele, A. Machado, S.A. Florescu, S.M. Pohrib, P. Subirats, L. Clusa Cuesta, J. Sui, C. Kenny, D. Krievins, E.A. Barzdina, C. Valadas Henriques, A.G. Kosa, M. Lazar, C. Muñoz-Almagro, A.M. Milagro, S. Bacci, A. Nardone</i>	
E0709	<b>Evaluation of the efficiency of reusable terminal filters for showers for nosocomial legionellosis prevention in a French university hospital</b> <i>N. Khanafer* (Lyon, France), A. Regard, L. Beraud, R. Sintes-Tissot, Q. Barriot, J.C. Saurin, M. Chuzeville, P. Vanhems, M. Chaboud</i>	
E0711	<b>Emerging uncommon non-fermenters and their decreasing antibiotic susceptibility in patients with prolonged hospital stay</b> <i>V. Khillan* (New Delhi, India), V.G. Nag P, P. Kale, A. Paul, A. Saran</i>	
E0712	<b>Air and surface sampling around mpox Clade 1b in hospitals in the UK</b> <i>S. Gould* (Liverpool, United Kingdom), B. Atkinson, B. Hack, T. Williams, J. Otter, Y. Ceesay, A. Alonsonso, G. Nebbia, S. Blundell, W. Newsholme, G. O'hara, M.G. Semple, T. Fletcher, J. Dunning</i>	
E0713	<b>Utilization of a healthcare facilities rapid assessment tool to define infection prevention and control and Water, Sanitation and Hygiene baseline criterion met during Democratic Republic of Congo mpox outbreak from August to November 2024</b> <i>A. Baller* (Geneva, Switzerland), N.R. Okum, G. Nsambi, K. Kabamba, Y.L. Soro, L. Kabego, V. Willet, N. Usman, H. Hamilton Hurwitz, M. Moon</i>	
E0714	<b>The REACT study: Exploring the BSI Potential of KPC, NDM, VRE, and CRAB rectal colonization</b> <i>M. Colaneri* (Milano, Italy), P. Giordani, S. Lerta, A. Sangani, V.A. Villano, A. Gori, M. Rettani, S. Milanesi, G. De Nicolao, R. Bruno</i>	
<hr/>		
EF100	14:45 – 15:45	Arena 2
		ePoster Flash Session
		ANT
Cefiderocol: an efficient Trojan horse?		
Chair	Anna Sramkova (Pilsen, Czech Republic)	
<hr/>		
E0715	<b>Acceleration of Emergence of Cefiderocol Resistance in Microfluidic Evolution System</b> <i>B. Li* (Beijing, China), S. Shen, Q. Wang, S. Wang, W. Wang, H. Wang</i>	
E0716	<b>The hidden link between cefiderocol resistance and increased virulence in <i>Klebsiella pneumoniae</i>. Insights from a TraDIS-based investigation</b> <i>E. Eger*</i>	

# ESCMID Global 2025 - Programme

E0729		<b>Impact of BCG vaccination on adaptive immune responses to mycobacterial and non-mycobacterial antigens in HIV-exposed, uninfected infants.</b> <i>R. Namakula*</i> (Bergen, Norway), <i>V. Nankabirwa, S. Cose, O. Namugga, M.G. Netea, H. Steinsland, H. Sommerfelt, K. Hanevik</i>
E0730		<b>Immune signature against <i>Klebsiella pneumoniae</i> proteins in a mother-baby cohort from Blantyre, Malawi.</b> <i>E. Heinz*</i> (Glasgow, United Kingdom), <i>J. Campo, O. Pearse, A. Zuza, A. Teng, J. Pablo, A. Oberai, J. Edgar, A. Shandling, K. Kawaza, N. Feasey</i>
E0731		<b>A comprehensive computational mapping of B-cell epitopes in the <i>Klebsiella pneumoniae</i> porinome.</b> <i>S. Prieto Martín Gil*</i> (Madrid, Spain), <i>S. Prieto Martín Gil, E. Gato, A. Pérez, M.J. Mcconnell, A.J. Martín Galiano</i>
E0732		<b>Chronic infection induces a broadly neutralizing antibody response to Elastase B of <i>Pseudomonas aeruginosa</i>.</b> <i>A. Albus*</i> (Cologne, Germany), <i>D. Kolling, K. Rox, D. Holzmänn, K. Mundry, M. Sánchez Agut, C. Meyer, R. Brock, J. Kutschera, K. Schmitt, J.A. Wilms, L. Ullrich, C. Kreer, M. Meyer-Willerscheidt, M. Hallek, E. Rietschel, S. Van Koningsbruggen-Rietschel, F. Klein, J. Koehnke, J. Rybníček, A. Simonis</i>
<hr/>		
KN137		<b>14:45 – 15:45</b> <span>Hall 1</span>
		Keynote Lecture
		<span>TRN</span>
<b><i>Staphylococcus aureus</i> host-microbe interaction: ecology, disease, and vaccine development</b>		
<i>Chairs</i>		<i>Werner Ruppitsch</i> (Vienna, Austria) <i>Annelies Zinkernagel</i> (Zurich, Switzerland)
K0376	14:45	<i>Juliane Bubeck Wardenburg</i> (St. Louis, United States)
<hr/>		
ME140		<b>14:45 – 15:45</b> <span>Hall 11</span>
		Meet-the-Expert
		<span>DX</span> <span>TRN</span>
<b>Bioinformatic tools from start to finish</b>		
M0381	14:45	<i>Vítor Borges</i> (Lisbon, Portugal)
M0382	14:57	<i>Clare Sloggett</i> (Melbourne, Australia)
<hr/>		
ME141		<b>14:45 – 15:45</b> <span>Hall 13</span>
		Meet-the-Expert
		<span>AMR</span> <span>CLN</span>
<b>AI use in antimicrobial stewardship</b>		
M0383	14:45	<i>Shruti Gohil</i> (Irvine, United States)
M0384	14:57	<i>Jose Ramon Pano-Pardo</i> (Zaragoza, Spain)
<hr/>		
OS097		<b>14:45 – 15:45</b> <span>Hall 14</span>
		1-hour Oral Session
		<span>PHEI</span>
<b>Update on zoonotic and enteric infections</b>		
<i>Chairs</i>		<i>Steen Ethelberg</i> <i>Kavitha Saravu</i> (Manipal, India)
O0696		<b>A large-scale epidemiological study of <i>Campylobacter</i> employing whole genome analysis reveals the evolution of highly virulent and multidrug-resistant clones in the UK.</b> <i>B. Lopes*</i> (Middlesbrough, United Kingdom), <i>A.S. Boatey-Biko</i>
O0697		<b>Population dynamics and evolution of multidrug resistant clones of <i>Shigella sonnei</i> in Metropolitan France.</b> <i>C. Silva Nodari*</i> (Paris, France), <i>I. Carle, M. Lejay-Collin, L. Philippot, C. Ruckly, L. Fabre, M. Pardos De La Gandara, F.X. Weill</i>

# ESCMID Global 2025 - Programme

	<b>acquired pneumonia in hospitalized adults in Germany</b> <i>D. Karssen* (Utrecht, Netherlands), L. Hessels, G. Barten-Neiner, W. Bauer, S. Franch, T. Fühner, C. Hassiepen, D.F. Heigener, B. Hullegie, R. Jahja, K.D. Johnson, J. Kremling, C. Roberts, G.G.U. Rohde, M. Ruggieri, J. Scheider, D. Stolz, T.D. Swarthout, T. Weiss, H. Van Werkhoven, M. Bonten, C. Prat-Aymerich</i>
O0688	<b>Community-acquired pneumonia identification from electronic health records in the absence of a gold standard: a Bayesian latent class analysis</b> <i>J. Wei* (Oxford, United Kingdom), K. Yuan, A. Luk, S. Walker, D. Eyre</i>
O0689	<b>Causes of death and risk factors for 90-day mortality and readmission in community-acquired pneumonia</b> <i>F. Al-Zergani* (Hvidovre, Denmark), C. Lundetoft Clausen, P. Ravn, M. Sebastian Roldgaard, L. Kolte, H. Sarac, M. Fally, S. Bastrup Israelsen, T. Benfield</i>
O0690	<b>Oropharyngeal carriage of gut-derived Enterobacterales increases RTI risk in long-term aged care residents</b> <i>S. Miller* (Adelaide, Australia), F. Zhang, S. Taylor, A. Shoubridge, E. Vasil, R. Woodman, L. Papanicolas, G. Rogers</i>

SY138	<b>14:45 – 15:45</b>	Hall 4
	1-hour Symposium	

AMR

## Global clones and evolving resistance mechanisms towards newer beta-lactams: Where are we heading?

<i>Chairs</i>	<i>Yesim Besli (Istanbul, Türkiye)</i> <i>Spyros Pournaras (Athens, Greece)</i>
---------------	--

S0377	14:45	<b>Carbapenemase-producing Enterobacterales: the not so good, the bad and the ugly</b> <i>Arjana Tambic Andrasevic (Zagreb, Croatia)</i>
S0378	15:15	<b>The <i>P. aeruginosa</i> frightening cocktail: high-risk clones, horizontally-acquired resistance and evolving mutational resistome</b> <i>Katy Jeannot (Besançon, France)</i>

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

OS096	<b>14:45 – 15:45</b>	Hall 5
	1-hour Oral Session	

AMR

## Trends in antifungal resistance

<i>Chairs</i>	<i>Alexandre Alanio (Paris, France)</i> <i>Ana Alastruey-Izquierdo (Madrid, Spain)</i>
---------------	---

O0691	<b>Turning resistance into vulnerability: leveraging genetic insights to predict collateral sensitivity and synergism for effective multidrug therapies</b> <i>K. Schmidlin* (Tempe, United States), K. Geiler-Samerotte</i>
O0692	<b>Role of the C2585G substitution in the <i>MRR1</i> gene in the development of azole resistance in <i>Candida parapsilosis sensu strictu</i></b> <i>I. Franconi* (Pisa, Italy), P. Noemi, A. Tavanti, A. Lupetti, R. Cosmeri, L. Maltinti, M. Falcone</i>
O0693	<b>Fungaemia in a tertiary Madrid hospital from 2007 to 2024: changes in species epidemiology, increase in echinocandin resistance and low patient-to-patient transmission in recent years</b> <i>J. Guinea* (Madrid, Spain), P. Escribano, G. Jesús, M. Machado, A. Burillo, P. Muñoz</i>
O0694	<b>A multicentre study for determination of epidemiological cutoff values for rezafungin and four comparators against <i>Candida auris</i> with EUCAST broth microdilution reference methodology</b> <i>J. Meletiadis* (Haidari, Greece), J. Guinea, S. Arikani-Akdagli, E.F.J. Meijer, J. Meis, M.C. Arendrup</i>
O0695	<b>Decoding <i>Candida auris</i> Resistance in Latin America: <i>Candida.app</i> vs. <i>Pathogenwatch</i></b> <i>J. Acosta España* (Quito, Ecuador), P. Eduarda, J.D. Acosta-España, A.</i>

# ESCMID Global 2025 - Programme

	<i>Allam* (Paris, France), S. Agsous, P. Baylac, K. La, N. Godron, F. Mougari, Z. Awad, E. Cambau</i>
E0753	<b><i>Pseudomonas aeruginosa</i> rapidly kills <i>Mycobacterium abscessus</i> in dual-species biofilms <i>in vitro</i></b> <i>M. Mcdaniel* (Nijmegen, Netherlands), J. Scoffield, J. Van Ingen</i>
E0754	<b>Distribution of contezolid in different tissues of mice and human patients infected with <i>Mycobacterium abscessus</i></b> <i>W. Nie* (Beijing, China), N. Chu</i>
E0755	<b>Exploration of clofazimine and bedaquiline activity against clinical strains of <i>Mycobacterium abscessus</i> to advance innovative therapeutic strategies</b> <i>C. Maria* (Madrid, Spain), M. Cano-Fernández, J. Esteban, P. López-Roa, A. Ruedas-López, J.J. Aguilera-Correa, M.C. Muñoz-Egea</i>
E0756	<b>Leveraging stem cell technology to identify new treatment options for nontuberculous mycobacteria</b> <i>S. Sarkar* (Parkville, Australia), K. Strumila, S. Yu, R. Werder, T. Johanssen, A. Hidalgo Gonzalez, E. Stanley, S. Ranganathan</i>
E0757	<b>Recovery of Non-Tuberculous Mycobacteria and Detection of Dominant Circulating Clones in Indoor Water Samples from Germany</b> <i>N. Wetzstein* (Frankfurt, Germany), M. Diricks, D. Frank, I. Friesen, S. Niemann, T. Wichelhaus</i>
E0758	<b>Deciphering the Epidemiology of <i>Mycobacterium chimaera</i>: Genetic Lineages, Environmental Sources, and Infection Prevention Insights</b> <i>G. Lorenzin* (Trento, Italy), M. Sandei, P. Fassan, A. Casadei, C. Scarparo</i>
E0759	<b>Evaluation of a novel media for susceptibility testing of <i>Mycobacterium avium-intracellulare</i> complex isolates</b> <i>T. Grams* (Salt Lake City, United States), S. Shakir</i>
E0760	<b>Emerging cases of <i>Mycobacterium chelonae</i> endocarditis associated with <i>BioIntegral</i> bioprostheses</b> <i>J. Kikhney* (Berlin, Germany), F. Pfäfflin, L. Kursawe, K. Sarbandi, I. Friesen, M. Stegemann, R. Schwarzer, D. Von Schöning, V. Falk, A. Moter</i>

EF106	16:15 - 17:15	Arena 3
	ePoster Flash Session	

The ABC (allergy, bloodstream infections and clinical decision support) in AMS	
Chair	Céline Pulcini (Nancy, France)

E0761	<b>Evaluation of the allergy fact checker, a clinical decision support system to promote non-invasive delabeling of incorrect penicillin allergy labels: a mixed-methods study</b> <i>D. Wets* (Leuven, Belgium), R. Schrijvers, I. Spriet, G. Van De Sijpe, L. Gilissen, C. Breynaert, T. Ieven, P. De Munter</i>
E0762	<b>Penicillin allergy assessment pathway versus usual clinical care for primary care patients with a penicillin allergy record to assess safety, de-labelling and antibiotic prescribing: The ALABAMA randomised controlled trial</b> <i>J. Sandoe* (Leeds, United Kingdom), S. Ahmed, K. Armitage, C. Bates, R. Bestwick, B. Jenny, C. Butler, J. Cook, F. Joanne, U. Galal, P. Howard, D. Howdon, S. Mort, R. Mujica-Mota, A. Negut, C. Porter, N. Powell, M. Santillo, R. Sargur, S. Savic, S. Tonkin-Crine, M. Wanat, R. West, M. Yang, L.M. Yu, S. Pavitt</i>
E0763	<b>Stewardship interventions reduced blood culture utilization by 40% during BD BACTEC™ Blood Culture media shortage</b> <i>X. Li* (Toronto, Canada), K. Katz, A. Ceentavida, R. Kozak, C. Vermeiren, P. Sheldrake, S. John, A. Belhaj, S. Hsieh, S. Patel, R. Lovinsky</i>
E0764	<b>Prescriptive Impact of Rapid Microbiological Diagnostics in Bloodstream Infections Caused by <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Staphylococcus aureus</i> (PRIMEKA): A Retrospective Single-Center Cohort Study</b> <i>F. Salvati* (Rome, Italy), F. Giovannenze, G.M. Leanza, M. Chiuchiarelli, A. Frater, M.L. Colombo, F. Iannarelli, B. Fiori, T. D'inzeo, R. Murri, C. Torti</i>

# ESCMID Global 2025 - Programme

ME145

16:15 – 17:15

Hall 15

CLN DX

Meet-the-Expert

Fungal meningitis: recognition and current status of management

M0393

16:15

Olivier Lortholary (Paris, France)

M0394

16:27

Janis Blair (Phoenix, United States)

JS2

16:15 – 17:15

Hall 16

PRO

Journal Session

Late-breaker research from the Lancet group: new interventions for familiar and new infectious diseases

Chairs

Syeda Saleha Hassan (London, United Kingdom)

Ursula Hofer (London, United Kingdom)

J011

16:15

TBA

J012

16:30

The spatio-temporal ecology of Oropouche virus: a laboratory-based modelling study across Latin America  
Jan Felix Drexler (Berlin, Germany)

J013

16:45

The WHO Bacterial Priority Pathogens List: guiding research and development, and informing innovative public health strategies to address antimicrobial resistance  
Hatim Sati (Geneva, Switzerland)

J014

17:00

Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPref3 OA) in older adults over three RSV seasons: a randomized trial  
Alberto Papi (Ferrara, Italy)

Co-organised with: The Lancet group

OS102

16:15 – 17:15

Hall 2

AMR DX

1-hour Oral Session

AI tools empowering AMR prediction in WGS and MALDI-TOF

Chairs

Oliver Nolte (Zürich, Switzerland)

Patricia Simner (Rochester, United States)

O0733

A scalable machine learning approach to predict antimicrobial susceptibility from whole genome sequencing data  
Y. Zhong\* (Liverpool, United Kingdom), A. Gerada, A. Howard, P. Green, W. Hope

O0734

Machine Learning-Based Antimicrobial Resistance Prediction of 11 antibiotics for *Klebsiella pneumoniae* from Clinical NGS Data  
J. Xinmiao\* (Beijing, China), X. Jia, J. Zhang, J. Chen, Q. Yang

O0735

AI-Powered Real-Time Plasmid Prediction Using Nanopore Sequencing  
E. Sauerborn\* (Munich, Germany), S. Atum, H. Urel, M. Peisker, N. Wantia, E. Foster-Nyarko, L. Urban

O0736

MALDI-TOF Prediction model based on machine learning algorithm for the detection of ST23 high-virulence *K. pneumoniae*  
L. Dortet\* (Le Kremlin-Bicêtre, France), L. Mancera Pascual, M.J. Arroyo

O0737

Predicting rifampicin resistance in *Mycobacterium tuberculosis complex* with a machine learning based MALDI-TOF MS approach  
Y.W. Sun\* (Taichung, Taiwan, China), P. Huang, B. Tsou, S.C. Chang, C.W. Lu, C.C. Chen, J. Yu

LB005

16:15 – 17:15

Hall 3

1-hour Oral Session

Emerging pathogens in humans, animals and vectors

L0026

Genome-wide association study identifies *ABCG1* as a susceptibility locus for tick-borne encephalitis  
P. Gampawar\* (Graz, Austria), M. Sagmeister, D. Ruzek,



# ESCMID Global 2025 - Programme

	on <i>Pseudomonas aeruginosa</i> and its molecular interactions <i>S. Kansal*</i> (Chandigarh, India), <i>U. Dutta, A. Angrup, P. Ray</i>	
O0741	Intra- and interspecific antagonism inhibits growth of <i>Staphylococcus aureus</i> in human nasal microbial communities <i>L. Brülisauer*</i> (Zurich, Switzerland), <i>M. Boumasmoud, S. Brugger, A.R. Hall</i>	
O0742	Combination therapy against drug resistance biomimetic dual-species biofilm model of <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> <i>P. Mojarrad*</i> (Helsinki, Finland), <i>P. Tammela, T. Laaksonen, Z. Gounani</i>	
<hr/>		
EF110	17:30 – 18:30	Arena 1
	ePoster Flash Session	
	<div>ANTCLNDX</div>	
Advancing diagnostics and treatment of endocarditis		
Chair	<i>Benoît Guery (Lausanne, Switzerland)</i>	
E0785	<b>18F-FDG-PET/CT improves source control of extra-cardiac complications in infective endocarditis</b> <i>J.M. Prins*</i> (Amsterdam, Netherlands), <i>S. Douiyeb, W. Van Gameren, D. Buis, T. Van Der Vaart, M. Boekholdt, J. Selder, D. Robbers-Visser, H. Verberne, H. Van Werkhoven, K. Sigaloff</i>	
E0786	<b>Comparing Duke criteria updates: Advancing IE diagnosis in patients with prosthetic intracardiac materials</b> <i>M. Papadimitriou Olivgeris*</i> (Sion, Switzerland), <i>M. Papadimitriou-Olivgeris, B. Ledergerber, N. Fourré, V. Zimmermann, N. Ianculescu, P. Monney, M. Frank, G. Tzimas, G. Domenichini, P. Tozzi, M. Kirsch, M. Van Hemelrijck, O. Dzemali, J. Epprecht, B. Guery, B. Hasse</i>	
E0787	<b><i>In vivo</i> Dalbavancin efficacy against methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and high-level aminoglycoside resistant (HLAR) <i>Enterococcus faecalis</i> (EFAE) experimental endocarditis model.</b> <i>C. García De La María*</i> (Barcelona, Spain), <i>C. García De La Mària, M.A. Cañas, M. Brunet, J. García-González, G. Cuervo, M. Espasa, M. Hernandez-Meneses, C. Falces, A. Perissinotti, B. Vidal, J.M. Tolosana, E. Sandoval, J. Llopis, A. Moreno, J.M. Miro</i>	
E0788	<b>Identification and validation of clinical phenotypes in <i>Staphylococcus aureus</i> blood stream infection and their association with mortality (FEN-AUREUS study)</b> <i>J. Rodríguez-Baño*</i> (Seville, Spain), <i>B. Gutiérrez-Gutiérrez, B. Gallego, A.J. Kaasch, M. Riediger, S. Rieg, M. Trigo, S. Sonsoles, F. Anguita-Santos, Á. Cano, R. Palacios, S. López-Cárdenas, M.T. Pérez-Rodríguez, F.J. Martínez-Marcos, E. Merino-Lucas, B. Anaya-Baz, A. Aizcorreta, A. Plata-Ciézar, M. Piscaglia, A. Aceituno, E. Ruiz-Gutiérrez, L. Romero-Calderón, A. Alemán-Rodríguez, E. Recacha, J. Torre-Cisneros, N. Merchante, Á. Pascual, L.E. López-Cortés</i>	
E0789	<b>Enterococcal Infective Endocarditis: demographics, comorbidities, diagnostic evaluation and mortality outcomes</b> <i>M. Singh*</i> (London, United Kingdom), <i>C. Watkins, H. Bristowe, M. Gunning, J. Galloway, R. Dworakowski, M. Arias</i>	
E0790	<b>Health related quality of life of patients with infective endocarditis – preliminary data of the DERIVE cohort</b> <i>C. Meyer-Schwickerath*</i> (Cologne, Germany), <i>K. Schmidt-Hellerau, J. Camp, K. Last, I. Joost, S. Rieg, N. Jung</i>	
E0791	<b>The optimal management of <i>Enterococcus faecium</i> catheter-related bloodstream infections: a gap to bridge</b> <i>I. Rancan*</i> (Florence, Italy), <i>M. Rinaldi, F. Malerba, B. Profiti, L. Ancillotti, M. Tumbarello, P. Viale, M. Giannella</i>	
E0792	<b>Ceftobiprole alone versus in combination with ampicillin against borderline penicillin-resistant, vancomycin-resistant <i>Enterococcus faecalis</i></b> <i>O. Funk*</i> (Brooklyn, United States), <i>I. Khan, J. Li, J. Cusumano</i>	
E0793	<b>Risk factors for in- hospital mortality in 500 cases of infective endocarditis</b> <i>C. Lamas*</i> (Rio De Janeiro, Brazil), <i>G. Pompeo, T. De Almeida, M. De Carvalho,</i>	

# ESCMID Global 2025 - Programme

		<b>Infection: A randomized controlled trial</b> <i>K. Angkanavisan* (Bangkok, Thailand), B. Sakboonyarat, C. Ungthammakhun</i>
E0808		<b>Oral switch vs. intravenous antibiotics treatment for serious carbapenem-resistant Enterobacterales and <i>Pseudomonas aeruginosa</i> infections on hospital discharge: the next frontier for oral switch?</b> <i>C. Arena* (Detroit, United States), A. Abed, R. Kenney, G. Suleyman, A. Shallal, S. Davis, M. Veve</i>
E0809		<b>Metallo-<math>\beta</math>-lactamase colonization and subsequent risk of infection: a retrospective study</b> <i>C. Lee Luna Fernandes* (Sao Paulo, Brazil), C. Vaiana, C. Amato, S. Castelbuono, G. Di Martino, F. Cardinale, F. Monaco, A. Cona, A. Mularoni</i>
E0810		<b>Polymyxin including therapy versus colistin including therapy in the therapy of carbapenem-resistant Gram-negative infections: A retrospective matched cohort study</b> <i>M. Mert Vahabi* (Van, Türkiye), D. Akyol Seyhan, B. Kenanoğlu, Ş. Yeniyoğlu, G. Şanlıdağ İşbilen, Ş. Dirik, D. Dağ, B. Özkara, M. Ceylan, C. Bulut Avşar, U. Önal, S. Ketentzi, A. Uyan Önal, A. Kaya, O. Acet, D. Kaya, N. Yalcin, G. Vatansever, C. Tol, Ş. Aydemir, D. Akdağ, H.A. Erdem, T. Yamazhan, H. Sipahi, B. Arda, O.R. Sipahi</i>
E0811		<b>Prognostic factors and role of clinical management in carbapenem-resistant <i>Acinetobacter baumannii</i> bacteraemia: results from a prospective, international, multicentre cohort (EURECA)</b> <i>F. Cogliati Dezza* (Seville, Spain), J.M. Bravo-Ferrer Acosta, B. Gutiérrez-Gutiérrez, B. Carevic, G. Dragovac, G.L. Daikos, M. Akova, L. Raka, A. Hristea, P. Viale, E. Shaw, E. Roilides, M. Antonelli, H. Akalin, A. Komnos, J.M. Reguera, A. Vince, M. Mašanovic, L. Radulović, C. Kirakli, C. Gogos, A. Bartoloni, C. Dan, P. Kapisyzi, M.E. Falagas, A. Vata, S. Benea, D. Tomescu, A. Meda Vasiesiu, L. Bukarica, N. Lukic, A. Cano, V. Pintado, A. Azap, H. Goosens, M.J.M. Bonten, J. Rodríguez-Baño</i>

SY147	17:30 – 18:30	Hall 11
	1-hour Symposium	

PHEI

## Avian influenza in mammals: jumps under the radar

<i>Chairs</i>	<i>Patricia Antunes (Porto, Portugal)</i> <i>Ana Vale (Dublin, Ireland)</i>
---------------	--

S0399	17:30	<b>Threat of highly pathogenic avian influenza to non-traditional hosts, including humans</b> <i>Thijs Kuiken (Rotterdam, Netherlands)</i>
S0400	18:00	<b>Recent changes in the epidemiology of avian influenza in relation to human health risks</b> <i>Ron Fouchier (Rotterdam, Netherlands)</i>

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Veterinary Microbiology (ESGVM), ESCMID Study Group for Respiratory Viruses (ESGREV), European Scientific Working group on Influenza (ESWI)

SY148	17:30 – 18:30	Hall 15
	1-hour Symposium	

CLN

## Echinococcosis: neglected but expanding

<i>Chairs</i>	<i>Daniel Grupel (Jerusalem, Israel)</i> <i>Francesca Tamarozzi (Negrar-Verona, Italy)</i>
---------------	---

S0401	17:30	<b>Expansion and diversity of cystic echinococcosis</b> <i>Pedro Legua (Lima, Peru)</i>
S0402	18:00	<b>Management of echinococcosis: evidence, eminence and new developments</b> <i>Beate Grüner (Ulm, Germany)</i>

Co-organised with: Österreichische Gesellschaft für Antimikrobielle Chemotherapie (ÖGACH), Österreichische Gesellschaft für Hygiene, Mikrobiologie und Präventivmedizin (ÖGHMP), Österreichische Gesellschaft für Infektionskrankheiten und Tropenmedizin (OEGIT), ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

# ESCMID Global 2025 - Programme

00774		<b>Aggregated summary of immunogenicity and safety for the chikungunya virus virus-like particle (VLP) vaccine development programme</b> <i>L. Tindale* (Toronto, Canada), J. Richardson, D. Anderson, J. Mendy, S. Muhammad, T. Loreth, V. Jenkins, P. Ajiboye, L. Bedell</i>
OS108	17:30 – 18:30	Hall 5
	CLN IPC	1-hour Oral Session
Novel approaches to preventing device-related infections		
Chairs	<i>Natividad Benito (Barcelona, Spain)</i> <i>Preeti Malani (Ann Arbor, United States)</i>	
00775		<b>Clinical and microbiological impact of antibiotic-impregnated catheters in ventriculoperitoneal shunt infections in adults.</b> <i>M. Sanz De Mena* (Barcelona, Spain), I. Pelegrín Senent, J. Gómez Junyent, J. Poblet Florentin, C. Iglesias, A. Siverio Parés, S. Gómez Zorrilla, L. Sorlí Redó, M. Montero, J.P. Horcajada</i>
00776		<b>Reducing drainage-associated meningitis by using an antiseptic dressing: A randomized controlled trial</b> <i>AntiRedMen</i> <i>S. Scheithauer* (Goettingen, Germany), O. Moerer, V. Rohde, N. Srivastava, T. Asendorf, K. Antweiler, D. Mielke, G. Uwe, N. Lennart, S. Friedrich, A. Beste, N. Kucheryava, M. Baehr</i>
00777		<b>Efficacy of antimicrobial envelopes in preventing cardiac implantable electronic device infections – systematic review and meta-analysis</b> <i>A. Mahajan* (Melbourne, Australia), C. Robson</i>
00778		<b>A bundled approach to reducing central line associated blood stream infections (CLABSI) in hemodialysis (HD) patients</b> <i>J. Guerrero* (Scarborough, Canada), A. Garga, S. Paramalingam, R. Lovinsky, F. Go</i>
00779		<b>Increased long-term mortality in patients with prosthetic joint infection after primary total hip arthroplasty – a cohort study with 89’709 patients</b> <i>N. Imhasly* (Lucerne, Switzerland), A. Widmer, C. Brand, V. Zdravkovic, A. Spoerri, K. Schmidlin, M. Wicki, M. Beck, R. Sommerstein</i>

## Tuesday, 15 April 2025

SY152	08:30 – 10:30	Hall 12
	PHEI VAX	2-hour Symposium
Out of the spotlight or out of reach? Vaccination of hard-to-reach groups		
Chairs	<i>Olivier Epaulard (Grenoble, France)</i> <i>Justyna Kowalska (Warsaw, Poland)</i>	
S0413	08:30	<b>Ukrainian war refugees and vaccination attitudes: experience from Poland</b> <i>Maria Ganczak (Zielona Gora, Poland)</i>
S0414	09:00	<b>Vaccination in migrants in Latin America: The challenges of transit through Darien, Panama</b> <i>Alfonso J. Rodriguez-Morales (Pereira, Colombia)</i>
S0415	09:30	<b>Are penitentiary systems ready for introducing vaccination programmes?</b> <i>Lara Tavoschi (Pisa, Italy)</i>
S0416	10:00	<b>HPV and other essential vaccinations for sex workers</b> <i>Debora Konopnicki (Brussels, Belgium)</i>
Co-organised with: ESCMID Vaccine Study Group (EVASG)		

SY153	08:30 – 10:30	Hall 13
	CLN	2-hour Symposium
Breaking new ground in febrile neutropaenia management		
Chairs	<i>Murat Akova (Ankara, Türkiye)</i> <i>Stefan Schwartz (Berlin, Germany)</i>	

# ESCMID Global 2025 - Programme

	<b>rescue old-time microscopy ?</b> <i>A. Aupaix*</i> (Hornu, Belgium), <i>L. Filippin, I. Mansoor, M. Chemaïs, D. Martiny, V.Y. Miendje Deyi, M. Deffontaine, C. Deckers, V. Verbelen, J. Brauner</i>
E0828	<b>Improving vector surveillance: evaluating a real-time PCR assay for <i>Leishmania</i> DNA detection in sandflies</b> <i>H. Alonso-Ezcurra*</i> (Zaragoza, Spain), <i>M.P. Peris, I. Ruiz-Arondo, J.A. Castillo, D. Martínez-Durán, S. Delacour, I. Ruiz-Zarzuela, I. De Blas, C. Cervera-Acedo, J.A. Oteo, F. Collantes, B. Dehesa, H. Alonso</i>
E0829	<b>Assessment of a new immunochromatographic assay for serological diagnosis of amoebic liver abscess</b> <i>R. Fleury*</i> (Besançon, France), <i>M.P. Brenier-Pinchart, P. Tirard-Collet, F. Gabriel, E. Pretot, F. Touafek, A. Marteau, S. Houze, C. Amiot, T.G. Nguyen, D. Dupont, A. Moreno-Sabater, F. Grenouillet</i>
E0830	<b>Human piroplasmosis: diagnostic lessons from a national parasitology reference laboratory in South Africa.</b> <i>C. Sriruttan-Nel*</i> (Johannesburg, South Africa), <i>J. Frean</i>

EF115	08:30 – 09:30	Arena 3
	ePoster Flash Session	

**DX** **PHEI**

## New genomic methods in clinical microbiology

*Chair* *Natacha Couto (Oxford, United Kingdom)*

E0831	<b>Prediction of antimicrobial minimum inhibitory concentration from <i>Escherichia coli</i> whole genome sequence data using machine learning</b> <i>A. Gerada*</i> (Liverpool, United Kingdom), <i>N. Harper, Y. Zhong, A. Howard, P.L. Green, W. Hope</i>
E0832	<b>Dynamically Optimized Reference Adaptive Sampling (DORAS) to streamline bacterial Multi-Locus Sequence Typing</b> <i>A. Ramette*</i> (Bern, Switzerland), <i>L. Borcard, M.A. Terrazos Miani, S. Gempeler, S. Neuenschwander</i>
E0833	<b>Prediction of antibiotic resistance in <i>Pseudomonas aeruginosa</i>, <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> from genomic data using machine learning and deep learning approaches</b> <i>E. Denakpo*</i> (Gif-Sur-Yvette, France), <i>N. Dias, F. Jay, B. Iorga</i>
E0834	<b>Machine learning pipeline accelerates identification of diagnostic targets for <i>Neisseria gonorrhoeae</i></b> <i>A. Verich*</i> (Sydney, Australia), <i>T. Applegate, D. Bauer, P. Ramarao-Milne, L. Sng, E. Trembizki, E. Mokany</i>
E0835	<b>Reliable bacterial genomic genotyping from Oxford Nanopore Technologies data – the ONT cgMLST Polisher</b> <i>N. Scherff*</i> (Muenster, Germany), <i>J. Rothgänger, D. Harmsen</i>
E0836	<b>Developing a core genome MLST (cgMLST) for <i>Mycoplasma pneumoniae</i></b> <i>C. Dixon*</i> (Cardiff, United Kingdom), <i>R. Mamede, M. Ramirez, H. Milton, P.M. Meyer Sauter, G. Greub, N. Couto, M.L. Beeton</i>
E0837	<b>Voyager: real-time taxonomic characterization of long-read mixed-species sequencing samples in sorted motif distance space</b> <i>S. Branders*</i> (Hamar, Norway), <i>M. Grabherr, R. Ahmad</i>
E0838	<b>VCP: a signature protein-based tool for accurate and rapid profiling of human gut virome</b> <i>J. Li*</i> (Shenzhen, China), <i>F. Yang, L. Xiong, X. Feng, H. Zhong</i>
E0839	<b>Genomic Data-Driven Machine Learning for Predicting Antimicrobial Resistance in ESCAPEE Pathogens</b> <i>A. Skoulakis*</i> (Lamia, Greece), <i>K. Daniilidis, S. Digenis, A. Hatzigeorgiou</i>

CGR	08:30 – 10:30	Hall 1
	Special Session	

**CLN**

## Clinical Grand Round

<i>Experts</i>	<i>Nina Khanna (Basel, Switzerland)</i> <i>Dimitrios P. Kontoyiannis (Houston, Tx, United States)</i> <i>Lior Neshet (Beersheba, Israel)</i> <i>David L. Paterson (Singapore, Singapore)</i>
----------------	---

# ESCMID Global 2025 - Programme

AMR

PHEI

2-hour Symposium

Using mathematical and epidemiological models to identify the drivers of AMR

Chairs

Marc J.M. Bonten (Utrecht, Netherlands)

Sarah Tschudin Sutter (Basel, Switzerland)

S0421	08:30	Quantifying the drivers of antiviral resistance: what does it take to prevent resistance evolution? <i>Roger Kouyos (Zürich, Switzerland)</i>
S0422	09:00	Inferring the determinants of AMR dynamics across bacterial pathogens <i>Lulla Opatowski (Paris, France)</i>
S0423	09:30	Modelling the evolution of resistance <i>Erida Gjini (Lisbon, Portugal)</i>
S0424	10:00	Assessing the associations of microbiome and socio-demographic dynamics on AMR <i>Katariina Pärnänen (Helsinki, Finland)</i>

EW157		08:30 – 10:30	Hall 15
		Educational Session	
		<div>DX</div> <div>PHEI</div>	
Endemic mycoses and mycetoma: underdiagnosed and underreported fungal diseases			
Chairs		Ana Alastruey-Izquierdo (Madrid, Spain) Rita Oladele (Lagos, Nigeria)	
W0433	08:30	Advances and gaps in the diagnosis and treatment of histoplasmosis <i>Diego Rodrigues Falci (Porto Alegre, Brazil)</i>	
W0434	08:50	Paracoccidioidomycosis: an update on diagnostic challenges <i>Beatriz L. Gomez (Bogota, Colombia)</i>	
W0435	09:10	What is new in Talaromycosis <i>Brown Lottie (London, United Kingdom)</i>	
W0436	09:30	Mycetoma: treatment challenges of a unique neglected tropical disease <i>Borna Nyaoke-Anoke (Nairobi, Kenya)</i>	

EW155

08:30 – 10:30

Hall 2

Educational Session

DX

PHEI

An update on arboviral disease challenges

Chairs

Misa Korva (Ljubljana, Slovenia)

Anna Papa-Konidari (Thessaloniki, Greece)

W0425

08:30

The global epidemiology of arboviral diseases

Chantal B.E.M. Reusken (Bilthoven, Netherlands)

W0426

08:50

Arboviral diseases transmitted by mosquitoes

Luisa Barzon (Padua, Italy)

W0427

09:10

Aboviral diseases transmitted by ticks

Joanna Maria Zajkowska (Białystok, Poland)

W0428

09:30

Arboviral diseases transmitted by sandflies

Rémi Charrel (Marseille, France)

Co-organised with: EURL-PH-VBV, Polish Association of Epidemiologists and Infectiologists

SY150		08:30 – 10:30	Hall 3
		2-hour Symposium	
	ANT		
Faecal microbiota transplantation and live biotherapeutic products: scientific and regulatory challenges			
Chairs		Lindsey Ann Edwards (London, United Kingdom) Ed J. Kuijper (Leiden, Netherlands)	
S0405	08:30	How can we recognise and deal with adverse events of Faecal Microbiota Transplantation? <i>Serena Porcari (Roma, Italy)</i>	
S0406	09:00	What to check? – An attempt at evidence-based donor screening <i>Elisabeth Terveer (Leiden,</i>	

# ESCMID Global 2025 - Programme

E0848		Efficacy of dimercaptosuccinic acid in combination with imipenem in a murine model of experimental sepsis due to metallo- $\beta$ -lactamase-producing <i>Pseudomonas aeruginosa</i> . S. Herrera-Espejo* (Seville, Spain), M. Bouvier, J. Findlay, L. Ceballos-Romero, J. Pachón, J.M. Cisneros, M.E. Pachón-Ibáñez, P. Nordmann
EF117	09:30 – 10:30	Arena 4
	CLN IPC	ePoster Flash Session
C. diff challenges: insights into treatment, monitoring, and infection prevention		
Chair	Kerrie Davies (Leeds, United Kingdom)	
E0849		Epidemiology, risk factors, and outcomes of nosocomial <i>Clostridioides difficile</i> infections: a cohort study in a tertiary hospital. L. Ruiz Salazar* (Madrid, Spain), T. Mata Forte
E0850		Long-read or short-read sequencing in <i>Clostridioides difficile</i> infection surveillance? M. Brajerová* (Prague, Czech Republic), M. Brajerova, P. Kinross, P. Drevínek, M. Krutova
E0851		"Beyond C. difficile Colitis": Exploring the Role of Fidaxomicin in preventing concomitant and secondary bloodstream infections in patients with <i>Clostridioides difficile</i> colitis. D.F. Bavaro* (Milan, Italy), D. Schumann, A. Cilli, L. Diella, D. Barbanotti, D. Mondatore, F. Medioli, M. Casana, A. Belati, L. Bussini, V. Cento, R. Epis, M. Bartoletti
E0853		Comparison of bezlotoxumab versus no-bezlotoxumab on recurrence in high-risk patients with <i>Clostridioides difficile</i> infection C. Arena* (Detroit, United States), A. Abed, R. Kenney, A. Shallal, S. Davis, M. Veve
E0854		Exploring bacterial contributors to C. difficile colonization resistance: comparative effects of vancomycin and fidaxomicin in humanised mice E. Montenegro-Borbolla* (Lausanne, Switzerland), L. Beldi, S. Hapfelmeier, G. Greub, C. Bertelli, B. Guery
E0855		An optimised vancomycin dosing regimen is effective against C. difficile, reduces gut microbiota impact and prevents recurrent C. difficile infection in a human in vitro gut model. J. Freeman* (Leeds, United Kingdom), C. Normington, E. Clark, K. Bentley, J. Altringham, A. Berry, W. Spittle, D. Ewin, A. Kirby, M. Wilcox, K. Davies
E0856		Cost and resource utilization of fidaxomicin in risk patients with recurrent or refractory <i>Clostridioides difficile</i> infection M. Engelhard* (Cologne, Germany), I. Alram, S.M. Wingen-Heimann, N. Pfeiffer, J.J. Vehreschild, M.J.G.T. Vehreschild, S.M. Hopff
E0857		Impact of a cohorting intervention on the incidence of hospital-acquired <i>Clostridioides difficile</i> infection (CDI): an interrupted time series analysis C.D. Moschopoulos* (Athens, Greece), M. Tsakona, S. Grigoropoulou, P. Kazakou, M. Kostoula, I. Kiani, C. Filis, K. Thomas, I. Grigoropoulos, K. Protopapas, E. Kalogeropoulou, S. Pournaras, N.V. Sipsas, G.L. Daikos, F. Kontopidou, A. Papadopoulos, S. Tsiodras, D. Kavatha
ME165	11:00 – 12:00	Hall 12
	PHEI	Meet-the-Expert
How to use citizen science for public health		
M0450	11:00	Anna Noel-Storr (Leamington Spa, United Kingdom)
M0451	11:12	Jani Sormunen (Turku, Finland)
Co-organised with: European Centre for Disease Prevention and Control (ECDC)		
SY164	11:00 – 12:00	Hall 15



# ESCMID Global 2025 - Programme

		<b>female participants (EAGLE-J)</b> <i>Y. Kayama* (Tokyo, Japan), S. Yamamoto, K. Fujii, A. Nimura, T. Maenaka, M. Ramirez, R. Banerjee, N.E. Scangarella-Oman, S. Mozzicato, S. Ura</i>
E0889	11:36	<b>Efficacy of Ceftolozane/Tazobactam vs. Ceftazidime/Avibactam in the Treatment of Nosocomial Pneumonia Caused by <i>Pseudomonas aeruginosa</i>: a multicentric retrospective study from the SUSANA cohort.</b> <i>A. Bitti* (Sassari, Italy), A. De Vito, M. Fois, E. Ricci, A. Bandera, A. Maccaro, S. Piconi, P. Maggi, G. Cenderello, M. Merli, G.V. De Socio, P. Morelli, P. Bonfanti, G. Madeddu</i>
E0890	11:42	<b>Experience of dalbavancin use for unlicensed indications in a UK tertiary infectious diseases setting</b> <i>C. Darlow* (Liverpool, United Kingdom), J. Parsons, D. Lucy, N. Wong</i>
E0891	11:48	<b>Investigator-driven randomised controlled trial of cefiderocol versus standard therapy for healthcare-associated and hospital-acquired gram-negative bacterial bloodstream Infections (BSI) : Hierarchical composite endpoint analysis with DOOR and generalised pairwise comparisons</b> <i>M. Hardy* (Maroochydore, Australia), D.L. Paterson, M. Chatfield, H. Bin Sulaiman, L. Po-Yu, M. Yilmaz, Z.N. Salmuna, M.Z. Mazlan, S. Anunnatsiri, R. Sirijatuphat, D. Chotiprasitsakul, D. Lye, J. Somani, S. Kalimuddin, V. Thamlikitkul, Y.T. Lee, Y.T. Lin, W.N.W. Ramli, H.C. Ong, P. Mootsikapun, A. Meesing, C.H. Tseng, T.K. Yeh, A.M.B. Hashim, P. Puangpatra, A. Aslan, P. Santanirand, T.T. Chiang, S. Archuleta, Y.F.Z. Chan, P.Y. Chia, B. Forde, H. Wright, A. Stewart, K. Ramsay, W.P. Ling, V. Rossi, T. Harris-Brown, P.N.A. Harris</i>
<hr/>		
EF124	11:00 - 12:00	<b>Arena 3</b>
	<div>DX</div>	ePoster Flash Session
<b>Thinking outside the box in urinary tract infection</b>		
	<i>Chair</i>	<i>Özlem Kurt Azap (Ankara, Türkiye)</i>
E0892		<b>Targeted NGS: a promising approach for pathogen detection of urinary tract infection</b> <i>W. Gao* (Beijing, China), P. Li, W. Han, D. Chen, L. Huang, P. Chen, B. Cheng, Y. Gu, C. Hu, J. Chen, Z. Zhang</i>
E0893		<b>Turnaround time of just four hours from sample collection to informed decision-making for complicated urinary tract infections in a urology ward, using culture-independent metagenomics</b> <i>A.B. Bellankimath* (Hamar, Norway), S. Branders, J. Ali, F. Asadi, T.E.B. Johansen, C. Imirzalioglu, T. Hain, F. Wagenlehner, R. Ahmad</i>
E0894		<b>Identification of Microorganism Types in Urinary Tract Infections Using Machine Learning and Flow Cytometry</b> <i>E. Flores* (Alicante, Spain), I. Gutierrez, R. Torreblanca, A. Blasco, R. Carbonell, M. Lopez-Garrigós</i>
E0895		<b>A New Approach In Diagnosis Of Urinary Tract Infections</b> <i>B. Dinc* (Ankara, Türkiye), F. Kırca, S. Kazıcı, Ö. Uslu, N. Çöplü</i>
E0896		<b>Diagnosis of urinary tract infections: from machine learning to clinical practice</b> <i>E. Flores* (Alicante, Spain), R. Torreblanca, I. Gutierrez, R. Carbonell, L.G. Maite, A. Blasco</i>
E0897		<b>Strategic testing optimisation practices for urinary tract infections (STOP-UTI): findings from LMIC hospital setting</b> <i>S. Sarika* (Tamil Nadu, India), B. Rithik Dharan</i>
E0898		<b>Rapid culture-independent mass spectrometry based proteomics methods for improving urinary tract infection diagnostics</b> <i>S. El-Ali* (Gothenburg, Sweden), L. Acha Alarcon, G. Alves, Y.K. Yu, R. Karlsson, E. Moore</i>
E0899		<b>Unraveling the complexity: Corynebacterium diversity and antimicrobial resistance hub in the urinary tract ecosystem</b> <i>E. Cappelli* (Porto, Portugal), A. Morais, T. Ribeiro, L. Peixe</i>
E0900		<b>Active surveillance in the diagnosis of sexually transmitted infections: performing PCR in negative urine cultures</b> <i>A. Castellano Verdasco* (Lleida, Spain),</i>



# ESCMID Global 2025 - Programme

SY162		11:00 – 12:00	Hall 11
		1-hour Symposium	
		AMR	
Antimicrobial stewardship across the lifespan from paediatrics to geriatrics			
Chairs		Lucy Catteau (Brussels, Belgium) Priya Nori (New York, United States)	
S0444	11:00	Antimicrobial Stewardship in paediatrics across different settings Taylor Morrisette (Charleston, United States)	
S0445	11:30	Stewardship in geriatrics: an exceedingly important target Dafna Yahav (Ramat-Gan, Israel)	
ME166		11:00 – 12:00	Hall 13
		Meet-the-Expert	
		DX	
Implementing AI in microbiological diagnostics: practical steps and quality control			
M0452	11:00	Oliver Nolte (Zürich, Switzerland)	
M0453	11:12	Jennifer Dien Bard (Los Angeles, United States)	
Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Swiss Society for Microbiology (SSM)			
SY163		11:00 – 12:00	Hall 14
		1-hour Symposium	
		AMR	
People-centred approach to strengthening the AMR response at primary care			
Chairs		Benedikt Huttner (Geneva, Switzerland) Mirfin Mpundu (Lusaka, Zambia)	
S0446	11:00	Implementation of WHO's people-centred interventions Nienke Van De sanDe Bruinsma (Geneva, Switzerland)	
S0447	11:30	Opportunities for strengthening AMR interventions in primary healthcare Sholpan Kaliyeva (Karaganda City, Kazakhstan)	
Co-organised with: World Health Organisation (WHO)			
OS122		11:00 – 12:00	Hall 16
		1-hour Oral Session	
		PRO	
Serious games - a serious business			
Chairs		Christian Kraef (Copenhagen, Denmark) Galadriel Pellejero-Sagastizábal (Zaragoza, Spain)	
O0878	The development process, impact and implementation of an educational VR-module in infection prevention and control for medical students and healthcare workers in The Netherlands. A. Tostmann* (Nijmegen, Netherlands), O. Coenen-Bouwman, B. Schippers, F. Luk, M. Graner, F. Van Hoek, N. Stikkelbroeck, M. Dronkers		
O0879	Impact of Professional Background on Performance in ToREIMC: A Gamified Medical Knowledge Platform A. Blanco-Di Matteo* (Pamplona, Spain), M. Morante Ruiz, M. Riesgo Magaña, M. Martín García		
O0880	Serious games and storytelling to enhance adolescents' capabilities for decision-making regarding meningococcal vaccination: a monocenter study T. Morris* (Saint-Etienne, France), S. Essalim, K. Atroune, V. Ronat, M. Moulin, R. Eichel, E. Botelho-Nevers, A. Gagneux-Brunon		
O0881	'The Sepsis Olympics': Raising awareness of the Sepsis 6 care bundle in an Irish Hospital through a clinical challenge game. C. Uhomuibhi* (Dublin, Ireland), K. Costelloe, J. Harte, N. Power, E. De Barra		
O0882	Improvement of learners' confidence in antibiotic		

# ESCMID Global 2025 - Programme

Corey, R. Maybank, A. Ong, Y. Kwak, J. Bennett, T. Russo, P. Mc Gann

**O0861** **Factors that affect plasmid transfer in multispecies biofilms** H. Y. Liu\* (Norwich, United Kingdom), M. Yasir, E. Trampari, G. Langridge, M. Webber

**O0862** **Identification of the *czc* metal efflux operon on a new plasmid type in a *Pseudomonas aeruginosa* clinical isolate belonging to ST357 O11A.** Valcek\* (Brussels, Belgium), D.I. Costescu Strachinaru, P. Soentjens, A. Stoefs, C. Van Der Henst

---

**OS119** **11:00 - 12:00** **Hall 7**  
1-hour Case Session

CLN

## Looking inside endovascular infections

*Chairs* Claus Moser (Copenhagen, Denmark)  
Matthaios Papadimitriou Olivgeris (Sion, Switzerland)

**O0863** **A Case of Persistent *Legionella micdadei* Aortitis with Endocarditis: Diagnostic and Therapeutic Challenges** V. Zwart\* (Breda, Netherlands), E. Kayabasi, H. De Groot, R. Bentvelsen

**O0864** **Management and Prognosis of Vascular Endograft Infections: Case Series** N. Scarpulla\* (Napoli, Italy), F. Patauner, L. Bertolino, R. Andini, A.M.C. Peluso, R. Gallo, E. Durante-Mangoni

**O0865** **Fungal frenzy: handling an uncommon etiology in prosthetic valve endocarditis** I. Cafarella\* (Naples, Italy), R. Gallo, F. Patauner, F. Luciano, L. Bertolino, A.M.C. Peluso, F. Boccia, R. Zampino, E. Durante-Mangoni

**O0866** **Successful Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused by *Enterococcus* spp.: Experience from Seven Cases in a Referral Center** F. Frondizi\* (Rome, Italy), G.M. Leanza, F. Catania, F. Sangiorgi, M. Chiuchiarelli, B. Andriolo, L. Vahedi, B. Liguoro, F. Giovannenze, E. Taddei, G. Scoppettuolo, C. Torti

**O0867** **Clinical Features and Outcomes of Gram-Negative Bacterial Endocarditis: A Case Series from a University Hospital** G. Oliva\* (Rome, Italy), F. Giovannenze, G.M. Leanza, F. Frondizi, M. Chiuchiarelli, B. Liguoro, B. Andriolo, E. Taddei, G. Scoppettuolo, C. Torti

---

**OS120** **11:00 - 12:00** **Hall 8**  
1-hour Oral Session

AMR

TRN

## Exploring Host-Pathogen Interactions and Immune Dynamics in Bacterial Virulence

*Chairs* Giovanni Delogu (Rome, Italy)  
Simon Foster (Sheffield, United Kingdom)

**O0868** **Bacteria and host responses in both mice and human lung organoid model revealed the role of a novel plasmid *pVirhS1* in hypervirulent Carbapenem-resistant *Klebsiella pneumoniae*** Y. Zhang\* (Shanghai, China), W. Liu, K. Lin, L. Chen, J. Wu, N. Jiang

**O0869** **Presence and role of hypervirulence-associated markers in *Klebsiella pneumoniae* groups based on LD50 value in mouse septic model** A. Avdeeva\* (Saint-Petersburg, Russian Federation), D. Kandina, E. Podvysotskaia, P. Chulkova, M. Velizhanina, J. Sopova, V. Lomonosova, V. Galushka, A. Afinogenova, V. Shapovalova, O. Sulian, I. Ageevets, V. Ageevets, S. Sidorenko

**O0870** **Meta-transcriptomic insights into Host-Pathogen Interactions in Necrotizing Soft Tissue Infections Using Differential Analysis** T. Vashist\* (Chandigarh, India), N. Rana, D. Nair, A. Angrup, V. Sharma, C. Tandup, P. Ray, A. Arora

**O0871** **Unveiling the hidden virulence of *Acinetobacter baumannii*: how the lipooligosaccharide core modulates immune responses and enhances interferon- $\gamma$  production** Y.T. Lee\* (Taipei, Taiwan,

# ESCMID Global 2025 - Programme

	<i>Jakab, Á. Sonnevend, Á. Tóth</i>
E0944	<b>Genomic multicentre surveillance of VIM-producing <i>Enterobacterales</i> shows spread driven by bacterial clones and plasmids in Germany from 2015 to 2021</b> <i>A. Wendel* (Cologne, Germany), J. Sattler, B. Bader, J. Müller, A. Hamprecht, S. Peter</i>
E0945	<b>Three distinct routes of virulence-resistance convergence in ST-395 <i>K. pneumoniae</i> from Eastern Europe over the last decade</b> <i>A. Sapre* (Silver Spring, United States), E. Nguyen, T. Luo, E. Mills, B. Corey, R. Maybank, A. Ong, V. Kondratiuk, V. Kovalchuk, M. Metreveli, N. Trapaidze, Y. Kwak, T. Musich, J. Bennett, P. Mc Gann, M. Martin, F. Lebreton</i>
E0946	<b>Carbapenemases in Germany in 2024: Report of the German National Reference Centre for Multidrug-resistant Gram-negative Bacteria</b> <i>N. Pfennigwerth* (Bochum, Germany), S. Möller, J. Eisfeld, F. Pankok, A. Anders, S. Gatermann</i>
E0947	<b>Unravelling divergent genomic modes of transmission of Carbapenemase-Producing Organisms in a single hospital in Singapore between 2019 and 2022</b> <i>V. Koh* (Singapore, Singapore), Z.Q. Lim, S.Q.D. Loy, N.M. Thevasagayam, S.R.S. Prakk, P.Y. Hon, X. Huan, Z.L. Kyaw, A.Y. Lin, P. Rao, P.P. De, S. Vasoo, K. Marimuthu, O.T. Ng</i>
E0948	<b>2011-2017 vs 2018-2024: comparison of carbapenem non-susceptibility trends among bloodstream <i>Klebsiella pneumoniae</i>, <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> isolates from Greek hospitals: data from the Electronic System for the AMR surveillance-WHONET-Greece</b> <i>M. Polemis* (Vari, Greece), A. Vatopoulos, K. Tryfinopoulou</i>

EF132	13:30 – 14:30	Arena 2
	ePoster Flash Session	

CLN

## Difficult-to-treat cases in the immunocompromised

Chair                      Nicolas Mueller (Zurich, Switzerland)

E0949	<b>A case of IRIS nocardiosis</b> <i>S.K. Dlamini* (Cape Town, South Africa), P. Namale, P. Arnab</i>
E0951	<b>Concurrent invasive disseminated Nocardia farcinica and Candida infections in a patient undergoing long-term glucocorticoid therapy for autoimmune thrombocytopenia: A case report</b> <i>N. Zhang* (Bengbu, China)</i>
E0952	<b>Subcutaneous paeohyphomycosis due to <i>Alternaria infectoria</i> in an immunosuppressed renal transplant recipient: successful multidisciplinary management</b> <i>E. Vetsiou* (London, United Kingdom), E. Rudd, S. Rai, K. Ahmed, S. Rao-Merugumala, A. Wasif, C. Shaw, A. Abdolrasouli, M. Arias</i>
E0953	<b>Lung nodules in a patient with breast cancer history... Not everything is cancer.</b> <i>E. Muñoa Hernández* (Chiapas, Mexico), E. Muñoa</i>
E0954	<b>Treatment of fulminant <i>Clostridioides difficile</i> infection using bacteria-free stool supernatant in adult hematological patients during chemotherapy-induced aplasia</b> <i>B.G. Szabo* (Budapest, Hungary), D. Korozs, A. Hardi, K. Jeszenszky, P. Remenyi, J. Sinko</i>
E0955	<b>Eradication of multidrug resistant <i>Pseudomonas aeruginosa</i> pneumonia in acute lymphoblastic leukemia patient with broad host-range phage</b> <i>P. Gadea* (Montevideo, Uruguay), J. Puig, M. Gómez, I. Ferrés, A. Galiana, F. Grill, G. Iraola</i>
E0956	<b>An Emerging fungal pathogen in immunocompromised hosts: A rare case of subcutaneous abscess caused by <i>Chondrostereum purpureum</i></b> <i>P. Kitjacharoenchai* (Bangkok, Thailand), A. Thammahong, J. Vanichanan</i>
E0957	<b>Unveiling a Rare Simultaneous Central Nervous System infection in an Immunocompromised Patient from Mexico</b> <i>E. Sienna Iracheta* (Tlalpan, Mexico), A. Magallanes Lopez, J.P. Venzor Castellanos, M.J. Corredor Nassar, A.P. Rodriguez Zulueta</i>

# ESCMID Global 2025 - Programme

P. Kristian

EF13413:30 – 14:30Arena 4

AMRDXIPC

ePoster Flash Session

Infection Controller's Daily

ChairCansu Cimen (Oldenburg, Germany)

- E0967Mortality and length of stay associated with antimicrobial-susceptible and resistant hospital-onset bloodstream infections at a tertiary referral hospital in Melbourne, AustraliaA. Stewardson\* (Melbourne, Victoria, Australia), S.J. Curtis, S.L. Lee, B.S. Cooper, J.M. Bell, G.W. Coombs, D. Daley, A.C. Cheng, D.W. Spelman, A.Y. Peleg
- E0968MRSA on the rise in neonatal care departmentsE. Herkes\* (Amsterdam, Netherlands), A. Schoffelen, R. Zwittink, J. Kluytmans, D. Notermans
- E0969Risk factors for OXA-carbapenemase-producing *Enterobacteriaceae* acquisition in Israel: a retrospective case control studyM. Amar\* (Haifa, Israel), R. Najjar-Debbiny, G. Weber, R. Yasin, A. Arbel, S. Shehade, I. Greenfeld, O. Salah, P. Shaked-Mishan, O. Barnett-Griness
- E0970Experience providing a rapid, reactive nanopore isolate sequencing service for bacterial outbreak investigation for hospitals in London, UKS. Raharison\* (Nice, France), A. Alcolea-Medina, L.B. Snell, M. Tan, G. Humayun, R. Chang, D. Ward, V. Enne, V. Patel, C. Alder, L. Sowole, R. Batra, S. Goldenberg, J. Edgeworth, J. Otter
- E0971Duration of colonization and time to de-isolation in patients with extended-spectrum beta-lactamase producing non-*Escherichia coli*/EnterobacterialesJ. Männer\* (St.Gallen, Switzerland), V. Steinacher, T. Dörr, M. Schlegel, P. Kohler
- E0972A tale of three cities: The comparative longitudinal epidemiology of vancomycin-resistant *Enterococcus faecium* from bloodstream infections at three tertiary care hospitals in Bavaria, GermanyA. Rath\* (Regensburg, Germany), B. Neumann, V. Rauschenberger, B. Kieninger, A. Eichner, J. Steinmann, S. Kampmeier, W. Schneider-Brachert
- E0973Molecular epidemiology and transmission dynamics of vancomycin-resistant *Enterococcus faecium* in Belgian hospitals (2022-2023)S. De Koster\* (Edegem, Belgium), S. Van Kleef-Van Koeveringe, H. Jansens, S. Vandamme, T. Demuyser, M. Vanden Driessche, Y. Glupczynski, S. Malhotra-Kumar, V. Matheeussen
- E0974Increasing Prevalence of Linezolid-resistant *Enterococci*: Outbreak or Overuse?R. Traynor\* (Cork, Ireland), G. Brennan, I. O Callaghan, E. Keily, E. Skelton, E. Kennedy, B. O Connell, J. Walsh, A. Doherty, C. Hickey
- E0975Continuous 2-year surveillance for airborne fungi at hospitals in the same city: Impact of season, construction, a construction accident and HEPA-filtered/positive pressure roomsM.H. Nguyen\* (Pittsburgh, United States), C. Clancy, Z. Wilkins, Y. Cho, B. Hao, E. Driscoll, S. Cheng, A. Sundermann, A. Ayres, S. Graham

EW17413:30 – 15:30Hall 11

CLNIPC

Educational Session

Best practices and emerging strategies in the management of ventilator- and healthcare-associated pneumonia

ChairsFusun Can (Istanbul, Türkiye)  
Jeroen Schouten (Nijmegen, Netherlands)

- W048113:30Artificial Intelligence to predict VAPMiia Jansson (Oulu, Finland)
- W048213:50Metagenomic approach to VAP diagnosisJacques

# ESCMID Global 2025 - Programme

00938	Combined use of (1,3)- $\beta$ -D-glucan and PCR in oral wash for <i>Pneumocystis jirovecii</i> pneumonia diagnosis in non-HIV population <i>A. Falcó Roget* (Mataró, Spain), A. Falcó-Roget, A. Albasanz-Puig, A.B. Pérez, S. Serradell, A. Guillén, E. Revilla, I. Los-Arcos, O. Len, I. Ruiz-Camps, M.T. Martín-Gómez</i>
00939	Iron levels in bronchoalveolar lavage fluid of hematological patients with suspected invasive pulmonary aspergillosis and their association with 12-week mortality: a retrospective cohort study <i>H. Lamberink* (Amsterdam, Netherlands), J. Heijmans, A. Wagemakers, K. Van Dijk</i>

SY168	13:30 – 15:30	Hall 2
	2-hour Symposium	

TRN

## Staphylococcus aureus: its expansion dynamics and interactions with its pals

Chair *Barbara C. Kahl (Münster, Germany)*

S0457	13:30	<b>S. aureus</b> and its special relationship to <b>S. epidermidis</b> <i>Andreas Peschel (Tübingen, Germany)</i>
S0458	14:00	Computational and in <i>vitro</i> evaluation of probiotic treatments for nasal <b>S. aureus</b> decolonization <i>Silvio Daniel Brugger (Zurich, Switzerland)</i>
S0459	14:30	Clonal population expansion of <b>S. aureus</b> occurs due to escape from a finite number of intraphagocyte niches <i>Simon Foster (Sheffield, United Kingdom)</i>
S0460	15:00	How bacteriophages and pathogenicity islands drive the evolution of <b>S. aureus</b> <i>John Chen (Singapore, Singapore)</i>

Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

EW172	13:30 – 15:30	Hall 3
	Educational Session	

CLN

VAX

## Beyond the gift of life: viral infection during pregnancy

Chairs *Gölsen Özkaya Sahin (Lund, Sweden)*  
*Simona Ruta (Bucharest, Romania)*

W0473	13:30	Hepatitis B during pregnancy: diagnosis, management and outcome <i>Tba</i>
W0474	13:50	RSV and Influenza during pregnancy: management and outcome <i>Monika Redlberger-Fritz (Vienna, Austria)</i>
W0475	14:10	Prenatal screening and prevention of congenital CMV: shifting concepts and consensus guideline <i>Marianne Leruez-Ville (Paris, France)</i>
W0476	14:30	Novel methods of vaccine administration to newborns <i>Tba</i>

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), European Society for Infectious Diseases in Obstetrics and Gynaecology (ESIDOG), Society on Liver Diseases in Africa (SOLDA), Gastroenterology and Hepatology Association of SubSaharan Africa (GHASSA)

SY169	13:30 – 15:30	Hall 4
	2-hour Symposium	

AMR

CLN

## Molecular epidemiology, resistance mechanisms and management of Gram-negative bacteria

Chairs *Agnes Maria Sonnevend (Pécs, Hungary)*  
*Kyriaki Xanthopoulou (Cologne, Germany)*

S0461	13:30	Globally emerging resistance patterns of Enterobacterales <i>Sasheela Ponnampalavanar (Kuala Lumpur, Malaysia)</i>
S0462	14:00	Non-fermenters still important globally: a review of spread and resistance <i>Anupa Thampy (Vellore, India)</i>
S0463	14:30	Innovative rapid diagnostic methodologies for Gram-negative pathogens <i>Laurent Dortet (Le Kremlin-</i>

# ESCMID Global 2025 - Programme

- O0932** Regulation of Novel Genes and Their Downstream Functions in the AI-2-Mediated Quorum Sensing System of *Klebsiella pneumoniae* X. Chu\* (Beijing, China), Q. Yang
- O0933** Exploring structural differences in biofilms of smooth and rough *Mycobacterium abscessus* clinical strains through confocal laser scanning microscopy C. Maria\* (Madrid, Spain), M. Cano-Fernández, J. Esteban, P. López-Roa, A. Ruedas-López, M.C. Muñoz-Egea
- O0934** Antibacterial and biofilm eradication of mupirocin-loaded nano-emulsions Z. Najmi\* (Novara, Italy), A.C. Scalia, A. Cochis, J. De Souza Nunes, J. Alkorta, L. Rimondini, D. Dupin

---

**OS126** **13:30 – 15:30** **Hall 8**

2-hour Oral Session

CLN DX PHEI

## Emerging viruses, diverse threats

*Chairs* Luisa Barzon (Padua, Italy)  
Karin Stiasny (Vienna, Austria)

- O0910** Epidemiological and clinical features of mpox during the clade Ib outbreak in South-Kivu, Democratic Republic of the Congo: a prospective cohort study I. Brosius\* (Antwerp, Belgium), E. Hasivirwe Vakaniaki, S. Sabiti Nundu, L. Liesenborghs, P. Mbala-Kingebeni, G. Mukari, P. Munganga, J.C. Tshomba, E. De Vos, E. Bangwen, Y. Mujula, A. Tsoumanis, C. Van Dijk, A. Alengo, L. Mutimba-Mambo, F. Mweshi Kumbana, J. Babingwa Muunga, D. Mazambi Mambo, J. Wakilongo Zangilwa, S. Bilembo Kitwanda, S. Houben, N. Hoff, J.C. Makangara-Cigolo, E. Kinganda-Lusamaki, M. Peeters, A. Rimoin, J. Kindrachuck, N. Low, P. Katoto, E. Bwenge Malembaka, J.H. Amuasi, O. Tshiani, R. Kojan, D. Muamba Kambaj, C. Kacita, D. Mukadi-Bamuleka, S. Ahuka-Mundeke, K. Vercauteren, T. Wawina-Bokalanga, J.J. Muyembe-Tamfum
- O0911** Tracing the origin, spread and molecular evolution of Dengue type 1 cases occurred in Northern Italy in 2023 G. Romano\* (Pavia, Italy), G. Ferrari, A.M.G. Pitrolo, F. Rovida, A. Piralla, F. Baldanti
- O0912** Dengue Country Risk Estimation: Vector Suitability and Imported Activity 2024. M. Torres Portillo\* (Toronto, Canada), K. Williams, R. Lababidi, A. Thomas, K. Khan
- O0913** Rat HEV in humans in Germany: presence but low detection rate, a screening study 2022 - 2023 L. Mueller\* (Berlin, Germany), M.L. Schmidt, T. Schwarz, T.D. Best, T. Bleicker, J. Panajotov, J. Jansen, J. Melchert, T. Mauno, C. Drosten, R. John, V.M. Corman
- O0914** Emergence of new enterovirus D68 lineage in Europe in 2023 associated with distinct amino acid substitutions in VP1 protein A. Hirvonen\* (Vantaa, Finland), C.K. Johannesen, P. Simmonds, T.K. Fischer, H. Harvala, K.S.M. Benschop
- O0915** Health-economic impacts of chikungunya vaccination in 34 countries J. Zhou\* (Oxford, United Kingdom), N. Salant, D. Smith, D. Hollingsworth, K. Pouwels, S. Radoykova, J. Lord, K. French
- O0916** Clinical importance of a new tick-borne *flaviviridae* virus, Alongshan Virus: retrospective serologic and molecular study in Switzerland F. Tagini\* (Lausanne, Switzerland), O. Opota, A. Eggermann, A. Coste, G. Greub
- O0917** From Trade Routes to Transmission Routes: Risk Assessment of Japanese Encephalitis Outbreak in Pakistan under China-Pakistan Economic Corridor Using One Health Approach S. Ahmad\* (Tampere, Finland)
- O0918** Building a screening protocol for the detection of Orthobunyavirus oropoucheense infection G. Gagliardi\* (Milan, Italy), D. Mileto, A. Mancon, L. Morelli, M. Cutrera, A. Cavallo, A. Rizzo, V. Micheli, A. Lombardi, A. Dolci